



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Board Meeting

## Public Meeting Binder

February 5, 2020

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

**NOTE:** In compliance with Act 655 of the 2018 Louisiana Legislature, the Board gives notice to its licensees and applicants of their opportunity to file a complaint about board actions or board procedures. You may submit such complaints to one or more of the following organizations: (1) Louisiana Board of Pharmacy; 3388 Brentwood Dr.; Baton Rouge, LA 70809; 225.925.6496; [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov). (2) Committee on House & Governmental Affairs; La. House of Representatives; PO Box 44486; Baton Rouge, LA 70804; 225.342.2403; [h&q@legis.la.gov](mailto:h&q@legis.la.gov). (3) Committee on Senate & Governmental Affairs; La. Senate; PO Box 94183; Baton Rouge, LA 70804; 225.342.9845; [s&q@legis.la.gov](mailto:s&q@legis.la.gov).

**NOTE:** In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Table of Contents – Public Meeting Binder

1 – A.	Table of Contents	002
1 – B.	Meeting Notice & Arrangements	
1 – C.	Acronyms	004
1 – D.	Agenda	009
2.	Invocation & Pledge of Allegiance	
3.	Quorum Call	
4.	Call for Additional Agenda Items & Adoption of Agenda	
5.	Consideration of Minutes from Previous Meetings ~ November 13, 2019	012
6.	Report on Action Items	044
7.	Confirmation of Acts	
8.	Opportunity for Public Comment	
*	Statement of Purpose & Mission of Board	
9.	Special Orders of the Day	
A.	Presentation of Pharmacist Gold Certificates	061
10.	Committee Reports	
A.	Finance	062
•	Consideration of <i>Interim Report for Fiscal Year 2019-2020</i>	063
B.	Application Review	072
C.	Reciprocity	073
•	List of Pharmacists Licensed by Reciprocity	074
D.	Violations	075
•	Consideration of Proposed Voluntary Consent Agreements	
E.	Impairment	076
•	Consideration of Committee Recommendations re Applications	
F.	Reinstatement	077
•	Consideration of Committee Recommendations re Applications	
G.	Tripartite	078
H.	Regulation Revision	079
•	Consideration of Comments & Testimony from December 27, 2019 Public Hearing	080
•	Consideration of <i>Legislative Proposal 2020-B ~ CDS Update (Draft #2)</i>	140
•	Consideration of <i>Legislative Proposal 2020-C ~ CDTM &amp; Pharmacist Prescriptive Authority (Draft #5)</i>	142
•	Consideration of <i>Regulatory Proposal 2019-G ~ Pharmacy Benefit Managers (Draft #3)</i>	146
•	Consideration of Regulatory Project 454-2019 Proposals	
➤	<i>Item 04 ~ Staffing Ratios for Pharmacy Interns (Draft #1)</i>	149
➤	<i>Item 12 ~ Practical Experience Requirements for Pharmacy Technician Candidates (Draft #1)</i>	150
•	Consideration of <i>Regulatory Proposal 2020-A ~ Marijuana Pharmacies (Draft #2)</i>	151
•	Consideration of <i>Regulatory Proposal 2020-B ~ Drugs of Concern (Draft #2)</i>	152
I.	Executive	153
•	Consideration of Proposed Revision of PPM.V.A.2 ~ PMP Advisory Council	154
•	Consideration of Proposed New PPM.III.J ~ Criminal Background Checks	157
•	Reconsideration of Approval of Legislative Proposal 2020-A ~ Renewal of Licenses & Permits (Draft #1) and Consideration of Draft #2	162
•	Consideration of Committee Recommendations	

11.	Staff Reports	
	J. Assistant Executive Director – Mr. Fontenot	166
	• Quarterly Report from Prescription Monitoring Program (PMP)	167
	• Consideration of Requests for Waivers from PMP Reporting Rule	181
	K. General Counsel – Mr. Finalet	183
	• Consideration of Proposed Voluntary Consent Agreements	
	L. Executive Director – Mr. Broussard	184
	• Narrative Report	185
	• Internal Reports	
	➤ Credentials Div. – Census Report	192
	➤ Credentials Div. – License Activity Report	204
	➤ Credentials Div. – Pending Application Report	205
	➤ Credentials Div. – Exceptions Report	206
	➤ Compliance Div. – Census Report	208
	➤ Compliance Div. – Complaint Investigation Policy Monitor	209
	• External Reports	
	• Examination Reports	
	➤ Technicians – ExCPT	210
	➤ Technicians – PTCB	211
	• Medical Cannabis Patient Distribution	219
	• Initial Report for Regular Session of 2020 Legislature	220
12.	Report from Marijuana Pharmacies (Mr. J. Douglas Boudreaux, Louisiana Association for Therapeutic Alternatives)	222
13.	New Agenda Items Added During Meeting	223
14.	Announcements	224
15.	Adjourn	226

## Acronyms

AACP	American Association of Colleges of Pharmacy
AAPS	American Association of Pharmaceutical Scientists
AAPT	American Association of Pharmacy Technicians
ACA	American College of Apothecaries
ACCME	Accreditation Council for Continuing Medical Education
ACCP	American College of Clinical Pharmacy
ACE	Advisory Committee on Examinations (NABP)
ACHC	Accreditation Commission for Health Care
ACPE	Accreditation Council for Pharmacy Education
ADA	American Dental Association
ADC	automated dispensing cabinet
ADS	automated dispensing system
AFDO	Association of Food & Drug Officials
AFPE	American Foundation for Pharmaceutical Education
AIHP	American Institute of the History of Pharmacy
AMA	American Medical Association
AMCP	Academy of Managed Care Pharmacy
AMS	automated medication system
APEC	Australian Pharmacy Examining Council
APhA	American Pharmacists Association
APPE	advanced pharmacy practice experience
ASAE	American Society of Association Executives
ASAP	American Society for Automation in Pharmacy
ASCP	American Society of Consultant Pharmacists
ASHP	American Society of Health-System Pharmacists
ASPEN	American Society of Parenteral & Enteral Nutrition
ASPL	American Society for Pharmacy Law
ATT	authorization to test
AVMA	American Veterinary Medical Association
AWARxE	NABP consumer protection program
BNDD	Bureau of Narcotics and Dangerous Drugs
BPS	Board of Pharmacy Specialties
CAC	Citizen Advocacy Center
CCAPP	Canadian Council for Accreditation of Pharmacy Programs
CCGP	Commission for Certification in Geriatric Pharmacy
CDC	U.S. Centers for Disease Control and Prevention
CDER	U.S. Center for Drug Evaluation and Research (FDA)
CDTM	collaborative drug therapy management
CDS	controlled dangerous substances
CE	continuing education
CFR	Code of Federal Regulations
CHPA	Consumer Healthcare Products Association
CLEAR	Council on Licensure, Enforcement and Regulation
CMI	consumer medication information
CMS	U.S. Centers for Medicare and Medicaid Services
CPD	continuing professional development
CPhA	Canadian Pharmacists Association
CPPA	Center for Pharmacy Practice Accreditation
CPSC	U.S. Consumer Product Safety Commission

DEA	U.S. Drug Enforcement Administration
DEQ	La. Department of Environmental Quality
DME	durable medical equipment
DMEPOS	durable medical equipment, prosthetics, orthotics, and supplies
DNV	Det Norske Veritas (Norwegian accreditation organization)
DOA	La. Div. of Administration
DOA – FPC	La. Div. of Administration – Facility Planning & Control
DOA – ORM	La. Div. of Administration – Office of Risk Management
DOA – OSR	La. Div. of Administration – Office of State Register
DOA – OSRAP	La. Div. of Administration – Office of Statewide Reporting & Accounting Policy
DOE	La. Dept. of Education
DPSC	La. Dept. of Public Safety & Corrections
DSCS	La. Dept. of State Civil Service
DSM	disease state management
EDK	emergency drug kit
ELTP	Electronic Licensure Transfer Program (NABP)
EPA	U.S. Environmental Protection Agency
EPCS	Electronic Prescribing of Controlled Substances (DEA)
ETS	Educational Testing Service
EU	European Union
ExCPT	Examination for the Certification of Pharmacy Technicians
FARB	Federation of Associations of Regulatory Boards
FBI	Federal Bureau of Investigation
FD&C	Federal Food, Drug & Cosmetic Act
FDA	U.S. Food & Drug Administration
FEIS	Fiscal & Economic Impact Statement
FIP	Federation Internationale Pharmaceutique
FMI	Food Marketing Institute
FPGEC	Foreign Pharmacy Graduate Examination Committee (NABP)
FPGEE	Foreign Pharmacy Graduate Equivalency Examination (NABP)
FSBPT	Federation of State Boards of Physical Therapy
FSMB	Federation of State Medical Boards
FRC	Foreign Pharmacy Graduate Equivalency Examination Review Committee (NABP)
FTC	U.S. Federal Trade Commission
GOHSEP	Governor’s Office of Homeland Security & Emergency Preparedness
GPhA	Generic Pharmaceutical Association
GPO	U.S. Government Publishing Office
gTLD	generic top level domain (Internet addresses)
HCFA	Health Care Financing Administration
HDMA	Healthcare Distribution Management Association
HIPAA	Health Insurance Portability and Accountability Act (of 1996)
HIPDB	Healthcare Integrity and Protection Data Bank
HMO	health maintenance organization
IACP	International Academy of Compounding Pharmacists
ICANN	Internet Corporation for Assigned Numbers and Names
ICPT	Institute for the Certification of Pharmacy Technicians
IDOI	Internet Drug Outlet Identification (NABP)
INEOA	International Narcotic Enforcement Officers Association
IOM	Institute of Medicine
IPPE	introductory pharmacy practice experience
IRS	U.S. Internal Revenue Service

ISMP	Institute for Safe Medication Practices
JCPP	Joint Commission of Pharmacy Practitioners
JLCB	Joint Legislative Committee on the Budget
LAC	Louisiana Administrative Code
LAMP	Louisiana Academy of Medical Psychologists
LANP	Louisiana Association of Nurse Practitioners
LAPA	Louisiana Academy of Physician Assistants
LASERS	La. State Employees Retirement System
LASIE	Louisiana Association of Self-Insured Employers
LBDDD	La. Board of Drug & Device Distributors
LBP	La. Board of Pharmacy
LDA	Louisiana Dental Association
LDAF	La. Dept. of Agriculture & Forestry
LDH	La. Dept. of Health
LDI	La. Dept. of Insurance
LDR	La. Dept. of Revenue
LFO	Legislative Fiscal Office
LHA	Louisiana Hospital Association
LIPA	Louisiana Independent Pharmacies Association
LLA	La. Legislative Auditor
LPA	Louisiana Pharmacists Association
LPC	Louisiana Pharmacy Congress
LPTA	Louisiana Physical Therapy Association
LPTB	Louisiana Physical Therapy Board
LSA	Louisiana Sheriffs' Association
LSBD	La. State Board of Dentistry
LSBME	La. State Board of Medical Examiners
LSBN	La. State Board of Nursing
LSBOE	La. State Board of Optometry Examiners
LSBPNE	La. State Board of Practical Nurse Examiners
LSBVM	La. State Board of Veterinary Medicine
LSHP	Louisiana Society of Health-System Pharmacists
LSMS	Louisiana State Medical Society
LSNA	Louisiana State Nurses Association
LTC	long term care
LTCF	long term care facility
LVMA	Louisiana Veterinary Medical Association
MPJE	Multistate Pharmacy Jurisprudence Examination (NABP)
MRC	MPJE Review Committee (NABP)
NABP	National Association of Boards of Pharmacy
NABP-F	National Association of Boards of Pharmacy Foundation
NABPLAW	National Association of Boards of Pharmacy – Law Database
NACDS	National Association of Chain Drug Stores
NADDI	National Association of Drug Diversion Investigators
NAMSDL	National Alliance for Model State Drug Laws
NAPLEX	North American Pharmacist Licensure Examination (NABP)
NAPRA	National Association of Pharmacy Regulatory Authorities (Canada)
NASCSA	National Association of State Controlled Substance Authorities
NASPA	National Alliance of State Pharmacy Associations
NASPER	National All Schedules Prescription Electronic Reporting Act
NCC MERP	National Coordinating Council for Medication Error Reporting and Prevention

NCPA	National Community Pharmacists Association
NCPDP	National Council for Prescription Drug Programs
NCPIE	National Council on Patient Information and Education
NCPO	National Conference of Pharmaceutical Organizations
NCSBN	National Council of State Boards of Nursing
NCVHS	National Committee on Vital and Health Statistics
NDC	National Drug Code
NDMA	Nonprescription Drug Manufacturing Association
NIPCO	National Institute for Pharmacist Care Outcomes
NISPC	National Institute for Standards in Pharmacist Credentialing
NOCA	National Organization for Competency Assurance
NPA	National Pharmacy Association
NPC	National Pharmaceutical Council
NPDB	National Practitioner Data Bank
NPTA	National Pharmacy Technician Association
NRC	NAPLEX Review Committee (NABP) Federal Nuclear Regulatory Commission
OAL	Optometry Association of Louisiana
OBRA	Omnibus Budget Reconciliation Act
OIG	Office of Inspector General
ONDCP	Office of National Drug Control Policy
ONDD	Office of Narcotics and Dangerous Drugs
OPEB	other post employment benefits
OSHA	Occupational Safety and Health Administration
PBM	pharmacy benefit management
PCAB	Pharmacy Compounding Accreditation Board
PCCA	Professional Compounding Centers of America
PCMA	Pharmaceutical Care Management Association
PCOA	Pharmacy Curriculum Outcomes Assessment (NABP)
PDMA	Prescription Drug Marketing Act
PEBC	Pharmacy Examining Board of Canada
PhRMA	Pharmaceutical Research and Manufacturers of America
PMP	Prescription Monitoring Program
PMP-i	Prescription Monitoring Program Interconnect (NABP)
PTAC	Pharmacy Technician Accreditation Commission
PTCB	Pharmacy Technician Certification Board
PTCE	Pharmacy Technician Certification Examination
PTEC	Pharmacy Technician Educators Council
PTTP	pharmacy technician training program
RFID/EPC	Radio Frequency Identification / Electronic Product Code
RS	Louisiana Revised Statutes
SAMSHA	U.S. Substance Abuse & Mental Health Services Administration
SEGBP	State Employees Group Benefit Program
TJC	The Joint Commission
TOEFL	Test of English as a Foreign Language
TOEFL iBT	Test of English as a Foreign Language Internet-based Test
TSE	Test of Spoken English
URAC	Utilization Review Accreditation Commission
USP	United States Pharmacopeia / United States Pharmacopeial Convention
USP DI	U.S. Pharmacopeia Dispensing Information
USP-NF	U.S. Pharmacopeia – National Formulary

VAWD	Verified-Accredited Wholesale Distributors (NABP)
Vet-VIPPS	Veterinary-Verified Internet Pharmacy Practice Sites (NABP)
VIPPS	Verified Internet Pharmacy Practice Sites (NABP)
VPP	Verified Pharmacy Practice (NABP)
WHO	World Health Organization
WHPA	World Health Professions Alliance



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



**NOTICE IS HEREBY GIVEN** that a meeting of the Board has been ordered and called for 9:00 a.m. on Wednesday, February 5, 2020 at the Xavier University Convocation Center, located at 7910 Stroelitz Street in New Orleans, LA 70125, for the purpose to wit:

## AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 01-22-2020

1. Call to Order
2. Invocation & Pledge of Allegiance
3. Quorum Call
4. Call for Additional Agenda Items & Adoption of Agenda
5. Consideration of Minutes from Previous Meetings – November 13, 2019
6. Report on Action Items
7. Confirmation of Acts
8. Opportunity for Public Comment
9. Special Orders of the Day
  - A. Presentation of Pharmacist Gold Certificates
    - PST.009577 Steve Vincent Campo
    - PST.009589 Reuben Rufus Dixon, Jr.
10. Committee Reports
  - A. Finance – Mr. Pitre
    - Review of Interim Report for Fiscal Year 2019-2020
  - B. Application Review – Mr. Soileau
  - C. Reciprocity – Mr. Cassidy
  - D. Violations – Mr. Indovina
    - Consideration of Proposed Voluntary Consent Agreements
      - (1) Case No. 19-0154 ~ PHY.005545 – Walgreen La. Co., Inc. d/b/a Walgreen Pharmacy No. 09526 [Pineville, LA]
      - (2) Case No. 19-0078 ~ PHY.002865 – Walgreen La. Co., Inc. d/b/a Walgreen Pharmacy No. 02980 [Baton Rouge, LA]
      - (3) Case No. 19-0329 ~ PHY.002868 – Walgreen La. Co., Inc. d/b/a Walgreen Pharmacy No. 02995 [Baton Rouge, LA]
      - (4) Case No. 19-0137 ~ PHY.007114 – Pensacola Apothecary, Inc. d/b/a Everwell Specialty Pharmacy [Pensacola, FL]
      - (5) Case No. 19-0193 ~ PHY.006617 – Best Life Pharmacy & Restaurant, Inc. d/b/a Best Life Pharmacy & Restaurant [New Orleans, LA]
      - (6) Case No. 19-0316 ~ PST.016625 – Kristian Raymond Hahn
      - (7) Case No. 19-0278 ~ PHY.003625 – Pharmaceutical Specialties, LLC d/b/a Pharmaceutical Specialties [Baton Rouge, LA]

**NOTE:** Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

**NOTE:** In compliance with Act 655 of the 2018 Louisiana Legislature, the Board gives notice to its licensees and applicants of their opportunity to file a complaint about board actions or board procedures. You may submit such complaints to one or more of the following organizations: (1) Louisiana Board of Pharmacy; 3388 Brentwood Dr.; Baton Rouge, LA 70809; 225.925.6496; [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov). (2) Committee on House & Governmental Affairs; La. House of Representatives; PO Box 44486; Baton Rouge, LA 70804; 225.342.2403; [h&q@legis.la.gov](mailto:h&q@legis.la.gov). (3) Committee on Senate & Governmental Affairs; La. Senate; PO Box 94183; Baton Rouge, LA 70804; 225.342.9845; [s&q@legis.la.gov](mailto:s&q@legis.la.gov).

**NOTE:** In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

10. Committee Reports
  - D. Violations – Mr. Indovina (cont.)
    - (8) Case No. 19-0206 ~ PHY.006032 – Chris' Pharmacy and Gifts, LLC d/b/a Chris' Pharmacy and Gifts [Maurepas, LA]
  - E. Impairment – Ms. Hall
    - Consideration of Committee Recommendations re Applications
  - F. Reinstatement – Mr. Moore
    - Consideration of Committee Recommendations re Applications
  - G. Tripartite – Mr. Resweber
    - Consideration of Committee Recommendations
  - H. Regulation Revision – Mr. McKay
    - Consideration of Comments & Testimony from December 27, 2019 Public Hearing
    - Consideration of [Legislative Proposal 2020-B ~ CDS Update \(Draft #2\)](#)
    - Consideration of [Legislative Proposal 2020-C ~ CDTM & Pharmacist Prescriptive Authority \(Draft #5\)](#)
    - Consideration of [Regulatory Proposal 2019-G ~ Pharmacy Benefit Managers \(Draft #3\)](#)
    - Consideration of Regulatory Project 454-2019 Proposals:
      - [Item 04 ~ Staffing Ratios for Pharmacy Interns \(Draft #1\)](#)
      - [Item 12 ~ Practical Experience Requirements for Pharmacy Technician Candidates \(Draft #1\)](#)
    - Consideration of [Regulatory Proposal 2020-A ~ Marijuana Pharmacies \(Draft #2\)](#)
    - Consideration of [Regulatory Proposal 2020-B ~ Drugs of Concern \(Draft #2\)](#)
  - I. Executive – Mr. Aron
    - Consideration of Proposed Revision of [PPM.V.A.2 ~ PMP Advisory Council](#)
    - Consideration of Proposed New [PPM.III.J ~ Criminal Background Checks](#)
    - Reconsideration of Approval of [Legislative Proposal 2020-A ~ Renewal of Licenses & Permits \(Draft #1\)](#) & Consideration of [Draft #2](#).
    - Consideration of Committee Recommendations
11. Staff Reports
  - J. Assistant Executive Director – Mr. Fontenot
    - Quarterly Report of Prescription Monitoring Program (PMP)
    - Consideration of Requests for Waivers from PMP Reporting Requirement
  - K. General Counsel – Mr. Finalet
    - Consideration of Proposed Voluntary Consent Agreements & Surrenders
      - (01) Case No. 19-0344 ~ PTC.027503 – Ashley Keleen Ferdinand
      - (02) Case No. 19-0349 ~ PST.018456 – Jamie Deshotels Pucheu

---

**NOTE:** Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

**NOTE:** In compliance with Act 655 of the 2018 Louisiana Legislature, the Board gives notice to its licensees and applicants of their opportunity to file a complaint about board actions or board procedures. You may submit such complaints to one or more of the following organizations: (1) Louisiana Board of Pharmacy; 3388 Brentwood Dr.; Baton Rouge, LA 70809; 225.925.6496; [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov). (2) Committee on House & Governmental Affairs; La. House of Representatives; PO Box 44486; Baton Rouge, LA 70804; 225.342.2403; [h&qa@legis.la.gov](mailto:h&qa@legis.la.gov). (3) Committee on Senate & Governmental Affairs; La. Senate; PO Box 94183; Baton Rouge, LA 70804; 225.342.9845; [s&q@legis.la.gov](mailto:s&q@legis.la.gov).

**NOTE:** In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

11. Staff Reports
  - K. General Counsel – Mr. Finalet (cont.)
    - (03) Case No. 19-0342 ~ PTC.026981 – Kayla Christine Sibley (Powell)
    - (03) Case No. 19-0351 ~ CPT.013721 – William Andrew Fletcher
    - (04) Case No. 19-0348 ~ PHY.006258 – Jan Erickson *d/b/a* Meds For Vets
    - (05) Case No. 19-0390 ~ PST,019759 – Arielle Marie Collins
  - L. Executive Director – Mr. Broussard
12. Report from Marijuana Pharmacies – Mr. Doug Boudreaux, La. Association for Therapeutic Alternatives
13. New Agenda Items Added During Meeting
14. Announcements
15. Adjourn

---

**NOTE:** Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

**NOTE:** In compliance with Act 655 of the 2018 Louisiana Legislature, the Board gives notice to its licensees and applicants of their opportunity to file a complaint about board actions or board procedures. You may submit such complaints to one or more of the following organizations: (1) Louisiana Board of Pharmacy; 3388 Brentwood Dr.; Baton Rouge, LA 70809; 225.925.6496; [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov). (2) Committee on House & Governmental Affairs; La. House of Representatives; PO Box 44486; Baton Rouge, LA 70804; 225.342.2403; [h&q@legis.la.gov](mailto:h&q@legis.la.gov). (3) Committee on Senate & Governmental Affairs; La. Senate; PO Box 94183; Baton Rouge, LA 70804; 225.342.9845; [s&q@legis.la.gov](mailto:s&q@legis.la.gov).

**NOTE:** In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Consideration of Minutes from Previous Meetings



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



# Minutes

**Regular Meeting  
&  
Administrative Hearing**

Wednesday, November 13, 2019 at 9:00 a.m.

Thursday, November 14, 2019 at 8:30 a.m.

**Location:**

Louisiana Board of Pharmacy  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700

# Table of Contents

<u>Agenda Item No.</u>	<u>Description</u>	<u>Page No.</u>
<i><u>Wednesday, November 13, 2019</u></i>		
1.	Call to Order	04
2.	Invocation & Pledge of Allegiance	04
3.	Quorum Call	04
4.	Call for Additional Agenda Items & Adoption of Agenda	05
5.	Consideration of Minutes from Previous Meeting	05
6.	Report on Action Items	05
7.	Confirmation of Acts	06
8.	Opportunity for Public Comment	06
*	Statement of Purpose	06
9.	Special Orders of the Day	06
	A. Annual Election of Board Officers	06
10.	Committee Reports	
	A. Finance	06
	B. Application Review	07
	C. Reciprocity	07
	D. Violations	17
	E. Impairment	07
	F. Reinstatement	09
	G. Tripartite	10
	H. Regulation Revision	10
	I. Executive	18
11.	Staff Reports	
	J. Assistant Executive Director	21
	K. General Counsel	22
	L. Executive Director	25
12.	Special Presentation – Contemporary Pharmacy Education Dr. Michael Cockerham, Associate Dean, ULM College of Pharmacy, & Dr. Kristi Rapp, Associate Dean, Xavier College of Pharmacy	18
13.	New Agenda Items Added During Meeting	12
14.	Announcements	27
15.	Recess	27

Agenda Item No.

Description

Page No.

Thursday, November 14, 2019

A.	Call to Order	27
B.	Invocation & Pledge of Allegiance	27
C.	Quorum Call	27
D.	Call for Additional Agenda Items & Adoption of Agenda	27
E.	Opportunity for Public Comment	28
*	Appearances	28
F.	Formal Hearings	28
G.	Adjourn	31

A regular meeting of the Louisiana Board of Pharmacy was held on Wednesday, November 13, 2019 at the office of the Louisiana Board of Pharmacy, located at 3388 Brentwood Drive in Baton Rouge, Louisiana 70809-1700. The meeting was held pursuant to public notice, each member received notice, and public notice was properly posted.

*1. Call to Order*

Mr. Carl Aron, President, called the meeting to order at 9:15 a.m.

*2. Invocation & Pledge*

Mr. Aron called upon Mr. Ronald Moore for the invocation. Dr. Robert Cloud then led the group in the Pledge of Allegiance.

*3. Quorum Call*

In the absence of the Secretary, Mr. Aron called upon the Executive Director, Mr. Malcolm Broussard, to call the roll of members to establish a quorum.

**Members Present:**

Mr. Carl W. Aron  
Mr. Allen W. Cassidy, Jr.  
Dr. J. Robert Cloud  
Ms. Jacqueline L. Hall  
Mr. Richard M. Indovina, Jr.      *(late arrival at 12:35 pm)*  
Mr. Kevin LaGrange  
Mr. Robert C. LeBas  
Mr. Richard Mannino  
Mr. Marty R. McKay  
Ms. Diane G. Milano  
Mr. Ronald E. Moore  
Mr. Blake P. Pitre  
Mr. Don L. Resweber  
Mr. Douglas E. Robichaux  
Mr. Richard A. Soileau  
Dr. Raymond J. Strong

**Member Absent:**

Mr. Rhonny K. Valentine

**Staff Present:**

Mr. Malcolm J. Broussard, Executive Director  
Mr. Carlos M. Finalet, III, General Counsel  
Mr. M. Joseph Fontenot, Assistant Executive Director  
Mr. Benjamin S. Whaley, Chief Compliance Officer

**Guests:**

Mr. Jeff Brown – Highgate Ventures  
Mr. Gregory Poret – Poret's Thrifty Way Pharmacy

Ms. Tiffany Lemoine – Thrifty Way Pharmacy  
Dr. Glenn Anderson – ULM College of Pharmacy  
Mr. Jeff Gaude – Walgreen & Co. Pharmacies  
Mr. Raymond LaBarbera – Albertson’s Pharmacies  
Ms. Elise Rigby – Cardinal Health  
Mr. Ben J. Sims – Brookshire Grocery Co.  
Dr. Kristen Laughlin – Genoa Healthcare  
Dr. Dana B. Antoon – Channell Drugs  
Mr. Russell Caffery – La. Independent Pharmacies Association  
Mr. Ivan Landry – Towne Pharmacy  
Dr. Scott M. Dietzway – PharMerica  
Mr. Steven Trahan – Institutional Pharmacies of Louisiana  
Mr. Robert Sonnier, Jr. – Institutional Pharmacies of Louisiana  
Dr. Tommy J. Woodard, Jr. – Prescriptions to Geaux  
Dr. Johnny R. Garcia, Jr. – AllianceRx Walgreens Prime  
Ms. Crystal Carter – La. Pharmacists Association  
Mr. Paul J. D’Aunoy – Central Admixture Pharmacy Services  
Ms. Linda Spradley – Spradley & Spradley  
Dr. Angie Huff – The Wellness Center  
Mr. Randal Johnson – La. Independent Pharmacies Association  
Ms. Mary Staples – National Association of Chain Drug Stores  
Dr. April M. Holley – La. Dept. of Health  
Dr. Richard Djapni – Honeycutt Drug Store  
Ms. Kim Hood – La. Dept. of Health

Mr. Broussard certified Mr. Indovina and Mr. Valentine were absent; however, the remaining 15 members were present, constituting a quorum for the conduct of official business. It was noted Mr. Indovina arrived later that day at approximately 12:35 pm.

*4. Call for Additional Agenda Items & Adoption of Agenda*

Mr. Aron asked if there were any additional agenda items to be added. None were requested. With no requests to amend the agenda, and without objection, the members adopted the posted agenda dated November 11, 2019. Mr. Aron requested authority to re-order the agenda as may become necessary and there were no objections to that request.

*5. Consideration of Minutes*

Mr. Aron reminded the members they had received the draft minutes from the Regular Board Meeting on August 14 and the Administrative Hearing on August 15, both held in Baton Rouge, Louisiana. With no objections, he waived the reading of the draft minutes. With no requests for amendment or any objection to their approval, Mr. Aron declared the minutes were approved as presented. Mr. Broussard reminded the members to sign the Minute Book.

*6. Report on Action Items*

Mr. Aron called on Mr. Broussard for the report. Mr. Broussard directed the members to a copy of the report in their meeting binder. There were no questions from the

members or guests.

#### 7. *Confirmation of Acts*

Pursuant to Mr. Aron's declaration that the officers, committees, and executive director had attended to the business of the Board since their last meeting in accordance with policies and procedures previously approved by the Board, Mr. McKay moved,

**Resolved**, that the actions taken and decisions made by the Board officers, Board committees, and Executive Director in the general conduct and transactions of Board business since August 15, 2019 are approved, adopted, and ratified by the entire Board.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

#### 8. *Opportunity for Public Comment*

Mr. Aron reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and for each agenda item upon which a vote is to be taken. He solicited general comments on non-agenda items from the guests present; none were offered.

#### \* *Statement of Purpose*

Mr. Aron reminded the members of the purpose and mission of the Board of Pharmacy by reciting the relevant portion of the Louisiana Pharmacy Practice Act. He urged the members to keep their legislative mandate in mind as they considered all the matters before them.

#### 9. *Special Orders of the Day*

Mr. Aron reminded the members and guests of the annual election of officers usually conducted at the final meeting of the calendar year. He announced he would conduct elections for each of the five officer positions in rank order, with the newly-elected officer assuming their position immediately. Mr. Don Resweber nominated the entire slate of current officers in their same positions. Mr. Aron requested additional nominations but none were offered; he then closed the nominations. Dr. Strong moved to re-elect, by acclamation, the current slate of officers in their same positions. With no member or public comments offered, the motion was adopted after a unanimous vote in the affirmative. The following members were re-elected to officer positions:

- Mr. Carl Aron – President
- Mr. Marty McKay – First Vice President
- Ms. Jacqueline Hall – Second Vice President
- Mr. Richard Soileau – Third Vice President
- Mr. Richard Indovina – Secretary

Mr. Aron congratulated all of the officers.

#### 10. *Committee Reports*

##### A. *Finance Committee*

Mr. Aron called upon Mr. McKay for the committee report. Mr. McKay reviewed the *Interim Report for Fiscal Year 2019-2020*, noting it was informational and did not require Board action. There were no member

questions. He then directed the members to the *Proposed Budget for Fiscal Year 2020-2021* in their meeting packet. He reported the committee reviewed the budget developed by staff, did not make any changes and voted to recommend its approval. He then moved,

**Resolved**, to approve and adopt the *Proposed Budget for Fiscal Year 2020-2021*.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

Finally, Mr. McKay expressed his appreciation to the other committee members for their ongoing efforts.

*B. Application Review Committee*

Mr. Aron called upon Mr. Soileau for the committee report. Mr. Soileau reported the committee had not met since the previous Board meeting.

*C. Reciprocity Committee*

Mr. Aron called upon Mr. Cassidy for the committee report. He reported the staff had evaluated 65 applications for pharmacist licensure by reciprocity since the last Board meeting and that none of them contained information that warranted a committee level review. In conformance with policies and procedures previously approved by the Board, the staff approved the applications and issued the credentials. He then reported staff had referred one applicant to the committee, and the committee interviewed the applicant earlier that day. He informed the members the committee had approved the issuance of an active and unrestricted license to the applicant and that action did not require approval by the Board. Mr. Cassidy then directed the members to a list of the new pharmacists licensed by reciprocity in their meeting binder.

Finally, he closed his report with appreciation to the other committee members for their ongoing efforts.

At this point, Mr. Aron re-ordered the agenda and indicated his intent to receive the report from the Violations Committee after lunch, when he expected the committee chair to arrive at the meeting.

*E. Impairment Committee*

Mr. Aron called upon Ms. Hall for the committee report. Ms. Hall reported the committee met the previous day to consider nine referrals from the staff – eight petitions for modification of previous orders and one application for a new credential. Following their interviews of the applicants and subsequent deliberations, the applicant for a new credential withdrew her application. Ms. Hall then presented the following recommendations to the members for their consideration.

**Lauren Ruffino Etienne (PST.019969)** Ms. Hall moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the

affirmative. The Board granted the applicant's petition for modification of previous orders, then removed Article 2e from her November 2018 Probation Board Order which had prevented her from accepting an appointment as the pharmacist-in-charge of a pharmacy; and further, reiterated all other terms shall remain in effect.

**Kacie Dore Keith (PST.020248)** Ms. Hall moved to approve the proposed order. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted her request for modification of previous orders, then terminated the probationary period originally scheduled to conclude on August 10, 2021 and restored the license to active and unrestricted status.

**Jeffery Charles Pierre (PST.020332)** Ms. Hall moved to approve the proposed order. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted his request for modification of previous orders, then terminated the probationary period originally scheduled to conclude on November 14, 2023 and restored the license to active and unrestricted status.

**John Sherwood Bannister (PST.015778)** Ms. Hall moved to approve the proposed order. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted his request for modification of previous orders, then terminated the probationary period originally scheduled to conclude on May 4, 2021 and restored the license to active and unrestricted status.

**Lauren Moore Caldwell (PST.020057)** Ms. Hall moved to approve the proposed order. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted her request for modification of previous orders, then conditioned the removal of all probationary terms and restoration of the license to active and unrestricted status upon the receipt of evidence of four hours of ACPE-accredited and pharmacist-specific continuing education on pharmacy ethics, and further, the continuing education records submitted in satisfaction of this requirement shall not be valid for future license renewal purposes.

**Terry James Veillon, Jr. (PST.018988)** Ms. Hall moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted his request for modification of previous orders, then removed Article 2e from his August 2018 Probation Board Order which had prevented him from accepting an appointment as the pharmacist-in-charge of a pharmacy; and further, reiterated all other terms shall remain in effect.

**Shelette Marie Wade (PST.014865)** Ms. Hall moved to approve the

proposed order. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted her request for modification of previous orders, terminated the probationary period originally scheduled to conclude on August 20, 2021 and restored the license to active and unrestricted status.

**Jason Conrad Dove (PST.015811)** Ms. Hall moved to approve the proposed order. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted his request for modification of previous orders, terminated the probationary period originally scheduled to conclude on August 6, 2029 and restored the license to active and unrestricted status.

Finally, Ms. Hall closed her report with appreciation to her fellow committee members for their work the previous day.

*F. Reinstatement Committee*

Mr. Aron called upon Mr. Moore for the committee report. Mr. Moore reported the committee met the previous day to consider four referrals from the staff – three petitions for reinstatement of lapsed credentials and one petition for modification of previous orders. Following their interviews of the applicants and subsequent deliberations, the committee continued one case due to illness of the applicant. The petitioner for modification of previous orders withdrew their application. Mr. Moore then presented the following recommendations to the members for their consideration.

**Ramona Lois Foster Cormier (CPT.005761)** Mr. Moore moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted the applicant's request for reinstatement of the lapsed certificate contingent upon the satisfaction of certain requirements identified within the consent agreement prior to November 13, 2021.

**Shanna Renee Venable Smith (CPT.003222)** Mr. Moore moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board granted the applicant's request for reinstatement of the lapsed certificate contingent upon the satisfaction of certain requirements identified within the consent agreement prior to November 13, 2021.

Mr. Moore closed his report with appreciation to the other committee members for their work the previous day.

G. *Tripartite Committee*

Mr. Aron called upon Mr. Resweber for the committee report. Mr. Resweber reported the committee had not met since the previous Board meeting but is scheduled to meet in connection with the next Board meeting in February 2020 in New Orleans.

H. *Regulation Revision Committee*

Mr. Aron called upon Mr. McKay for the committee report. Mr. McKay reported the committee met on September 17 and October 17 to consider the items on their posted agendas. He reported the committee had approved three regulatory proposals as well as several items from the comprehensive rule review (Regulatory Project 454-2019). He directed the members to copies of the following proposal documents in their meeting binders.

*Regulatory Proposal 2019-C ~ Automated Medication Systems*

Mr. McKay reported the committee combined two assigned topics – review of the rules for automated medication systems compared to the NABP Model Rules for Automated Medication Systems and Telepharmacy in addition to the current pilot project for automated medication systems, as well as a revision to that chapter of rules to enable the use of such systems in correctional facilities which are not licensed by the state health department. The committee combined all of those initiatives into a single proposal, which they voted to recommend to the Board. Mr. McKey then moved,

**Resolved**, to approve *Regulatory Proposal 2019-C ~ Automated Medication Systems (Draft #7)*, and further, to authorize the Executive Director to promulgate the proposed rule amendment upon the instruction of the President, and further, to authorize the President to approval acceptable amendments as may become necessary during the promulgation process.

Mr. McKay answered questions from four members; there were no public comments. The motion was adopted after a unanimous vote in the affirmative.

*Regulatory Proposal 2019-F ~ Prescription Monitoring Program (PMP)*

Mr. McKay reminded the members of several proposals relative to the state prescription monitoring program, as well as their directive to pause a recently initiated regulatory project relative to the program. The committee developed a new proposal combining all of those initiatives as well as a new effort to reduce the duplicative language in the current chapter of rules for the program. He noted much of the language in the current rule copies the language of the PMP Law, and the new proposal reduces much of the duplication. He then moved,

**Resolved**, to approve *Regulatory Proposal 2019-F ~ Prescription Monitoring Program (Draft #3)*, and further, to authorize the Executive Director to promulgate the proposed rule amendment

upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

Regulatory Proposal 2019-H ~ Pharmacist License Display (Draft #1)

Mr. McKay reported the staff discovery of a rule overlooked during a 2012 regulatory project which removed the requirement for pharmacists, interns, technicians, and technician candidates to publicly display copies of their credentials. He noted the discovery consists of a single sentence in the chapter of rules for pharmacists. The committee votes to recommend the Board's approval of this proposal to remove that single sentence. He then moved,

**Resolved**, to approve Regulatory Proposal 2019-H ~ Pharmacist License Display (Draft #1), and further, to authorize the Executive Director to promulgate the proposed rule amendment upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

There were no member questions. Mr. McKay replied to a question from one guest. The motion was adopted after a unanimous vote in the affirmative.

Regulatory Project 454-2019 ~ Comprehensive Rule Review

Mr. McKay reminded the members of the progress of the regulatory project mandated by Act 454 of the 2018 Legislature. The committee reviewed draft proposals for the 20 topics which the Board referred to the committee. Although the draft proposals for five of the topics were deferred until the committee's next meeting, the committee voted to send 12 proposals representing 15 of the topics to the Board for its consideration.

- Item 01 ~ Rest Breaks (Draft #2)

The committee voted to recommend a proposal prohibiting any person licensed by the Board from being required to practice for longer than six hours without a rest break. Mr. McKay moved,

**Resolved**, to approve Regulatory Proposal 454-2019-01 ~ Rest Breaks (Draft #2), and further, to authorize the Executive Director to promulgate the proposed rule upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

Mr. McKay answered questions from three members; there were no public comments. The motion was adopted after a unanimous vote in the affirmative.

- *Item 03 ~ Medication Administration (Draft #1)*

The committee voted to recommend a proposal revising the section of rules relative to medication administration, to remove the requirement for a separate authority to administer document and to require pharmacy technicians to obtain the required education and training before administering medications. Mr. McKay moved,

**Resolved**, to approve Regulatory Proposal 454-2019-03 ~ Medication Administration (Draft #1), and further, to authorize the Executive Director to promulgate the proposed rule amendment upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

Several members questioned the inclusion of pharmacy technicians in the training requirements for the medication administration registration. During the discussion, questions were raised about the administration of immunizations without prescription orders or medical orders, and whether the pharmacist could delegate the administration of such immunizations to pharmacy interns. Prior to any vote, Mr. McKay withdrew his motion for the approval of the regulatory proposal so the Board could consider the question of whether a pharmacist could delegate the administration of immunizations without a prescription or medical order to a pharmacy intern.

Mr. Aron noted the question of whether a pharmacist could delegate the administration of immunizations without a prescription or medical order to a pharmacy intern was not on the agenda. Mr. McKay moved to add a new agenda item for the Board to interpret a portion of the pharmacy practice act, more specifically La. R.S. 37:1218 and 37:1218.1 relative to the authority of a pharmacist to delegate the administration of immunizations without a prescription or medical order to a pharmacy intern. He suggested the issue was urgent due to planned activities for pharmacy interns to participate in immunization clinics. The motion was adopted after a unanimous roll call vote in the affirmative. Mr. Aron indicated he would add that item as Agenda Item 13.A. He then re-ordered the agenda to consider that new business item.

### *13. New Agenda Items Added During Meeting*

#### *A. Delegation of Immunizations Without Medical Orders to Pharmacy Interns.*

Mr. Aron requested staff to prepare printed copies of the R.S. 37:1218 and 37:1218.1 for the members to review prior to their discussion. He placed the meeting in recess at 10:35 am and then reconvened the meeting at 11:00 am.

Following substantial discussion, Mr. Soileau moved

**Resolved**, that the Board interpret La. R.S. 37:1218 and 37:1218.1 such that a properly credentialed pharmacist may delegate the administration of immunizations without medical orders to a properly credentialed pharmacy intern.

There were no further member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

At this point, Mr. Aron returned to the report from the Regulation Revision Committee, in particular the regulatory proposal relative to medication administration.

## 10. Committee Reports

### H. Regulation Revision Committee

- *Item 03 ~ Medication Administration (Draft #1)*

To re-open the discussion on the proposal, Mr. McKay moved, **Resolved**, to approve Regulatory Proposal 454-2019-03 ~ Medication Administration (Draft #1), and further, to authorize the Executive Director to promulgate the proposed rule amendment upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

Prior to any vote, Mr. McKay moved to amend the proposal by removing all references to pharmacy technicians. There were no further member questions or public comments. The motion to amend the proposal was adopted after a unanimous vote in the affirmative. Mr. Aron requested staff to renumber the amended proposal as Draft #2. He then asked if there was any further discussion on Draft #2 of the proposal. There were no further member or public comments. The motion for approval of the amended proposal – Regulatory Proposal 454-2019-03 ~ Medication Administration (Draft #2) – was adopted after a unanimous vote in the affirmative.

At this point, Mr. Aron declared a luncheon recess. He placed the Board in recess at 11:40 am. The members reconvened at 12:35 pm. It was noted Mr. Indovina arrived to the meeting during the luncheon recess. Mr. Aron resumed the report of the Regulation Revision Committee and asked Mr. McKay to continue with his report.

- *Item 16 ~ Renewal of Licenses & Permits (Draft #1)*

Mr. McKay reported staff reviewed the law and rule and identified several instances where annual renewals are required. To give the Board the option of instituting renewal cycles of more than one year, staff developed a legislative proposal to make the appropriate adjustments in the pharmacy law as well as a regulatory proposal to make the appropriate adjustments therein. He reported the committee voted to recommend the approval of the legislative proposal and the rejection of the regulatory proposal. He then moved,

**Resolved**, to approve Legislative Proposal 2020-A ~ Renewal of Licenses & Permits (Draft #1), and further, to authorize the filing of same in the Regular Session of the 2020 Legislature upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the legislative process.

Mr. McKay replied to a question from one member; there were no public comments. The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

**Resolved**, to reject Regulatory Proposal 454-2019-16 ~ Pharmacy Permits (Draft #1), and further, to request the Executive Director to communicate this rejection to the commentator who made the request.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- *Item 17&18 ~ Square Footage & Storage Space (Draft #1)*

The committee voted to recommend the approval of a regulatory proposal to repeal certain minimum specifications for pharmacies, including the minimum square footage, counter space, and aisle space, as well as the references to storage space and equipment. Mr. McKay moved,

**Resolved**, to approve Regulatory Proposal 454-2019-17 & 18 ~ Square Footage & Storage Space (Draft #1), and further, to authorize the Executive Director to promulgate the proposed rule amendment upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

Mr. McKay replied to a question from one member; there were no public comments. The motion was adopted after a unanimous vote in the affirmative.

- *Item 22 ~ PIC Change Notice (Draft #1)*

The committee agreed with a request to change the amount of time a pharmacy has to communicate the change of the pharmacist-in-charge (PIC) of the pharmacy, from 10 days to 30 days. The committee noted the proposal does not change the amount of time within which the pharmacy must designate a new PIC after the departure of the previous PIC – that is still 10 days. Mr. McKay moved,

**Resolved**, to approve Regulatory Proposal 454-2019-22 ~ PIC Change Notice (Draft #1), and further, to authorize the Executive Director to promulgate the proposed rule amendment upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

Mr. Aron replied to a question from one member; there were no public comments. The motion was adopted after a unanimous vote in the affirmative.

- *Item 26 ~ Retention of Scanned Prescriptions (Draft #2)*

The committee agreed with a request to remove the one year retention requirement for a hardcopy prescription form after it has been imaged in the pharmacy information system, allowing for the retention of the imaged record for the two year period already required by pharmacy law. Mr.

McKay moved,

**Resolved**, to approve Regulatory Proposal 454-2019-26 ~ Retention of Scanned Prescriptions (Draft #2), and further, to authorize the Executive Director to promulgate the proposed rule amendment upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- *Item 28 ~ DEA Registration on Permit Applications (Draft #1)*

The committee agreed with a request to remove the current language related to a federal DEA registration on the application form for a new pharmacy permit. Mr. McKay moved,

**Resolved**, to approve Regulatory Proposal 454-2019-28 ~ DEA Registration on Permit Applications (Draft #1), and further, to authorize the Executive Director to promulgate the proposed rule amendment upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- *Item 37&38 ~ Electronic Capture of Faxed Prescriptions (Draft #1)*

The committee agreed with a request to amend the current rule to allow for the electronic capture of faxed prescriptions as well as a second request to remove the 2016 expiration date in the current rule. Mr. McKay moved,

**Resolved**, to approve Regulatory Proposal 454-2019-37 & 38 ~ Electronic Capture of Faxed Prescriptions (Draft #1), and further, to authorize the Executive Director to promulgate the proposed rule amendment upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- *Item 39 ~ Technician & Intern Entry of Verbal Prescriptions (Draft #1)*

The committee received a request to expand the current authority for pharmacists to record verbal prescription orders directly into a pharmacy information system without the necessity of preparing a written record, to allow pharmacy interns and pharmacy technicians to also perform such tasks and hold the supervising pharmacist accountable for such actions. The committee voted to recommend the rejection of the proposal. Mr. McKay moved,

**Resolved**, to reject Regulatory Proposal 454-2019-39 ~ Technician & Intern Entry of Verbal Prescriptions (Draft #1), and further, to

request the Executive Director to communicate this rejection to the commentator who made the request.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- *Item 40 ~ Prescription Receipt & Verification (Draft #2)*

The committee received a request to repeal the rule as redundant and unnecessary. While there was support for that idea relative to the first part of the rule concerning receipt of prescriptions, the committee determined it appropriate to clarify the rule relative to verification of prescriptions. Mr. McKay moved,

**Resolved**, to approve Regulatory Proposal 454-2019-40 ~ Prescription Receipt & Verification (Draft #2), and further, to authorize the Executive Director to promulgate the proposed rule amendment upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- *Item 41&43 ~ Refills & Expiration Date of Schedule V Prescriptions (Draft #1)*

The committee agreed with a request to amend the rules for Schedule V prescriptions to align the refill provisions and expiration date of such prescriptions with current federal rule. Mr. McKay moved,

**Resolved**, to approve Regulatory Proposal 454-2019-41 & 43 ~ Refills & Expiration Date of Schedule V Prescriptions (Draft #1), and further, to authorize the Executive Director to promulgate the proposed rule amendment upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- *Item 42 ~ Emergency Refill Authorization (Draft #1)*

The committee agreed with a request to extend the current allowance for emergency refill authorization, from up to a 72-hour supply in the current rule to allow up to a 30-day supply. Mr. McKay moved,

**Resolved**, to approve Regulatory Proposal 454-2019-42 ~ Emergency Refill Authorization (Draft #1), and further to authorize the Executive Director to promulgate the proposed rule amendment upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

Mr. Aron and Mr. McKay replied to questions from several members. There were no public comments. The motion was adopted after a

unanimous vote in the affirmative.

Finally, Mr. McKay closed his report with appreciation to the committee members and staff for their ongoing efforts.

At this point, Mr. Aron re-ordered the agenda to return to the report from the Violations Committee.

*D. Violations Committee*

Mr. Aron called upon Mr. Indovina for the committee report. Mr. Indovina reported the committee held preliminary hearings on September 18, 2019 to consider their posted agenda which included nine cases: four pharmacists, two pharmacy technicians, two pharmacy permits, and one DME permit. Two respondents failed to appear and were scheduled for formal administrative hearings held the day after the Board meeting. After interviews and deliberations at the committee meeting, the committee members voted to take no action against two of the respondents, and to issue non-disciplinary Letters of Noncompliance to three respondents. The members voted to offer proposed voluntary consent agreements to both of the remaining respondents. Both of them accepted their proposals, and Mr. Indovina then presented both recommendations to the Board for its consideration.

**Quality Medical Care & Services, LLC d/b/a Quality Medical Care & Services [Ville Platte, LA] (DME.000259):** Mr. Indovina moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of \$10,000 plus administrative and investigative costs, and further, directed the publication of the Board action in its quarterly newsletter.

**Fred's Stores of Tennessee, Inc. d/b/a Fred's Pharmacy No. 1666 [Franklinton, LA] (PHY.005034):** Mr. Indovina moved to approve the proposed voluntary consent agreement. Mr. Indovina replied to a question from one member; there were no public comments. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the permit, and further, assessed administrative costs. Mr. Indovina reported the store closed permanently on August 22, 2019.

Mr. Indovina then presented the Complaint Investigation Monitor Report. He noted the 179 open cases carried forward from the previous fiscal year, the addition of 143 new cases, and the closure of 126 cases as of November 1, leaving 196 cases still open that day. Of the 126 case closures, the average number of days for staff to complete their case investigation was 60 days. Of the case closures, 5 of them [3.9%] exceeded the policy goal of 180 days for completion of case investigations.

Mr. Indovina reported the committee was scheduled to meet on December

18-19 to consider the 20 cases on that docket, which includes eight pharmacists, one pharmacy technician, and 11 pharmacy permits.

Finally, he concluded his report with appreciation to the other committee members for their ongoing efforts. He also expressed his appreciation for the compliance officers for their work.

At this point, Mr. Aron re-ordered the agenda to Agenda Item 12.

*12. Special Presentation – Contemporary Pharmacy Education (Dr. Michael Cockerham, Associate Dean, ULM College of Pharmacy & Dr. Kristi Rapp, Associate Dean, Xavier College of Pharmacy)*

Mr. Aron invited Dr. Cockerham and Dr. Rapp to deliver their presentation describing the current accreditation standards for pharmacy education and how each school's curriculum delivers contemporary pharmacy education to pharmacy interns. Dr. Cockerham also presented a list of educational resources for currently licensed pharmacists seeking to improve their knowledge base relative to skills not taught in their original pharmacy education. Drs. Cockerham and Rapp replied to questions from several members and guests. Mr. Aron expressed his appreciation to both educators for their presentations.

At this point, Mr. Aron re-ordered the agenda to consider the report from the Executive Committee.

#### *10. Committee Reports*

##### *I. Executive Committee*

Mr. Aron reported the committee had met the previous day to consider the items on their posted agenda. He indicated Mr. McKay was prepared to offer motions on behalf of the committee.

- *Addition of Flavors to Medications*

Mr. Aron reported receipt of a request from FLAVORx, a company that supplies custom flavoring systems to pharmacies. The company was concerned about a recent USP announcement that the USP intends to classify all flavoring of commercially manufactured oral liquid medications as nonsterile compounding, which would require compliance with the standards in USP Chapter 795. The company requested the Louisiana Board promulgate a rule to exempt flavoring of commercially available oral liquid medications from the definition of compounding, and included suggested limitations for the proposed rule such as requiring the flavoring agents to be nonallergenic and inert and for the flavoring agent not to exceed 5% of the drug product's total volume.

Mr. Aron reported the committee reviewed Louisiana's statutory definition of compounding as well as a recent decision by the Arkansas State Board of Pharmacy on the same request by the company to that state board. The committee determined a rule amendment would not be required but suggested an enforcement policy for the Board's compliance officers. Mr. McKay then moved,

**Resolved**, that the Board adopt an enforcement policy such that

the addition of nonallergenic and inert flavoring agents to commercially available liquid oral products resulting in a change in the final product volume of less than 5% shall not require a prescriber's order or a full compounding log.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

- *Orders for Laboratory Testing*

Mr. Aron reported receipt of an inquiry from a laboratory asking whether it was within the scope of practice for a pharmacist to order patient-specific clinical laboratory assessments. The pharmacist in question supplemented the original request with information suggesting at least 30 states permit pharmacists to order and interpret laboratory assessments and provided a copy of the guidelines issued by the California State Board of Pharmacy for pharmacists ordering and managing laboratory tests.

Mr. Aron reported the committee reviewed the statutory definition for the practice of pharmacy. The committee determined additional information would be useful with respect to this request, including whether there are any issues with interpretation of laboratory tests given the inclusion of that activity within the medical practice act, whether there are any limitations on laboratories accepting orders for laboratory tests from pharmacists, and whether such activities should be performed independently by pharmacists or restricted to the confines of collaborative practice agreements. The committee requested staff collect additional information to assist their development of a recommendation for the Board.

At Mr. Aron's suggestion, the board members agreed by consensus to take the request under advisement and requested staff collect further information for the members' consideration.

- *Penicillin Allergy Skin Testing*

Mr. Aron reported receipt of a request from a pharmacist to add penicillin skin testing services to the scope of practice for Louisiana pharmacists. The pharmacist provided information on the unique commercially available prescription drug product as well as relevant articles in professional publications and sample protocols from multiple healthcare facilities.

Mr. Aron reported the committee believed this practice would most likely be restricted to hospital settings and that such activities would likely be governed by hospital policies and procedures approved by medical and pharmacy leadership. The committee also had some of the same questions as the previous topic such as whether pharmacists should have independent authority for such activities or be restricted to the confines of a collaborative practice agreement. The committee requested staff collect additional information to assist their development of a recommendation for the Board.

At Mr. Aron's suggestion, the board members agreed by consensus to take the request under advisement and requested staff collect further information for the members' consideration.

- *Memorandum of Understanding with RxCheck™*

Mr. Aron described RxCheck™ as an interstate information sharing hub which can connect state prescription monitoring programs. Although it could be considered as an alternative to the PMP InterConnect™ system used by the Louisiana PMP, the scope and volume of activity in each of the systems demonstrates the PMP InterConnect™ to be the superior system.

The federal government has recently begun inserting special conditions into its federal grants which require grant fund recipients to connect to RxCheck™. As an example, the La. Dept. of Health has qualified for a federal grant of approximately \$4 million for its opioid crisis activities; however, the federal government has conditioned the award of the grant upon the Board's agreement to connect its PMP to RxCheck™.

In order for the Board to connect its PMP to RxCheck™, the Board must first enter into a Memorandum of Understanding (MOU) with the owner of RxCheck™, the Integrated Justice Information System (IJIS) Institute. Mr. Aron reported the committee reviewed the proposed MOU and voted to recommend its approval to the Board. He cautioned that IJIS has apparently recently demonstrated some tendency to change some of the conditions, so he asked for some flexibility from the Board for any potential changes that might be necessary after the Board's approval and before its final acceptance by IJIS. After considerable discussion by the members, Mr. McKay moved,

**Resolved**, to authorize the Executive Director, upon the instruction of the President, to execute the Memorandum of Understanding with the Integrated Justice Information System Institute, Inc. for the Louisiana Board of Pharmacy, subject to any additional amendments approved by the President of the Board.

Mr. Aron replied to a question from three members. There were no public comments. The motion was adopted after a unanimous vote in the affirmative.

- *Request for Dept. of Health re Hepatitis C Elimination Project*

Mr. Aron reported receipt of two requests from the Dept. of Health relative to their Hepatitis C Elimination Project. The project, which began in July 2019 and runs for a five-year period of time, relies on a unique subscription pricing model for the drug sofosbuvir which is used for the treatment of hepatitis C. The department has a need to identify all Louisiana patients receiving that and other drugs used for the treatment of hepatitis C so it cannot rely solely on Medicaid claims data. The department has requested the addition of those drugs to the list of Drugs of Concern so that all pharmacies will report those transactions to the PMP database, which is accessible to the department's epidemiologist.

Given the adverse impact of hepatitis C on the state's population, the department has requested the implementation of an emergency rule so the department can have access to the data sooner than later.

Mr. Aron reported the committee reviewed both a regulatory proposal to add the requested drugs to the Drugs of Concern list as well as a proposed emergency rule to implement that requirement immediately. After discussion by several members, Mr. McKay moved,

**Resolved**, to approve Regulatory Proposal 2019-J ~ Hepatitis Drugs of Concern (Draft #1), and further, to authorize the Executive Director to promulgate the proposed rule amendment upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

Mr. Aron replied to questions from several members. A representative of the state health department provided information to the members concerning the project and their request to the Board. There were no further public comments. The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

**Resolved**, to approve the Declaration of Emergency for Hepatitis Drugs of Concern, and further, to authorize the Executive Director to file the declaration with all of the offices and agencies required by the Administrative Procedure Act to receive such declarations, and further, to set the effective date of the Emergency Rule for Hepatitis Drugs of Concern as November 13, 2019.

Mr. Aron replied to questions from several members. A representative of the state health department provided additional information to the members. There were no further public comments. The motion failed after a unanimous roll call vote in the negative.

Finally, Mr. Aron closed his report with appreciation for the other committee members and their work the previous day.

At this point, Mr. Aron declared a brief recess. It was noted the members recessed at 3:20 pm and then reconvened at 3:40 pm. Mr. Aron resumed the sequence of the posted agenda.

## 11. Staff Reports

### J. Report of Assistant Executive Director

Mr. Aron called upon Mr. Fontenot for his report. He directed the members to the quarterly report of the prescription monitoring program, detailing the prescription transaction counts as well as queries from prescribers, dispensers, and law enforcement agencies. He answered a question from one member.

Mr. Fontenot then directed the members to the requests from 27 pharmacies seeking a waiver from the duty to report zero prescription transaction reports to the prescription monitoring program. Mr. McKay then moved,

**Resolved**, to authorize the issuance of full PMP reporting waivers to:

- > PHY.007929-NR – America’s Pharmacy Source (OH);
  - > PHY.007958-NR – Blue Sky Specialty Pharmacy (SC);
  - > PHY.007905-HOS – Bridgepoint Continuing Care Hospital – East Jefferson General Hospital Campus (LA);
  - > PHY.007959-NR – Chewy Pharmacy (KY);
  - > PHY.007990-NR – Chewy Pharmacy (AZ);
  - > PHY.007978-HOS – Cobalt Rehabilitation Hospital – New Orleans Campus (LA);
  - > PHY.007972-NR – CVS Specialty Pharmacy No. 48640 (ID);
  - > PHY.007939-HOS – DeQuincy Memorial Hospital (LA);
  - > PHY.007943-NR – ExperienceCare Specialty Pharmacy (TX)
  - > PHY.007955-IR – HaloCare Specialty Therapeutics (LA);
  - > PHY.007999-HOS – Intensive Specialty Hospital (LA);
  - > PHY.002441-CH – M. L. King Center Pharmacy (LA);
  - > PHY.007968-NR – Mississippi Center for Advanced Medicine (MS);
  - > PHY.004512-HOS – Morehouse General Hospital Pharmacy (LA);
  - > PHY.007003-NR – Noble Health Services (NY);
  - > PHY.007966-HOS – North Shore Rehabilitation Hospital (LA);
  - > PHY.007956-HOS – Northshore Extended Care Hospital (LA);
  - > PHY.007933-NR – Omnicare of Spartanburg (SC);
  - > PHY.007964-NR – Onco360 (TX);
  - > PHY.007897-NR – One Choice Pharmacy (TX);
  - > PHY.007957-NR – PANTHERx Specialty Pharmacy (PA);
  - > PHY.007931-NR – PharmaCare Remote Resources (TX);
  - > PHY.007983-HOS – RiverBridge Specialty Hospital (LA);
  - > PHY.007970-NR – Roman Health Pharmacy (NY);
  - > PHY.007975-NR – Roman Health Pharmacy (FL);
  - > PHY.007921-NR – TrustedMedRx (FL); and
  - > PHY.007927-NR – Vital Rx of Tennessee (TN)
- once they have executed the standard consent agreement for that purpose.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

Finally, Mr. Fontenot indicated completion of his report.

**K. Report of General Counsel**

Mr. Aron called upon Mr. Finalet for his report. Mr. Finalet presented the following proposed voluntary consent agreements to the members for their consideration.

**Amber Mone Loup (PST.018248):** Mr. McKay moved to accept the voluntary surrender of the credential. There were no member questions or public comments. The motion was adopted after a unanimous vote in the

affirmative. The Board accepted the voluntary surrender, resulting in the active suspension of the license for an indefinite period of time effective August 16, 2019.

**Kelly Ann Sereal (CPT.010475):** Mr. Soileau moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of \$250 plus administrative costs.

**Amy Rebecca Douglass Johnson (PST.021377):** Mr. McKay moved to accept the voluntary surrender of the credential. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender, resulting in the active suspension of the license for an indefinite period of time effective August 22, 2019.

**William Andrew Fletcher (CPT.013721):** Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Maria Latraz Harrison (CPT.006379):** Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Leslie Ann Huffman (CPT.012424):** Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Arielle Michelle Harris (CPT.013907):** Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Transition Pharmacy, LLC d/b/a Transition Pharmacy [Trevose, PA] (PHY.006813):** Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand; and further, assessed a fine of \$10,000 plus administrative costs.

**Trinity Diane Larson (CPT.014696):** Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Paige Marie Childers (CPT.013387):** Mr. McKay moved to accept the voluntary surrender of the credential. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender, resulting in active suspension of the certificate for an indefinite period of time effective September 9, 2019.

**Billy Joe Reeves (PST.010381):** Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand; and further, assessed a fine of \$1,000 plus administrative costs.

**April Latrice Vaughn (CPT.008865):** Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the certificate effective September 18, 2019; and further, permanently prohibited the acceptance of any future reinstatement application or any other application for any credential issued by the Board.

**Positudes, Inc. d/b/a The Alliance Pharmacy (PHY.006206):** Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand; and further, assessed a fine of \$5,000 plus administrative costs.

**EHT Pharmacy, LLC d/b/a Curexa [Egg Harbor Township, NJ] (PHY.007700):** Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand; and further, assessed a fine of \$10,000 plus administrative costs.

**Keenan Mitchell Wheeler (CPT.010403):** Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the certificate effective October 14, 2019; and further, permanently prohibited the acceptance of any future reinstatement application or any other application for any credential issued by

the Board.

**George Lamar Munn, Jr. (PST.009445):** Mr. McKay moved to accept the voluntary surrender of the credential. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender, resulting in the active suspension of the license for an indefinite period of time effective October 22, 2019.

**Dawn Renee Saltzman (CPT.006791):** Mr. McKay moved to approve the proposed voluntary consent agreement. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Chandler Evan Bennett Riley (PTC.027746):** Mr. McKay moved to accept the voluntary surrender of the credential. There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender, resulting in the active suspension of the registration for an indefinite period of time effective November 13, 2019.

Finally, Mr. Finalet indicated the completion of his report.

*L. Report of Executive Director*

Mr. Aron called upon Mr. Broussard for his report. Mr. Broussard directed the members to his report in the meeting binder. He reviewed the following topics:

- Meeting Activity
- Reports
  - Internal Reports
    - Credentials Division
      - Census Report
      - Licensure Activity Report
      - Application Activity Report
      - Exceptions Report
    - Compliance Division
      - Census Report
      - Complaint Investigation Policy Monitor
  - External Reports
    - Administrative and Legislative Agency Reports
- Examinations
  - MPJE
  - NAPLEX
  - ExCPT
  - PTCE

- Operations
    - Credentials Division
    - Compliance Division
    - Administrative Division
    - Marijuana Pharmacies
  - State Activities
    - La. Dept. of Health – Office of Public Health
    - La. State Board of Medical Examiners
    - La. Dept. of Agriculture & Forestry
    - La. State Board of Optometry Examiners
    - La. Dept. of Health – Bureau of Health Services Financing
    - La. Dept. of Health – Office of Behavioral Health & Bureau of Health Services Financing
  - Regional & National Activities
    - National Association of Boards of Pharmacy (NABP)
    - NABP-AACP District 6
    - MALTAGON
    - Enhancing Well-being & Resilience Among the Pharmacist Workforce – A National Consensus Conference
      - Board member Jackie Hall reported on her attendance and participation in this national invitational conference. She directed the members to the set of 50 consensus recommendations developed at the conference and noted in the report. She indicated the recommendations reflect opportunities to support meaningful and actionable change by addressing improvements in several areas:
        - Pharmacist work conditions and patient safety;
        - Payment models;
        - Relations between pharmacists and employers;
        - Pharmacist and student pharmacist well-being;
        - Well-being education and training;
        - Communications; and
        - Data, information, and research on pharmacist well-being.
    - Ms. Hall indicated her awareness of a recent survey by the Tennessee State Board of Pharmacy of the pharmacists in that state to obtain data relevant to the topic. She questioned whether the Louisiana Board could conduct a similar survey. Mr. Aron directed staff to contact the staff at the Tennessee board and obtain a copy of the survey for discussion by the Board's Executive Committee.
- Food & Drug Administration – *Drug Shortages: Root Causes and Potential Solutions*

- International Activities  
International Pharmaceutical Federation (FIP)  
dotPharmacy Verified Websites Program

Finally, Mr. Broussard indicated the completion of his report.

*13. New Agenda Items Added During Meeting*

One topic was added to the agenda, relative to an interpretation of the pharmacy law relative to the administration of immunizations by pharmacy interns. The new agenda item was discussed and disposed of during the report of the Regulation Revision Committee.

*14. Announcements*

Mr. Aron directed the members to the announcements in their meeting binder. He announced the next meeting of the Board would be held on February 5, 2020 at Xavier University in New Orleans, La.

*15. Recess*

Having completed the tasks itemized on the posted agenda, with no further business pending before the Board and without objection, Mr. Aron recessed the meeting at 4:25 p.m.

\*

\*

\*

An Administrative Hearing was convened on Thursday, November 14, 2019 in the Boardroom of the Board's office, located at 3388 Brentwood Drive in Baton Rouge, Louisiana. The hearing was held pursuant to public notice, each member received notice, each respondent received notice (unless specifically stated otherwise in the official transcript), and public notice was properly posted.

*A. Call to Order*

Mr. Aron called the hearing to order at 8:20 a.m.

*B. Invocation & Pledge*

Mr. Aron called upon Mr. Moore for the invocation. Mr. Cassidy then led the group in the Pledge of Allegiance.

*C. Quorum Call*

Mr. Aron called upon Secretary Indovina and he called the roll of members to establish a quorum. After doing so, he certified Mr. Mannino and Mr. Valentine were absent; however, the remaining 15 members were present, constituting a quorum for the conduct of official business.

*D. Call for Additional Agenda Items & Adoption of Agenda*

Mr. Aron asked if there were any additional agenda items, and none were requested. With no objection, the Board adopted the posted agenda dated October 26, 2019.

### *E. Opportunity for Public Comment*

Mr. Aron reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and prior to the vote on each agenda item. He solicited general comments on non-agenda items from the guests present, and none were offered.

### *Appearances*

Mr. Aron indicated he would serve as the Hearing Officer. Mr. Carlos Finalet served as the Prosecuting Attorney. Ms. Susan Erkle served as the Official Recorder, and Mr. Malcolm Broussard served as the Hearing Clerk.

Mr. Aron informed the members the cases on the agenda originated with the Violations Committee, and that the members of that committee in attendance at their June 11, 2019 meeting would be recused from the hearings. In particular, Dr. Cloud, Ms. Hall, Mr. Indovina, Mr. Robichaux, and Mr. Valentine were excused. He reminded the other members they should recuse themselves should the need arise.

Without objection, Mr. Aron waived the reading of the posted agenda and instead directed the insertion thereof into these minutes. The posted agenda is re-created here.

## **A G E N D A**

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.  
Revised 10-26-2019

- A. Call to Order
- B. Invocation & Pledge of Allegiance
- C. Quorum Call
- D. Call for Additional Agenda Items & Adoption of Agenda
- E. Opportunity for Public Comment
- \* Appearances
- F. Formal Hearings
  - 1. Case No. 18-0502 ~ CPT.007313 – Renee Marie Mims
  - 2. Case No. 19-0135 ~ PST.015945 – Harold Scott Otwell
- G. Adjourn

### *F. Formal Hearings*

With Mr. Aron's approval, Mr. Finalet began the hearings by calling the second case listed on the agenda.

**Harold Scott Otwell (PST.015945)** Mr. Finalet appeared for the Board. The respondent, Harold Scott Otwell, did not appear and was not represented by counsel. Mr. Aron ruled the hearing would proceed as noticed in the form of a

default proceeding. Mr. Finalet offered an opening statement, presented no witnesses and four exhibits and then proffered proposed Findings of Fact, Conclusions of Law, and Board Order. Mr. Finalet tendered the matter to the hearing panel for its consideration. Mr. Soileau moved to enter into executive session for the purpose of deliberating the disciplinary matter and discussing the respondent's professional competency and fitness for practice. There were no member questions or public comments. The motion for executive session was adopted after a unanimous roll call vote in the affirmative.

It was noted the hearing panel entered into executive session at 8:25 a.m. and then reconvened at 8:45 a.m. Mr. Aron returned the hearing panel to open session; he reported no decision was made during the executive session and questioned the members as to their disposition of the case.

Dr. Strong then moved,

**Resolved**, that the hearing panel, having heard the testimony and considered the evidence, accept the Findings of Fact as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. Dr. Strong then moved,

**Resolved**, that the hearing panel accept the Conclusions of Law as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. Dr. Strong then moved,

**Resolved**, that the hearing panel enter the following order at this time:

It is ordered, adjudged, and decreed that Louisiana Pharmacist License No. 15945, held by Harold Scott Otwell, shall be, and is hereby, revoked effective on the entry of this order; and further, the respondent shall pay the following assessments:

- (1) A fine of \$5,000;
- (2) The administrative hearing fee of \$250; and
- (3) The investigative and hearing costs, including the costs of the prosecuting attorney and the official recorder; and

It is further ordered, the acceptance of any future application for the reinstatement of the license or any application for any other credential issued by the Board shall be conditioned upon the satisfaction of the following terms:

- (1) Respondent shall have paid all assessments levied herein;
- (2) Respondent shall have no pending legal or disciplinary matters against him in any jurisdiction; and
- (3) Respondent shall have all pharmacist licenses held in all other jurisdictions reinstated and without restrictions.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

**Renee Marie Mims (CPT.007313)** Mr. Finalet appeared for the Board. The respondent, Renee Marie Mims, did not appear and was not represented by counsel. Mr. Aron ruled the hearing would proceed as noticed in the form of a default proceeding. Mr. Finalet offered an opening statement, presented no witnesses and eight exhibits and then proffered proposed Findings of Fact, Conclusions of Law, and Board Order. Mr. Finalet tendered the matter to the hearing panel for its consideration. Mr. Moore moved to enter into executive session for the purpose of deliberating the disciplinary matter and discussing the respondent's professional competency and fitness for practice. There were no member questions or public comments. The motion for executive session was adopted after a unanimous roll call vote in the affirmative.

It was noted the hearing panel entered into executive session at 9:10 a.m. and then reconvened at 9:35 a.m. Mr. Aron returned the hearing panel to open session; he reported no decision was made during the executive session and questioned the members as to their disposition of the case.

Mr. McKay then moved,

**Resolved**, that the hearing panel, having heard the testimony and considered the evidence, accept the Findings of Fact as proposed by the Prosecuting Attorney, modify them by amending Item 5 to add a second sentence which reads *"The signature log indicates all five prescriptions entered into evidence were signed for by different persons other than the respondent."* [Board Exhibit B3f], adopt the amended findings as our own, and then enter them into the hearing record.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

**Resolved**, that the hearing panel accept the Conclusions of Law as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

**Resolved**, that the hearing panel enter the following order at this time:

It is ordered, adjudged, and decreed that Louisiana Pharmacy Technician Certificate No. 7313, held by Renee Marie Mims, shall be, and is hereby, revoked effective on the entry of this order; and further, the respondent shall pay the following assessments:

- (1) A fine of \$5,000;
- (2) The administrative hearing fee of \$250; and
- (3) The investigative and hearing costs, including the costs of the prosecuting attorney and the official recorder; and

It is further ordered, the acceptance of any future application for the reinstatement of the certificate or any application for any other credential issued by the Board shall be conditioned upon the satisfaction of the following terms:

- (1) Respondent shall have paid all assessments levied herein;
- (2) Respondent shall have no pending legal or disciplinary

- matters against her in any jurisdiction; and
- (3) Respondent shall have received a favorable recommendation for her return to the practice of pharmacy without posing a threat to the public's health, safety, or welfare pursuant to a medical evaluation from an addiction medicine specialist approved by the Board at her own expense.

There were no member questions or public comments. The motion was adopted after a unanimous vote in the affirmative.

Mr. Finalet indicated completion of the cases scheduled for that day. Mr. Aron expressed his appreciation to Ms. Erkle for her recording services that day.

*G. Adjourn*

Having completed the tasks itemized on the posted agenda, with no further business pending before the Board, and without objection, Mr. Aron adjourned the hearing at 9:40 a.m.

Respectfully submitted,

---

Richard M. Indovina, Jr.  
Secretary



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Report on Action Items



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



February 5, 2020

## Agenda Item 6: Report on Action Items

Pursuant to your annual election of officers, we communicated the results of that election in the January 2020 edition of your quarterly newsletter, and we also reported those results to NABP.

During the report from the Finance Committee, you approved the Proposed Budget for Fiscal Year 2020-2021. We reported that budget document to the various administrative and legislative agencies required to receive your budget documents.

During the reports from the Violations, Impairment and Reinstatement Committees and General Counsel, as well as during the Administrative Hearing, you took disciplinary action against a number of credentials. We entered those decisions in the eLicense system which enables their public access in the credential verification module of the Board's website. We filed the required reports on those actions to the NABP Disciplinary Clearinghouse and the National Practitioner Data Bank. We also published your actions in the January 2020 edition of your quarterly newsletter, with the exception of those cases exempted from such publication by your policies.

During the report from the Regulation Revision Committee, you approved three regulatory proposals for promulgation:

- *Proposal 2019-C ~ Automated Medication Systems*
- *Proposal 2019-F ~ Prescription Monitoring Program*
- *Proposal 2019-H ~ Pharmacist License Display*

We initiated the promulgation process by filing the required documents with the Occupational Licensing Review Commission on Nov. 25. We have received notice all three projects have been placed on the agenda for the Commission's next meeting on February 28.

With respect to Regulatory Project 454-2019, you reviewed several proposals from the committee, with the following results:

- You approved *Item 01 ~ Rest Breaks* without amendment;
- You approved *Item 03 ~ Medication Administration* with amendments;
- You approved *Legislative Proposal 2020-A ~ Renewal of Licenses & Permits* without amendment, and you rejected *Item 16 ~ Pharmacy Permits*;
- You approved *Items 17 & 18 ~ Square Footage & Storage Space* without amendment;
- You approved *Item 22 ~ PIC Change Notice* without amendment;
- You approved *Item 26 ~ Retention of Scanned Prescriptions* without amendment;
- You approved *Item 28 ~ DEA Registration on Permit Applications* without amendment;
- You approved *Items 37 & 38 ~ Electronic Capture of Faxed Prescriptions* without amendment;
- You rejected *Item 39 ~ Technician & Intern Entry of Verbal Prescriptions*;
- You approved *Item 40 ~ Prescription Receipt & Verification* without amendment;
- You approved *Items 41 & 43 ~ Refills & Expiration Date of Schedule V Prescriptions* without amendment; and
- You approved *Item 42 ~ Emergency Refill Authorizations* without amendment.

For the items you approved with or without amendments, we will hold those items until the committee reports the remaining items to you for your consideration. When you complete your work on those remaining items, we will then initiate the promulgation process for all of the items in the project at the same time. For the items you rejected, we will inform the commentator who

requested those changes when we file the required report to the legislative oversight committee. A copy of the [Project 454-2019 Summary Report](#) is attached to this report. During the committee report, more specifically during your consideration of the proposed amendment of Section 521 of the Board's rules relative to medication administration, you adopted an interpretation of La. R.S. 37:1218 and 1218.1 relative to the administration of immunizations without medical orders by pharmacy interns. We added that formal interpretation to your [Policy & Procedure Manual](#), and we also posted that document in the *Public Library* section of your website.

During the report from the Executive Committee, you approved three documents, rejected one proposal, and took two items under advisement.

- With respect to the request for a new rule exempting the addition of flavoring agents to prescription medications from the definition of compounding, you declined to promulgate a new rule. Instead, you adopted an enforcement policy statement. We communicated your decision to the firm filing the request. We added that policy document to your [Policy & Procedure Manual](#), and we also posted that policy document in the *Public Library* section of your website.
- With respect to the proposed Memorandum of Understanding with Integrated Justice Information Systems (IJIS) Institute to enable access to the alternative RxCheck hub for state prescription monitoring programs, you approved that document with permission for the Board President to approve any acceptable amendments that might become necessary subsequent to your approval. On Nov. 22, we executed that document on your behalf with no amendments.
- You approved *Regulatory Proposal 2019-J ~ Hepatitis Drugs of Concern* without amendment. You rejected the associated proposed *Declaration of Emergency for Hepatitis Drugs of Concern*. Subsequent to your meeting, the Board President authorized the combination of this regulatory proposal with *Proposal 2019-F ~ Prescription Monitoring Program*. Since both proposals affect language in the chapter of rules for the state prescription monitoring program, it was determined appropriate to combine both proposals into [Regulatory Project 2020-1 ~ Prescription Monitoring Program](#). We initiated the promulgation process for that project by filing the required documents with the Occupational Licensing Review Commission on Nov. 25. A copy of the [Project Promulgation Record](#) is attached to this report.
- With respect to the requests relative to orders for laboratory testing as well as penicillin skin testing, you took both requests under advisement and requested staff development of one or more proposals for your consideration.

You previously approved proposed action plans for several new laws. A copy of the [Legislative Action Plan Implementation Report](#) is attached to this report.

During the report from the Assistant Executive Director, you approved requests from 27 pharmacies for waivers from the PMP reporting requirement contingent upon their execution of the standard consent agreement for that purpose. The staff has forwarded those consent agreements to the requesting pharmacies and recorded the exceptions for those pharmacies properly executing those agreements.

During the report from the Executive Director, you requested a copy of a pharmacist survey conducted by the Tennessee State Board of Pharmacy relative to pharmacist well-being. Staff obtained a copy of those survey questions and provided it to the Executive Committee.

Respectfully submitted,  
Malcolm J Broussard  
Executive Director

Louisiana Board of Pharmacy  
Regulatory Project 454-2019

<u>Item No.</u>	<u>Source</u>	<u>Rule</u>	<u>Request</u>	<u>Preliminary Decision</u>	<u>Current Status of Request</u>
1	Nguyen, K.	(none)	Requested mandatory lunch breaks for pharmacists	Assigned to Cmte	Item 1 11/13/2019 Board approved Draft #2
2	NACDS	§511	Remove requirement to notify Board of employment changes	Board declined to change	Item 2 9/3/2019 Board gave notice
3		§521.B	Eliminate separate Authority to Administer document, allowing the prescription for the medication to allow that activity, for the life of the prescription.	Assigned to Cmte	Item 3 11/13/2019 Board approved Draft #2
4		§709.B	Eliminate ratios for pharmacy interns.	Assigned to Cmte	Item 4 2/5/2020 On Board agenda
5		§901	Amend definition of pharmacy technician training program to allow the Board to approve programs that are not nationally accredited.	Board declined to change	Item 5 9/3/2019 Board gave notice
6		§903.A.2.c.i	Change proof of enrollment requirement for pharmacy technician training program, to allow either nationally accredited or board approved, but not both.	Board declined to change	Item 6 9/3/2019 Board gave notice
7		§903.A.3.f	Remove requirement for pharmacy technicians and pharmacy technician candidates to notify the Board of pharmacy employment changes.	Board declined to change	Item 7 9/3/2019 Board gave notice
8		§903.B.2	Eliminate requirement for pharmacy technician training programs to notify the Board when pharmacy technician candidates separate from the program.	Board declined to change	Item 8 9/3/2019 Board gave notice
9		§903.D.1	Remove board approval of pharmacy technician certification examinations and specify such examinations must be accredited by National Commission for Certifying Agencies.	Board declined to change	Item 9 9/3/2019 Board gave notice
10		§903.D.2	Remove time delay on re-examination for technicians.	Project 2019-9 in process	Item 10 12/27/2019 Public hearing
11		§905.A.3.a	Amend eligibility for pharmacy technician certificate to allow for completion of either a nationally-accredited or a board-approved training program.	Board declined to change	Item 11 9/3/2019 Board gave notice
12		§905.A.3.b	Reduce the experiential training requirement for pharmacy technician candidates, from 600 hours to 320 hours (8 weeks), or in the alternative, 400 hours as required by PTCB.	Assigned to Cmte	Item 12 2/5/2020 On Board agenda
13		§907.A.2	Eliminate staffing ratios for pharmacy technician candidates and pharmacy technicians.	Assigned to Cmte	Item 13 1/22/2020 Cmte deferred consideration

Louisiana Board of Pharmacy  
Regulatory Project 454-2019

<u>Item No.</u>	<u>Source</u>	<u>Rule</u>	<u>Request</u>	<u>Preliminary Decision</u>		<u>Status of Request</u>
14	§907.A.3		Re-frame the scope of practice for pharmacy technicians and pharmacy technician candidates from a list of prohibited tasks to a list of permitted tasks, citing a list of activities associated with medication dispensing and assisting with clinical duties.	Board declined to change	Item 14	9/3/2019 Board gave notice
15	§1101.C		Remove the requirement for the signature of the PIC on the application for a new pharmacy permit, and require only the name of the PIC on the form.	Board declined to change	Item 15	9/3/2019 Board gave notice
16	§1101.C.2		Change the pharmacy permit renewal cycle, from annual to biennial.	Assigned to Cmte	Item 16	11/13/2019 Board rejected Draft #1
17	§1103		Remove structural requirements such as square footage, counter space, and aisle space.	Assigned to Cmte	Item 17	11/13/2019 Board approved Draft #1
18	§1103.H.1		Remove the first sentence specifying storage space.	Assigned to Cmte	Item 18	11/13/2019 Board approved Draft #1
19	§1103.K		Remove the requirement for a printed law book.	Project 2019-17 in process	Item 19	12/27/2019 Public hearing
20	§1105.A.1.b		Reduce the amount of practice experience to qualify for a PIC privilege, from 2 years to either 6 months or one year.	Board declined to change	Item 20	9/3/2019 Board gave notice
21	§1105.A.2		Remove the minimum number of hours a PIC must be physically present and practicing in the pharmacy.	Board declined to change	Item 21	9/3/2019 Board gave notice
22	§1105.I		Change the amount of time a pharmacy has to give notice of a change in the PIC of the pharmacy.	Assigned to Cmte	Item 22	11/13/2019 Board approved Draft #1
23	§1109		Clarify that a pharmacist assisting a patient in a clinical capacity does not create a pharmacist absence from the pharmacy.	Board agreed to clarify	Item 23	9/3/2019 Board issued clarification
24	§1111		Clarify that a pharmacist assisting a patient in a clinical capacity does not create a temporary absence from the pharmacy.	Board agreed to clarify	Item 24	9/3/2019 Board issued clarification
25	§1113		Repeal the prohibition on mechanical dispensing devices, or allow when approved by the Board.	Proposal 2019-C in Cmte	Item 25	11/13/2019 Board approved Draft #7; now Project 2020-2.
26	§1123.K.2		Remove the requirement to store hardcopy prescription forms for one year, in favor of allowing imaging systems to retain those records for at least two years.	Assigned to Cmte	Item 26	11/13/2019 Board approved Draft #2.
27	§1131.A.1		Remove the requirement for a PIC signature, in favor of the signature of an authorized representative.	Board declined to change	Item 27	9/3/2019 Board gave notice
28	§1131.A.4		For pharmacy opening procedures, remove the language relative to a federal DEA registration.	Assigned to Cmte	Item 28	11/13/2019 Board approved Draft #1

Louisiana Board of Pharmacy  
Regulatory Project 454-2019

<u>Item No.</u>	<u>Source</u>	<u>Rule</u>	<u>Request</u>	<u>Preliminary Decision</u>	<u>Item</u>	<u>Date</u>	<u>Status of Request</u>
29	§1201		Amend the definition of 'final check of work' to allow for technology solutions in lieu of mandatory human checks.	Proposal 2019-C in Cmte	Item 29	11/13/2019	Board approved Draft #7; now Project 2020-2.
30	§1207.A		Amend the rule to designate the PIC or verifying pharmacist as accountable for the accuracy of the automated medication system, with additional clarification that counting machines are not considered as automated medication systems.	Proposal 2019-C in Cmte	Item 30	11/13/2019	Board approved Draft #7; now Project 2020-2.
31	§2307.A.1.c		Remove the two-year practice requirement for the PIC privilege.	Board declined to change	Item 31	9/3/2019	Board gave notice
32	§2425.A.1		Reduce the mileage distance for telepharmacy dispensing sites, from 20 miles to 10 miles.	Project 2019-4 in process	Item 32	12/27/2019	Public hearing
33	§2425.A.6		Remove the requirement for a telepharmacy dispensing site to close if a new community pharmacy opens within 20 miles of the telepharmacy dispensing site.	Project 2019-4 in process	Item 33	12/27/2019	Public hearing
34	§2425.E.2.c		Remove references to staffing parameters and staffing ratios.	Assigned to Cmte	Item 34	1/22/2020	Cmte deferred consideration
35	§2425.E.3.g		Amend patient counseling rule in telepharmacy dispensing site to require such counseling only on new prescriptions and only require an offer to counsel for prescription refills.	Assigned to Cmte	Item 35	1/22/2020	Cmte deferred consideration
36	§2511.C.1		Remove the minimum size of a prescription form.	Board declined to change	Item 36	9/3/2019	Board gave notice
37	§2511.C.5		Allow for electronic capture of facsimile prescriptions.	Assigned to Cmte	Item 37	11/13/2019	Board approved Draft #1
38	§2511.C.5.d		Remove the 2016 expiration date.	Assigned to Cmte	Item 38	11/13/2019	Board approved Draft #1
39	§2511.D.1		Allow a pharmacy intern or pharmacy technician to enter a transcription of a verbal prescription directly into a pharmacy information system, with the pharmacist held accountable.	Assigned to Cmte	Item 39	11/13/2019	Board rejected Draft #1
40	§2513		Repeal the section on receipt and verification of prescriptions as redundant and unnecessary.	Assigned to Cmte	Item 40	11/13/2019	Board approved Draft #2
41	§2519.B.2		Remove C-V prescriptions, in alignment with 21 CFR 1306.22.	Assigned to Cmte	Item 41	11/13/2019	Board approved Draft #1
42	§2521		Extend the 72-hour allowance for emergency refills to a 30-day supply, or in the alternative, an exception for unit-of-use items.	Assigned to Cmte	Item 42	11/13/2019	Board approved Draft #1
43	§2525.B.2		Remove the 6-month expiration for C-V prescriptions	Assigned to Cmte	Item 43	11/13/2019	Board approved Draft #1
44	§2733.C.1.a		Remove the annual inventory requirement for controlled substances in pharmacies as unnecessary.	Board declined to change	Item 44	9/3/2019	Board gave notice
45	§2747.B.5		Allow for the partial dispensing of Schedule II prescriptions when requested by patients.	Project 2019-12 in process	Item 45	12/27/2019	Public hearing

Louisiana Board of Pharmacy  
Regulatory Project 454-2019

<u>Item No.</u>	<u>Source</u>	<u>Rule</u>	<u>Request</u>	<u>Preliminary Decision</u>		<u>Status of Request</u>
46	CVS Health	§907	Eliminate staffing ratios for pharmacy technician candidates and pharmacy technicians. <i>[Duplicate of Item 13]</i>	Assigned to Cmte	Item 46	1/22/2020 Cmte deferred consideration
47		§1109	Clarify that a pharmacist assisting a patient in a clinical capacity does not create a pharmacist absence from the pharmacy.	Board agreed to clarify	Item 47	9/3/2019 Board issued clarification
48		§1111	Clarify that a pharmacist assisting a patient in a clinical capacity does not create a temporary absence from the pharmacy.	Board agreed to clarify	Item 47	9/3/2019 Board issued clarification

Louisiana Board of Pharmacy  
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2020-3	Pharmacist Display of License	2/28/2020						OLRC hearing for approval to begin promulgation process
2020-2	Automated Medication Systems	2/28/2020						OLRC hearing for approval to begin promulgation process
2020-1	Prescription Monitoring Program	2/28/2020						OLRC hearing for approval to begin promulgation process
2019-18	Cannabis MDI	11/20/2019 9/3/2019	12/27/2019					OLRC issued waiver from 1st review
2019-17	Pharmacy Records	11/20/2019 8/29/2019	12/27/2019					OLRC approved initiation of promulgation
2019-16	Pharmacy Compounding	11/20/2019 8/29/2019	12/27/2019					OLRC approved initiation of promulgation
2019-15	Drug Disposal by Pharmacies	11/20/2019 8/29/2019	12/27/2019					OLRC approved initiation of promulgation
454-2019	Comments on Entirety of Rules	5/20/2019	6/26/2019					
2019-14	Rulemaking Procedures	11/20/2019 4/22/2019	12/27/2019					OLRC issued waiver from 1st review
2019-13	CDS License for 3PL Providers	11/20/2019 4/22/2019	12/27/2019					OLRC issued waiver from 1st review
2019-12	Partial Fill of C-II Prescriptions	11/20/2019 4/22/2019	12/27/2019					OLRC issued waiver from 1st review
2019-11	Continuing Education Records	11/20/2019 8/29/2019	12/27/2019					OLRC approved initiation of promulgation

Louisiana Board of Pharmacy  
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2019-10	License Transfer for Pharmacy Technicians	11/20/2019 8/29/2019	12/27/2019 OLRC approved initiation of promulgation					
2019-9	Delays of Licensure Examinations	11/20/2019 8/29/2019	12/27/2019 OLRC approved initiation of promulgation					
2019-8	Dispensing of Prescription Refills	11/20/2019 4/12/2019	12/27/2019 OLRC issued waiver from 1st review					
2019-7	Veterinary Hospital Pharmacy	11/20/2019 4/12/2019	12/27/2019 OLRC issued waiver from 1st review					
2019-6	Prescription Monitoring Program	With additional PMP-related regulatory proposals, this project was deferred in favor of Project 2020-1 (see above). 4/12/2019 OLRC issued waiver from 1st review						
2019-5	Correctional Center Pharmacies	11/20/2019 4/12/2019	12/27/2019 OLRC issued waiver from 1st review					
2019-4	Telepharmacy Dispensing Sites	11/20/2019 8/29/2019	12/27/2019 OLRC approved initiation of promulgation					
2019-3	Investigational Drugs	11/20/2019 4/12/2019	12/27/2019 OLRC issued waiver from 1st review					
2019-2	Pharmacy Immunizations	11/20/2019 4/12/2019	12/27/2019 OLRC issued waiver from 1st review					
2019-1B	Licensing of Marijuana Pharmacies	11/20/2019 8/29/2019	12/27/2019 OLRC approved initiation of promulgation					
2019-1A	Marijuana Pharmacies	4/20/2019 3/20/2019 9/3/2019	5/29/2019 OLRC issued waiver from 1st review OLRC issued waiver from 2nd review	9/3/2019	[none]	10/20/2019		

Louisiana Board of Pharmacy  
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2018-3	Drugs of Concern - Naloxone	9/20/2018	10/26/2018	12/3/2018	[none]	1/20/2019	2019	2/26/2019
2018-2	La. Uniform Prior Authorization	8/20/2018	9/28/2018	10/25/2018	[none]	12/20/2018 <i>Delayed effective date: 1/1/2019</i>	2019	2/26/2019
2018-1	Pharmacy Benefit Managers	5/20/2018	6/25/2018	9/11/2018	10/8/2018	<i>Sen. H&amp;W Cmte rejected proposed rule.</i>		
2017-2	Equivalent Drug Product Interchange	4/20/2017	5/30/2017	9/27/2017	[none]	11/20/2017	11/20/2017	2/6/2018
2017-1	Internship Requirements	4/20/2017	5/30/2017	9/27/2017	[none]	11/20/2017 <i>Delayed effective date: 1/1/2018</i>	1/1/2018	2/6/2018
2016-6	Marijuana Pharmacy	1/20/2017	3/2/2017 6/26/2017	<i>Comments prompted substantive revision, requiring a second public hearing</i> 7/5/2017		8/20/2017	2017	2/6/2018
2016-5	Reinstatement of CDS License	11/17/2016 3/15/2017	Emergency Rule #1 issued; it expired 3/17/2017. Emergency Rule #2 issued; it was cancelled upon publication of the Final Rule.			1/20/2017	2017	2/6/2018
2016-4	Standing Orders for Distribution of Naloxone	8/10/2016 12/7/2016 4/5/2017	Emergency Rule #1 issued; it expired 12/8/2016. Emergency Rule #2 issued; it expired 4/6/2017. Emergency Rule #3 issued; it was cancelled upon publication of the Final Rule.			1/20/2017	2017	2/6/2018
2016-3	Medication Synchronization	4/20/2016	5/25/2016	8/1/2016	[none]	9/20/2016	2016	2/1/2017
2016-2	Pharmacist-in-Charge of Nonresident Pharm	4/20/2016	5/25/2016	11/14/2016	[none]	1/20/2017	2017	2/6/2018
2016-1	CDS Prescriptions	4/20/2016	5/25/2016	6/3/2016	[none]	7/20/2016	2016	2/1/2017

Louisiana Board of Pharmacy  
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2015-9	Accreditation of Technician Training Program	11/30/2015 3/24/2016 7/21/2016 11/17/2016 3/15/2017 7/10/2017 11/6/2017  1/20/2017	Emergency Rule #1 issued; it expired 3/28/2016. Emergency Rule #2 issued; it expired 7/22/2016. Emergency Rule #3 issued; it expired 11/18/2016. Revised Emergency Rule issued; it expired 3/17/2017 Emergency Rule #5 issued; it expired 7/13/2017 Emergency Rule #6 issued; it will expire 11/7/2017 Emergency Rule #7 issued; it was cancelled upon publication of the Final Rule.  3/1/2017 6/26/2017	<i>Comments prompted substantive revision, requiring a second public hearing</i> 11/6/2017	[none]	12/20/2017 <i>Delayed effective date: 1/1/2018</i>	1/1/2018	2/6/2018
2015-8	Remote Access to Medical Orders	7/20/2015	8/26/2015	9/8/2015	[none]	10/20/2015	2016	2/22/2016
2015-7	Remote Processor Pharmacy Permit	7/20/2015	8/26/2015	9/8/2015	[none]	10/20/2015	2016	2/22/2016
2015-6	Telepharmacy Services Permit	7/20/2015	8/26/2015	9/8/2015	[none]	10/20/2015	2016	2/22/2016
2015-5	Electronic Signature on Fax Prescription	6/1/2015 9/21/2015  7/20/2015	Emergency Rule; will expire on 09/30/2015 Emergency Rule re-issued; will expire on publication of Final Rule.  8/26/2015	9/8/2015	[none]	10/20/2015	2016	2/22/2016
2015-4	Compounding for Office Use for Veterinarians	6/1/2015 9/21/2015 1/15/2016 2/24/2016 7/20/2015	Emergency Rule; will expire on 09/28/2015 Emergency Rule re-issued; will expire on 01/19/2016 Emergency Rule re-issued; will expire on 05/14/2016 Emergency Rule re-issued; will expire on publication of Final Rule 8/26/2015 4/19/2016	<i>Comments prompted substantive revision, requiring a second public hearing</i> 5/10/2016	[none]	6/20/2016	2016	2/1/2017
2015-3	Electronic Product Verification	4/20/2015	6/25/2015	6/29/2015	[none]	8/20/2015	2016	2/22/2016
2015-2	Expiration Date of Schedule II Prescriptions	12/20/2014	1/28/2015	3/3/2015	[none]	4/20/2015	2016	2/22/2016

Louisiana Board of Pharmacy  
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2015-1	Dispenser Reporting to PMP	12/20/2014	1/28/2015	3/3/2015	[none]	4/20/2015	2016	2/22/2016
2014-6	Special Event Pharmacy Permit	9/20/2014	10/30/2014	11/18/2014	[none]	1/20/2015	3/15/2015	2/22/2016
2014-5	Prescriptions	6/20/2014	7/28/2014 10/30/2014	<i>Comments prompted substantive revision, requiring a second public hearing</i> 11/18/2014		1/20/2015	3/15/2015	2/22/2016
2014-4	Pharmacy Compounding	8/8/2014 12/5/2014	Emergency Rule - valid for 120 days Emergency Rule re-issued; expired on publication of Final Rule on 1/20/2015.					
		9/20/2014	10/30/2014	11/18/2014	[none]	1/20/2015	3/15/2015	2/22/2016
2014-3	Pharmacy Records	3/20/2014	4/29/2014 9/30/2014	<i>Comments prompted substantive revision, requiring a second public hearing</i> 10/3/2014		11/20/2014	3/15/2015	3/13/2015
2014-2	Veterinarian Exclusion from PMP	3/20/2014	4/29/2014	5/8/2014	[none]	6/20/2014	3/15/2015	3/13/2015
2014-1	PMP Delegates	3/20/2014	4/29/2014	5/8/2014	[none]	6/20/2014	3/15/2015	3/13/2015
2013-06	Penal Pharmacy Permit Revision	7/20/2013	8/27/2013	10/3/2013	[none]	11/20/2013	1/15/2014	2/7/2014
2013-05	Collaborative Drug Therapy Management	7/20/2013	8/27/2013	11/8/2013	[none]	12/20/2013	1/15/2014	2/7/2014
2013-04	Preferential Licensing for Military Personnel	7/20/2013	8/27/2013	9/23/2013	[none]	11/20/2013	1/15/2014	2/7/2014
2013-03	Technician Training Programs [Chap. 9]	4/20/2013	5/30/2013	6/4/2013	[none]	7/20/2013	1/15/2014	2/7/2014
2013-02	Hospital Off-Site Satellite Pharmacies [Chap.	1/20/2013	2/27/2013	3/15/2013	[none]	5/20/2013	1/15/2014	2/7/2014

Louisiana Board of Pharmacy  
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2013-01	Compounding for Prescriber Use ~ ER-1	12/13/2012	Emergency Rule - valid for 120 days		1/18/2013	<i>Sen H&amp;W Cmte rejected Emergency Rule</i>		
	Compounding for Prescriber Use ~ ER-2	1/31/2013 5/29/2013 9/27/2013 2/6/2014 4/4/2014	Replacement Emergency Rule - valid for 120 days Replacement Emergency Rule re-issued - expired 8/4/2014; see Project 2014-4 above for new ER					
	Compounding for Prescriber Use [Chap 25]	1/20/2013  1/20/2014	2/27/2013 5/30/2013	<i>Comments prompted substantive revision, requiring a second public hearing</i> <i>Comments prompted substantive revision; additional hearing required</i>				
			Time has expired for the 2013 Notice of Intent - New Project & Notice of Intent required.					
2012-11	DME Permit [Chapter 24]	11/20/2012	12/27/2012	1/5/2013	[none]	3/20/2013	4/15/2013	2/7/2014
2012-10	PMP [Chapter 29]	7/20/2012	8/27/2012	1/2/2013	[none]	2/20/2013	4/15/2013	3/8/2013
2012-09	CDS in EDK [§1713, 2743]	7/20/2012	8/27/2012	1/2/2013	[none]	2/20/2013	4/15/2013	3/8/2013
2012-08	CDS Lic. For Non-Resident Distributor [§2705]	7/20/2012	8/27/2012	1/2/2013	[none]	2/20/2013	4/15/2013	3/8/2013
2012-07	Security of Rx Dept [§1103]	7/20/2012	8/27/2012	1/2/2013	[none]	2/20/2013	4/15/2013	3/8/2013
2012-06	Interstate Remote Processing [§1139, 1143]	7/20/2012	8/27/2012	1/2/2013	[none]	2/20/2013	4/15/2013	3/8/2013
2012-05	Institutional Pharmacy [§1705, 1727]	7/20/2012	8/27/2012	1/2/2013	[none]	2/20/2013	4/15/2013	3/8/2013
2012-04	Chapter 24 - DME Permits ~ Emergency Rule	5/2/2012 8/31/2012 12/28/2012	Emergency Rule - valid for 120 days Emergency Rule re-issued - valid for 120 days Emergency Rule re-issued - valid for 120 days					2/7/2014 2/7/2014 2/7/2014
2012-03	Remote Processing [§1143, 1525]	1/20/2012	2/28/2012	3/19/2012	[none]	5/20/2012	4/15/2013	3/8/2013
2012-02	Hospital Pharmacy [§1501, 1512, 1513]	1/20/2012	2/28/2012	3/19/2012	[none]	5/20/2012	4/15/2013	3/8/2013

Louisiana Board of Pharmacy  
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2012-01	E-Communications [§505, 905, 1203]	1/20/2012	2/28/2012	3/19/2012	[none]	5/20/2012	4/15/2013	3/8/2013
2011-07	Penal Pharmacy [Chapter 18]	1/20/2012	2/28/2012	3/19/2012	[none]	5/20/2012	4/15/2013	3/8/2013
2011-02	Cognitive Services [§525]	1/20/2012	2/28/2012	3/19/2012	[none]	5/20/2012	4/15/2013	3/8/2013
2011-01	PIC Requirements [§1105]	1/20/2012	2/28/2012	3/19/2012	[none]	5/20/2012	4/15/2013	3/8/2013
2009-04	Digital Imaging of Prescriptions [§1123]	12/20/2009	1/27/2010	2/26/2010	[none]	4/20/2010	1/31/2011	4/5/2011
2009-03	Prescription Transfers [§2523]	12/20/2009	1/27/2010	2/26/2010	[none]	4/20/2010	1/31/2011	4/5/2011
2009-02	Pharmacy Interns [§709]	12/20/2009	1/27/2010	2/26/2010	[none]	4/20/2010	1/31/2011	4/5/2011
2009-01	Drugs of Concern [§2901]	12/20/2009	1/27/2010	2/26/2010	[none]	4/20/2010	1/31/2011	4/5/2011
2008-03	CDS [Chapter 27]	6/20/2008	7/30/2008	8/21/2008	[none]	10/20/2008	1/31/2011	3/16/2009
2008-02	Pharmacies [§1107.B + §1727]	4/20/2008	5/28/2008	6/2/2008	[none]	7/20/2008	1/31/2011	3/16/2009
2008-01	Pharmacy Interns [ §521.G + §705.C]	4/20/2008	5/28/2008	6/2/2008	[none]	7/20/2008	1/31/2011	3/16/2009
2007-01	Prescription Monitoring Program [Chapter 29]	4/20/2007	5/30/2007	6/5/2007	[none]	7/20/2007	1/31/2011	2/13/2008
2006-03	Pharmacy Practice	11/20/2006 3/30/2007	12/27/2006 4/20/2007	<i>Comments prompted substantive revision, requiring a second public hearing</i> 5/3/2007		6/20/2007	1/31/2011	2/13/2008
2006-02	Proposal No. 2006-11 - Certified Preceptors	9/20/2006	10/30/2006	11/1/2006	[none]	12/20/2006	1/31/2011	3/30/2007
2006-01	Proposal No. 2006-11 - Certified Preceptors	9/1/2006	Emergency Rule - valid for 120 days		[none]	N/A	N/A	3/30/2007
2005-03	§705 - Practical Experience for Interns	12/20/2005	1/25/2006	1/30/2006	[none]	4/20/2006	9/1/2006	3/30/2007
2005-02	§705 - Practical Experience for Interns	12/20/2005	Emergency Rule - valid for 120 days		[none]	N/A	N/A	3/30/2007

Louisiana Board of Pharmacy  
Regulatory Projects - Promulgation Record

Project No.	Project Name	1st Report Notice of Intent	Public Hearing	2nd Report Hearing Record	Oversight Hearing	Final Rule Published	Law Book Published	3rd Report Completion
2005-01	§907 - Scope of Practice for Technicians	6/20/2005	7/27/2005	8/25/2005 1/30/2006	<i>Refiled report due to disruption caused by Hurricanes Katrina &amp; Rita</i>			
					2/14/2006	6/20/2006	9/1/2006	3/30/2007
2004-01	Chapter 8 →Chapter 9: Pharmacy Technician	8/20/2004	9/27/2004	10/5/2004	[none]	11/20/2004	1/1/2005	3/18/2005
2003-01	Complete Revision of Board Rules	7/20/2003	8/26/2003	8/28/2003	[none]	10/20/2003	1/1/2004	2/27/2004
2001-01	§1109 - Prescription Forms	9/20/2001	10/25/2001	11/5/2001	[none]	11/20/2001	1/1/2002	N/A
2000-04	Chapter 7 - Pharmacy Interns	6/20/2000	7/27/2000	8/28/2000	[none]	10/20/2000	12/1/2000	N/A
2000-03	Chapter 8 - Pharmacy Technicians	4/20/2000 7/20/2000	5/30/2000 8/24/2000	7/5/2000 8/28/2000	<i>Comments prompted substantive revisions, requiring a 2nd hearing</i>			
					[none]	10/20/2000	12/1/2000	N/A
2000-02	§3517 - Drug Donations / Charitable Pharmac	4/20/2000	5/30/2000	6/20/2000	[none]	8/20/2000	10/1/2000	N/A
2000-01	§3517 - Drug Donations / Charitable Pharmac	3/20/2000	Emergency Rule - valid for 120 days		[none]	N/A	N/A	N/A
1999-01	Chapter 12 - Automated Medication Systems	9/20/1999	11/29/1999	3/13/2000	[none]	6/20/2000	6/1/2000	N/A

Louisiana Board of Pharmacy  
Action Plans to Implement Legislation

<u>Bill</u>	<u>Act</u>	<u>Topic</u>	<u>Citation(s)</u>	<u>Law Book</u>	<u>Rules</u>	<u>PPM</u>	<u>Guidance</u>	<u>Forms</u>	<u>Completion</u>
HB 138	2019-354	Revised definitions; new drugs in Schedule I	40:961 and 964	8/1/2019					8/1/2019
HB 243	2019-423	Reporting of opioid-related overdoses	40:978.2.1	8/1/2019					8/1/2019
HB 284	2019-426	Prescriber overrides of 7-day supply	40:978(G)(2)	8/1/2019					8/1/2019
HB 358	2019-284	Cannabis metered-dose inhalers	40:1046(A)(1)	8/1/2019	Reg. Project 2019-18 in process				
HB 375	2019-219	CBC for CDS license applicants	40:973.1	8/1/2019	Assigned to Cmte				
HB 423	2019-227	Repeal of student loan disqualifications	37:2951 repealed					8/1/2019	8/1/2019
HB 433	2019-161	Pharmacist may decline to fill prescription	37:1219(D through F)	8/1/2019	Board determined no rule needed				8/14/2019
HB 452	2019-231	Scheduling of mitragynine	40:964 and 40:989.3	8/1/2019					8/1/2019
HB 491	2019-164	Hemp-derived CBD oil products	40:961.1	8/1/2019			8/14/2019		8/14/2019
HB 507	2019-331	7% tax on gross sales of marijuana products	40:1046(H)(8)(a)	8/1/2019					8/1/2019
HB 614	2019-256	Public notice for public records	44:33.1(B)						8/1/2019
SB 41	2019-124	Licensure and regulation of PBMs	37:1252 et seq; 40:2861 et seq	8/1/2019	Reg. Proposal 2019-G in Cmte				
SB 53	2019-080	Access to PMP by federal jurisdictions	40:1007(G)	8/1/2019	Reg. Project 2020-1 in process				
SB 99	2019-052	Board member qualifications	37:1174(A)(4)	8/1/2019	Board determined no rule needed				8/14/2019
SB 119	2019-351	Palliative Care Advisory Council	40:2018.6			PPM.I.B.6			8/14/2019
SB 241	2019-204	Revision of APA re small business impact	49:953 et seq				OSR		10/7/2019





**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Special Orders of the Day

### Presentation of Pharmacist Gold Certificates

In recognition of 50 years of licensed practice

PST.009577 issued to Steve Vincent Campo on 08-28-1969

PST.009589 issued to Reuben Rufus Dixon, Jr. on 08-28-1969



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Finance Committee



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Finance Committee

Interim Report  
Fiscal Year 2019-2020

February 5, 2020

Blake P. Pitre  
Chair

Louisiana Board of Pharmacy  
 FY 2019-2020  
 Statement of Assets, Liabilities, Equity

	FY 18-19 Final (A)	FY 19-20 Q2 12/31/2019
<b>ASSETS &amp; DEFERRED OUTFLOWS</b>		
<b>Assets</b>		
<b>&gt; Current Assets</b>		
* Cash		
General Operations		
HancockWhitney Bank	228,043.77	228,158.76
Iberia Bank	1,692,446.15	1,331,985.87
Investment Accounts - Iberia Bank		
Money Market Funds	268,913.41	273,067.65
Funds Maturing Within One Year	<u>297,229.20</u>	<u>1,197,500.39</u>
* Total Cash & Cash Equivalents	2,486,632.53	3,030,712.67
* Accounts Receivable		
Grants		
End of Year Deposits	210,667.00	0.00
CPSC Inspections	20,100.00	0.00
Returned Checks & Consent Orders	3,000.00	0.00
	<u>1,195.00</u>	<u>180.00</u>
* Total Accounts Receivable	234,962.00	180.00
* Accrued Interest Receivable		
	11,671.80	11,470.13
* Prepaid Expenses		
Critical Point Staff Education		
MetrC Oriduct ID Module	1,995.00	0.00
Appriss Additional Deliverables	15,000.00	0.00
Essential Solutions	33,850.00	882.30
PMP Gateway Integration Project	2,989.10	374.59
Drug Price Transparency Website	390,643.04	1,034,667.01
Information Systems	16,907.72	0.00
	<u>1,906.85</u>	<u>0.00</u>
* Total Prepaid Expenses	463,291.71	1,035,923.90
<b>Total Current Assets</b>	<b>3,196,558.04</b>	<b>4,078,286.70</b>
<b>&gt; Noncurrent Assets</b>		
* Investment Accounts		
Iberia Bank - General Reserve Fund		
Iberia Bank - OPEB Reserve Fund	1,071,526.95	454,911.51
Iberia Bank - Pension Reserve Fund	960,691.67	724,673.04
	<u>1,711,007.96</u>	<u>1,716,375.64</u>
	3,743,226.58	2,895,960.19
* Fixed Assets		
Land: Lot 5-A, Towne Center Business Park		
Land: Lot 1-A-2, Leonard Place Subdivision	709,079.90	709,079.90
Office Building - 3388 Brentwood Drive	295,860.00	295,860.00
Office Equipment	1,354,876.72	1,354,876.72
Furniture	230,345.19	230,345.19
Software: Licensure & Website	177,074.08	177,074.08
Accumulated Depreciation	408,560.00	408,560.00
	<u>(995,793.19)</u>	<u>(1,023,543.70)</u>
	2,180,002.70	2,152,252.19
<b>Total Noncurrent Assets</b>	<b>5,923,229.28</b>	<b>5,048,212.38</b>

Louisiana Board of Pharmacy  
 FY 2019-2020  
 Statement of Assets, Liabilities, Equity

	FY 18-19 Final (A)	FY 19-20 Q2 12/31/2019
<i>Total Assets</i>	9,119,787.32	9,126,499.08
<b>Deferred Outflows of Resources</b>		
OPEB Reserve Fund	71,452.00	71,452.00
Pension Reserve Fund	972,930.00	972,930.00
<i>Total Deferred Outflows of Resources</i>	1,044,382.00	1,044,382.00
<b><u>TOTAL ASSETS &amp; DEFERRED OUTFLOWS</u></b>	<b>10,164,169.32</b>	<b>10,170,881.08</b>
<b>LIABILITIES, DEFERRED INFLOWS, &amp; EQUITY</b>		
<b>Liabilities</b>		
> Current Liabilities		
Unearned grant revenue	1,443,299.76	1,034,667.00
Accrued salaries and benefits	45,716.43	0.00
Unemployment taxes payable	184.03	127.89
State taxes withheld	4,820.00	0.00
Accounts payable	12,482.87	65,490.19
Compensated absences (ST)	44,648.86	44,648.86
PES fee payable	200.00	112,500.00
Other post employment benefits (OPEB) payable	47,351.00	47,351.00
<i>Total Current Liabilities</i>	1,598,702.95	1,304,784.94
> Long Term Liabilities		
Compensated absences (LT)	90,377.73	90,377.73
Other post employment benefits (OPEB) payable	1,881,586.00	1,881,586.00
Net pension liability	5,297,583.00	5,297,583.00
<i>Total Long Term Liabilities</i>	7,269,546.73	7,269,546.73
<b><i>Total Liabilities</i></b>	<b>8,868,249.68</b>	<b>8,574,331.67</b>
<b>Deferred Inflows of Resources</b>		
OPEB Reserve Fund	154,202.00	154,202.00
Pension Reserve Fund	80,208.00	80,208.00
<b><i>Total Deferred Inflows of Resources</i></b>	<b>234,410.00</b>	<b>234,410.00</b>
<b>Equity</b>		
Fund Balance at End of Prior Year	(1,600,918.63)	(1,331,780.55)
Fund Balance - designaated	241,038.00	241,038.00
Invested in Capital Assets	2,180,002.70	2,152,252.19
Net Income	241,387.57	300,629.77
<b><i>Total Equity</i></b>	<b>1,061,509.64</b>	<b>1,362,139.41</b>
<b><u>TOTAL LIABILITIES, DEFERRED INFLOWS, &amp; EQUITY</u></b>	<b>10,164,169.32</b>	<b>10,170,881.08</b>

Louisiana Board of Pharmacy  
 Fiscal Year 2019-2020  
 Statement of Equity

	FY 18-19 Final (A)	FY 19-20 Q2 12/31/2019
Balance of Equity at Beginning of Year	820,122.07	1,061,509.64
GASB Restatements	0.00	0.00
Net Income	241,387.57	300,629.77
Balance of Equity at End of Year	1,061,509.64	1,362,139.41
 Components of Equity:		
Fund Balance at End of Prior Year	(1,600,918.63)	(1,345,631.34)
Fund Balance - designated	241,038.00	241,038.00
Invested in Fixed Assets	<u>2,180,002.70</u>	<u>2,166,102.98</u>
	820,122.07	1,061,509.64

Louisiana Board of Pharmacy  
 FY 2019-2020  
 Statement of Revenue, Expenses, and Budget Performance  
**Revenue**

	FY 18-19 Final (A)	FY 19-20 Q2 12/31/2019	FY 19-20 Budget (A#1)
<b>Licensing Fees</b>			
PST License Application Fee	170,400.00	53,400.00	170,000.00
PST License Reciprocity Application Fee	48,750.00	20,250.00	49,000.00
PST License Renewal Fee	872,200.00	843,850.00	872,000.00
PNT Registration Application Fee	3,520.00	2,740.00	3,500.00
PTC Registration Application Fee	27,125.00	14,775.00	28,000.00
CPT Certificate Application Fee	55,400.00	21,300.00	55,000.00
CPT Certificate Renewal Fee	340,500.00	10,200.00	340,000.00
PHY Permit Application & Renewal Fee	280,925.00	257,025.00	281,000.00
AMS Registration Application & Renewal Fee	21,750.00	4,350.00	23,000.00
DME Permit Application & Renewal Fee	85,350.00	80,150.00	87,000.00
EDK Permit Application & Renewal Fee	11,725.00	1,450.00	13,000.00
CDS License Application & Renewal Fee	531,170.00	244,295.00	532,000.00
Credential Reinstatement Fee	25,340.00	14,500.00	26,000.00
Delinquent Renewal Fee for PST & CPT	14,500.00	5,812.50	14,000.00
Delinquent Renewal Fee for PHY & CDS	11,647.50	7,142.50	12,000.00
<b>Sales of Goods &amp; Services</b>			
Product Charge for Duplicate Credentials	4,350.00	1,945.00	4,500.00
Product Charge for Pharmacist Original Certificate	5,475.00	3,900.00	6,000.00
Product Charge for Pharmacist Silver Certificate	500.00	300.00	500.00
Product Charge for Law Book & Supplement	375.00	360.00	500.00
Product Charge for Official List of Licensees	25,650.00	12,900.00	26,000.00
Product Charge for Document Copies	272.00	26.50	500.00
Service Charge for Document Certification	4,240.00	2,020.00	5,000.00
Service Charge for Inspection Services for U.S. CPSC	6,000.00	0.00	3,000.00
Service Charge for PNT Practical Experience	350.00	120.00	500.00
Disposal of Assets	0.00	0.00	0.00
<b>Administrative Fees</b>			
Recovery of Bank Charges for NSF Fees	200.00	300.00	500.00
Handling & Mailing Fees	377.00	79.00	500.00
<b>Enforcement Activities</b>			
Administrative Hearing Fee	22,750.00	10,500.00	23,000.00
Fines	268,250.00	139,250.00	265,000.00
Cost Recoveries	25,653.33	17,995.00	25,000.00
<b>Prescription Monitoring Program (PMP)</b>			
PMP Assessments	591,220.00	276,775.00	591,000.00
<b>Grants</b>			
Private Grants	81,200.00	0.00	42,000.00
Government Grants	367,367.24	408,632.76	0.00
Miscellaneous Revenue	283.06	0.00	1,000.00
<b>TOTAL REVENUE</b>	<b>3,904,815.13</b>	<b>2,456,343.26</b>	<b>3,500,000.00</b>

Louisiana Board of Pharmacy  
 FY 2019-2020  
 Statement of Revenue, Expenses, and Budget Performance  
**Expenses**

	FY 18-19 Final (A)	FY 19-20 Q2 12/31/2019	FY 19-20 Budget (A#1)
<b>Operations</b>			
Equipment Rentals	14,974.91	7,431.03	15,000.00
Equipment Maintenance	2,201.88	2,239.92	2,200.00
Telephone	18,034.76	7,463.48	29,000.00
Printing	18,099.33	13,151.25	17,000.00
Postage	60,055.00	30,014.60	60,000.00
Dues & Subscriptions	10,671.61	10,964.90	12,000.00
Financial Service Charges	52,713.75	47,189.34	53,000.00
Office Meeting Expenses	5,067.38	2,455.53	5,000.00
Office Supply Expenses	21,956.05	9,603.29	22,000.00
Utilities	10,422.52	4,180.78	11,000.00
Civil Service Assessments (DSCS)	7,966.00	8,321.00	8,400.00
Office Insurance (ORM)	16,980.00	21,269.00	22,000.00
Depreciation of Fixed Assets	55,621.06	27,750.51	55,000.00
Acquisitions	5,676.36	0.00	100,000.00
Miscellaneous Expenses	0.00	0.00	0.00
<b>Personal Services</b>			
Salaries for Employees	1,669,429.89	832,299.11	1,789,000.00
Wages for Temporary Labor	12,420.31	7,374.65	20,000.00
Payroll Taxes (FICA & FUTA)	28,503.45	13,846.68	36,000.00
Health Insurance Premiums (SEGBP)	170,746.80	89,815.50	197,000.00
Pension Plan Premiums (LASERS)	655,213.95	338,642.20	727,000.00
Other Post-Employment Benefits (OPEB)	13,687.00	0.00	15,000.00
Board Member Per Diem	30,000.00	13,275.00	30,000.00
<b>Professional Services</b>			
Accounting & Expense Reimbursement	28,129.50	21,882.00	30,000.00
Legal & Expense Reimbursement	47,564.60	810.00	50,000.00
Information Systems	117,017.59	107,506.85	154,000.00
Prescription Monitoring Program	137,915.04	103,006.90	208,000.00
PMP Statewide Integration Project	384,274.96	391,725.04	0.00
Drug Price Transparency Website	64,292.28	16,907.72	42,000.00
Property Management	22,091.28	10,493.33	30,000.00
<b>Staff Expenses</b>			
Executive Director	4,822.99	2,485.00	5,000.00
General Counsel	9,868.05	5,695.02	10,000.00
Assistant Executive Director	4,853.17	1,864.06	5,000.00
Compliance Officer - Travel	6,995.39	1,537.03	7,000.00
Compliance Officer - Rental Cars	8,991.96	2,497.40	9,000.00
Compliance Officer - Fuel for Rental Cars	3,328.07	1,231.32	4,000.00
Compliance Officer - Conference Travel Expenses	2,710.29	13,662.28	14,000.00
House Staff Travel & Education	25.00	40.00	400.00
Mileage	28,049.76	16,693.56	30,000.00
<b>Board Expenses</b>			
Board Meetings	17,492.94	8,748.39	18,000.00
Committee Meetings	9,520.15	3,222.95	10,000.00
Conference Travel Expenses	19,782.78	3,139.40	20,000.00
President's Expenses	7,233.21	3,804.75	8,000.00
Mileage - Members & President	19,831.98	8,771.76	20,000.00
<b>TOTAL EXPENSES</b>	<b>3,825,233.00</b>	<b>2,213,012.53</b>	<b>3,900,000.00</b>

Louisiana Board of Pharmacy  
 FY 2019-2020  
 Summary of Income Fund Balance Changes

**Summary**

	FY 18-19 Final (A)	FY 19-20 Q2 12/31/2019	FY 19-20 Budget (A#1)
<b>Income Statement</b>			
Total Revenue	3,904,815.13	2,456,343.26	3,500,000.00
Total Expenses	3,825,233.00	2,213,012.53	3,900,000.00
Net Ordinary Income	79,582.13	243,330.73	(400,000.00)
Other Income & Expenses			
Investments	161,805.44	57,299.04	0.00
Net Income	241,387.57	300,629.77	(400,000.00)

	FY 18-19 Final (A)	FY 19-20 Q2 12/31/2019	FY 19-20 Budget (A#1)
<b>Fund Balance</b>			
Beginning Fund Balance	820,122.07	1,061,509.64	1,061,509.64
Total Income	4,066,620.57	2,513,642.30	3,500,000.00
Total Expenses	3,825,233.00	2,213,012.53	3,900,000.00
Other Adjustments	0.00	0.00	0.00
Ending Fund Balance	1,061,509.64	1,362,139.41	661,509.64
Reservations of Fund Balance	(1,750,000.00)	(1,750,000.00)	(1,750,000.00)
Unreserved Fund Balance	(688,490.36)	(387,860.59)	(1,088,490.36)

*Notes on Reservation of Fund Balance*

Unfunded Pension Liability	1,000,000.00	1,000,000.00	1,000,000.00
Unfunded OPEB Liability	500,000.00	500,000.00	600,000.00
Compensated Absences	150,000.00	200,000.00	150,000.00
Building Renovation & Repair	<u>100,000.00</u>	<u>50,000.00</u>	<u>0.00</u>
<i>Total</i>	<i>1,750,000.00</i>	<i>1,750,000.00</i>	<i>1,750,000.00</i>

## Investment Account ~ Portfolio Snapshots

### Reserve Account



Holdings by Investor  
H5E-049797

Prepared for: LA Board of Pharmacy

As of: 12/31/19

LA Board of Pharmacy

Account Name: Louisiana Board of Pharmacy

Account Number: H5E049797

Account Type: Non-Profit Organization

ASSET	TICKER	INVESTMENT OBJECTIVE	MGT. NAME	QUANTITY	PRICE (\$)	VALUE (\$)
BROKERAGE MONEY MARKET		CASH	BROKERAGE MONEY MARKET	59,758.63	1.00	59,758.63
CASH		CASH		1,178.13	1.00	1,178.13
US TREAS INFLAT PROT	912828NM8	LONG-TERM BOND		25,000.00	1.19	29,919.71
US TREASUR NT 1.25% UST NOTE DUE 03/31/21	TSRYS44942	NON-CLASSIFIED		457,000.00	1.00	456,347.44
US TREASURY N/B 1.375% 31 AUG 2020	TSRYS44942	NON-CLASSIFIED		593,000.00	1.00	594,736.61
US TREASURY N/B 1.625% 30 JUN 2020	912828XH8	NON-CLASSIFIED		145,000.00	1.00	145,000.00
Louisiana Board of Pharmacy Total:						\$1,286,940.52
LA Board of Pharmacy Total:						\$1,286,940.52

### OPEB Account



Holdings by Investor  
H5E-077160

Prepared for: LA Board of Pharmacy

As of: 12/31/19

LA Board of Pharmacy

Account Name: OPEB Reserve account

Account Number: H5E077160

Account Type: Non-Profit Organization

ASSET	TICKER	INVESTMENT OBJECTIVE	MGT. NAME	QUANTITY	PRICE (\$)	VALUE (\$)
BROKERAGE MONEY MARKET		CASH	BROKERAGE MONEY MARKET	117,064.97	1.00	117,064.97
CASH		CASH		1,433.13	1.00	1,433.13
U.S. TREASURY NOTES 1.875 6/30/20	912828VJ6	NON-CLASSIFIED		100,000.00	1.00	100,121.00
US TREASUR NT 1.25% UST NOTE DUE 03/31/21	TSRYS44942	NON-CLASSIFIED		728,000.00	1.00	726,960.47
US TREASURY N/B 1.375% 31 AUG 2020	TSRYS44942	NON-CLASSIFIED		241,000.00	1.00	241,705.77
US TREASURY N/B 1.625% 30 JUN 2020	912828XH8	NON-CLASSIFIED		61,000.00	1.00	61,000.00
OPEB Reserve account Total:						\$1,248,285.34
LA Board of Pharmacy Total:						\$1,248,285.34

## Pension Account



Holdings by Investor  
H5E-102679

Prepared for: LA Board of Pharmacy

As of: 12/31/19

LA Board of Pharmacy

Account Name: Pension Reserve account

Account Number: H5E102679

Account Type: Non-Profit Organization

ASSET	TICKER	INVESTMENT OBJECTIVE	MGT. NAME	QUANTITY	PRICE (\$)	VALUE (\$)
BROKERAGE MONEY MARKET		CASH	BROKERAGE MONEY MARKET	85,707.16	1.00	85,707.16
CASH		CASH		7,925.63	1.00	7,925.63
US TREASUR NT 1.25% UST NOTE DUE 03/31/21	TSRYS44942	NON-CLASSIFIED		648,000.00	1.00	647,074.71
US TREASURY N/B 1.375% 31 JAN 2021	TSRYS44942	NON-CLASSIFIED		297,000.00	1.00	297,875.17
US TREASURY N/B 1.625% 30 JUN 2020	912828XH8	NON-CLASSIFIED		29,000.00	1.00	29,000.00
US TREASURY N/B 2% 31 DEC 2021	912828U81	NON-CLASSIFIED		769,000.00	1.01	775,159.69
Pension Reserve account Total:						\$1,842,742.36
LA Board of Pharmacy Total:						\$1,842,742.36



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Application Review Committee



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Reciprocity Committee

**New Pharmacist Credentials Issued by Reciprocity  
Issued Since 10/30/2019**

	<u>Applicant</u>	<u>Interviewer</u>	<u>Result</u>		
1	Monica Register Jolley (TN)	Waived	PST.023278	issued	11/07/19
2	Brittany Marie Patterson (GA)	Waived	PST.023280	issued	11/07/19
3	Aimee Michele Watts (OH)	Waived	PST.023281	issued	11/07/19
4	Juliana Frances Camelo (AZ)	Waived	PST.023282	issued	11/07/19
5	Athansios Mastrokostas (NY)	Committee	PST.023285	issued	11/13/19
6	Mary Adeola Tokunboh (NC)	Waived	PST.023287	issued	11/13/19
7	Chris Vi Chan (OR)	Waived	PST.023289	issued	11/15/19
8	Henry James Dunklau IV (AL)	Waived	PST.023290	issued	11/15/19
9	Jessica Lynn Turner (GA)	Waived	PST.023291	issued	11/19/19
10	Troy Allan Lizyness (MI)	Waived	PST.023293	issued	11/21/19
11	James Nicholas Miller (TX)	Waived	PST.023294	issued	11/27/19
12	Jerri Ann Britt (NC)	Waived	PST.023297	issued	11/27/19
13	Maria Jimena Resendiz Garnica (VA)	Waived	PST.023298	issued	12/06/19
14	Wesly Adam Pierce (SC)	Waived	PST.023299	issued	12/06/19
15	Walker Harbard Taylor (MS)	Waived	PST.023300	issued	12/10/19
16	Mayur Keshabhai Patel (MI)	Waived	PST.023307	issued	01/02/20
17	Lauren Elissa Ferguson (KY)	Waived	PST.023308	issued	01/02/20
18	Karen Lynne Tarbotton (PA)	Waived	PST.023309	issued	01/02/20
19	Melissa Katherine Crews (KY)	Waived	PST.023310	issued	01/02/20
20	Katharine Judith Kempf (MO)	Waived	PST.023311	issued	01/02/20
21	Runglak Kitiyasavatdi (FL)	Waived	PST.023312	issued	01/02/20
22	Kaylee Samirah Al-Saigh (TX)	Waived	PST.023313	issued	01/02/20
23	Sammy Khayat (TX)	Waived	PST.023314	issued	01/02/20
24	Linh Van Nguyen (TX)	Waived	PST.023315	issued	01/02/20
25	Nhu-Y Thi Nguyen (GA)	Waived	PST.023316	issued	01/02/20
26	Bonny Dukes Hendrix (GA)	Waived	PST.023317	issued	01/02/20
27	Jennifer Hong (CA)	Waived	PST.023318	issued	01/02/20
28	Tramaine Preston Smith (FL)	Waived	PST.023319	issued	01/02/20
29	Charmaine Punsalan Saratan (FL)	Waived	PST.023320	issued	01/02/20
30	Martin Reyes Rodriguez (MI)	Waived	PST.023321	issued	01/02/20
31	Emerson Giovanni Molina (FL)	Waived	PST.023322	issued	01/02/20
32	Brian Ervin Lewis (NJ)	Waived	PST.023323	issued	01/02/20
33	Donald Patrick Clark Jr. (KY)	Waived	PST.023324	issued	01/06/20
34	Michael Allen Moreland (VA)	Waived	PST.023325	issued	01/06/20
35	Joshua Reiter (NY)	Waived	PST.023326	issued	01/06/20
36	Matthew Paul Malachowski (AL)	Waived	PST.023327	issued	01/06/20
37	Daniel Richard Robinson (FL)	Waived	PST.023328	issued	01/06/20
38	Jason Alan Frederick (AZ)	Waived	PST.023330	issued	01/06/20
39	Jaime LeAnn St. Claire (RI)	Waived	PST.023331	issued	01/06/20
40	Matthew James Terrasi (MA)	Waived	PST.023332	issued	01/06/20
41	Erik Matthew Clausen (CA)	Waived	PST.023333	issued	01/06/20
42	Ernest Ding-Jui Tam (NV)	Waived	PST.023334	issued	01/09/20
43	Micah Paul Benford (KY)	Waived	PST.023336	issued	01/09/20
44	Tien Khanh Luu (TX)	Waived	PST.023337	issued	01/09/20
45	Mikaela Anne Ekobena (SD)	Waived	PST.023338	issued	01/10/20
46	Nikita Patton (KY)	Waived	PST.023340	issued	01/14/20
47	Nury Cecilia Whitford (TX)	Waived	PST.023341	issued	01/14/20
48	Talha Aseem Akhtar (NY)	Waived	PST.023342	issued	01/16/20
49	Eric Reid Cornell (NC)	Waived	PST.023343	issued	01/16/20
50	David Kenneth Turnbull (OR)	Waived	PST.023344	issued	01/16/20
51	Brent Alan Matthews (TX)	Waived	PST.023345	issued	01/16/20
52	Maria Eleni Hockenberry (PA)	Waived	PST.023347	issued	01/16/20
53	Monica Ayala (TX)	Waived	PST.023348	issued	01/16/20
54	Lacy Michelle Burns (TN)	Waived	PST.023349	issued	01/16/20
55	Kristen Paige Turner (KY)	Waived	PST.023350	issued	01/16/20
56	Angela Marie Keo (GA)	Waived	PST.023352	issued	01/21/20

**Total: 56**



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Violations Committee



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Impairment Committee



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Reinstatement Committee



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Tripartite Committee



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Regulation Revision Committee



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Public Hearing Record

December 27, 2019



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Table of Contents

Guest Register	03
Hearing Transcript	04
Comment Letter 1 from National Association of Chain Drug Stores	35
Comment Letter 2 from Albertsons Companies	38
Comment Letter 3 from TelePharm	39
<i>Summaries of Comments &amp; Testimony</i>	
Project 2019-1B ~ Licensing of Marijuana Pharmacies	40
Project 2019-2 ~ Pharmacy Immunizations	41
Project 2019-3 ~ Investigational Drugs	43
Project 2019-4 ~ Telepharmacy Dispensing Sites	44
Project 2019-5 ~ Correctional Center Pharmacy	45
Project 2019-7 ~ Veterinary Hospital Pharmacy	46
Project 2019-8 ~ Dispensing of Prescription Refills	47
Project 2019-9 ~ Delays of Licensure Examinations	49
Project 2019-10 ~ License Transfer for Pharmacy Technicians	50
Project 2019-11 ~ Continuing Education Records	51
Project 2019-12 ~ Partial Fills of Schedule II Prescriptions	52
Project 2019-13 ~ Controlled Substance License for Third Party Logistics Providers	53
Project 2019-14 ~ Rulemaking Procedures	54
Project 2019-15 ~ Drug Disposal by Pharmacies	55
Project 2019-16 ~ Pharmacy Compounding	58
Project 2019-17 ~ Pharmacy Records	59
Project 2019-18 ~ Cannabis Metered Dose Inhaler	60

# Louisiana Board of Pharmacy

Public Hearing Attendance Record ~ December 27, 2019

Regulatory Projects 2019-1B through 2019-18

Name	Address	E-mail	Group or Agency Represented
1. TJ Woodward	2450 Cottonwood Ave BR, LA 70808	tj@rxstogeaux.com	Capital Wellness Solutions/Prescriptions to Geaux
2.			
3.			
4.			
5.			

**In The Matter Of:**  
*STATE OF LOUISIANA PARISH OF EAST BATON ROUGE*  
*LOUISIANA BOARD OF PHARMACY*

---

*Public Hearing*  
*December 27, 2019*

---

*Associated Reporters, Inc.*  
*2431 South Acadian Thruway*  
*Suite 550*  
*Baton Rouge, La. 70808*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

STATE OF LOUISIANA  
PARISH OF EAST BATON ROUGE  
LOUISIANA BOARD OF PHARMACY

An Public Hearing was held by the  
Louisiana Board of Pharmacy, on Friday,  
December 27, 2019, at their office located  
at 3388 Brentwood, Baton Rouge, Louisiana  
70809 beginning at 9:00 a.m.

BEFORE:

Susan Erkel  
Certified Court Reporter  
In and For the State of  
Louisiana



## P R O C E E D I N G S

MR. FINALET:

Good morning. Today is Friday, December 27, 2019. The time is 9:00 a.m. We're assembled in the Boardroom at the Louisiana Board of Pharmacy located at 3388 Brentwood Drive in Baton Rouge, Louisiana. My name is Carlos Finalet. I serve the Board of Pharmacy as its General Counsel. In his absence, the Board President, Carol Aron, has requested that I moderate this hearing. I now call this Public Hearing to order.

As a courtesy to everyone else in the room, please take time to silence your cell phones or other electronic devices. Further, should you find it necessary to take or make a telephone call, please step outside the meeting room to do so.

For your safety, the emergency exit path from this room is through the door into the lobby and through the front door through which you entered the building. For your comfort, the restrooms are located in the lobby --

1 ladies on the opposite side of the  
2 lobby, just past the receptionist's  
3 window, and gentlemen just outside the  
4 door to this room.

5 In addition, we have a water cooler  
6 in this room. Please help yourself.  
7 For your peace of mind, please ensure  
8 that you did not park in one of the  
9 three spaces between this building and  
10 the back of the building in front of  
11 this one, or in front of the building in  
12 front of this one. Those parking spaces  
13 do not belong to the Board, and tow  
14 trucks are regular visitors to that  
15 area. Additional parking is available  
16 at the rear of the Perlis clothing store  
17 on Jefferson Highway, and there is a  
18 stairway connecting that parking lot to  
19 the Board's parking area in front of our  
20 building.

21 This hearing is held in accordance  
22 with Administrative Procedures Act and  
23 the Open Meetings Law. As required by  
24 these laws, this hearing is convened  
25 pursuant to public notice and notice has

1           been properly posted.

2           The purpose of today's hearing is to  
3           receive public comments and testimony on  
4           the 17 regulatory projects listed on the  
5           agenda for today's hearing. The Board  
6           published its Notices of Intent for all  
7           these projects in November 2019 edition  
8           of the Louisiana Register. Further, the  
9           Board filed its first reports with the  
10          legislative oversight committees on  
11          November 8 and then distributed  
12          electronic Notice of Rulemaking Activity  
13          on November 9, 2019 to its electronic  
14          List of Interested Parties, as well as  
15          all its licensees.

16          As indicated in the Notices, the  
17          Board has convened this public hearing  
18          to receive public comments and testimony  
19          on all 17 of these regulatory projects.  
20          The Board will consider the comments and  
21          testimony offered today during their  
22          next meeting on February 5, 2020, to  
23          determine whether any revisions to the  
24          proposed rule amendments are necessary.  
25          We will reply to your comments as soon

1 as possible thereafter.

2 Prior to making any comments today,  
3 we ask that you sign the guest register  
4 for this event. Copies of today's  
5 agenda and the notices are available at  
6 the registration desk or rather,  
7 actually right in front of you. The  
8 proposed rule amendments are also  
9 available in the Public Library section  
10 of the Board's website, as well as the  
11 website of the Louisiana Register.

12 While we may answer questions to  
13 clarify language or interpretation, it  
14 is not our intent to debate any issues  
15 today. Again, the purpose of this  
16 hearing is to receive your comments and  
17 testimony for the Board's consideration.  
18 As indicated in the notices, the  
19 deadline for all comments and testimony  
20 on these proposed rules amendments is  
21 12:00 noon today.

22 We are now prepared to receive your  
23 comments and testimony. As you begin  
24 your comments, we ask that you identify  
25 yourself and any organization that you

1 may represent. Please identify which  
2 regulatory topic for which you are  
3 submitting comments or testimony.

4 Before we take any oral statements, I  
5 do want to enter into the record two  
6 written comments that were submitted to  
7 the Board Office, one on December 23,  
8 2019 from the National Association of  
9 Chain Drug Stores, specifically by its  
10 representative Steven C. Anderson,  
11 President and its CEO. And then the  
12 second written comment was submitted on  
13 December 26, 2019 by Albertsons  
14 Companies, specifically by its  
15 representative, Pharmacist Robert  
16 Geddes, Director of Pharmacy,  
17 Legislative and Regulatory Affairs.

18 So if there are any oral statements,  
19 comments that the public would like to  
20 make, now is would be the time.

21 MR. WOODARD:

22 I guess I might as well just to get  
23 everything on the record, Carlos. TJ  
24 Woodard here representing Capitol  
25 Wellness Solutions. I notice the first

1 item on the agenda, Licensing Marijuana  
2 Pharmacies, and I'm not sure exactly how  
3 this pertains to us or if I'm even -- if  
4 this is the right venue to bring things  
5 up, but there's a few things that we've  
6 noticed over the first few months of  
7 establishing, opening, running, and now  
8 we've done it for several months so we  
9 kind of have a feel of what's working  
10 and what's not working.

11 And I guess maybe just bullet points  
12 to bring up at a future meeting with  
13 Board Members to discuss, there are kind  
14 of three, well four critical issues that  
15 I think we're -- kind of prohibit our  
16 growth and the effective running of our  
17 marijuana pharmacies. The first I would  
18 say, delivery, and I don't know exactly  
19 what mechanism, if it's me as the  
20 pharmacist in charge of delivery, and if  
21 it's a third-party company delivery.

22 We have several patients that we've  
23 seen and we've established a  
24 relationship with that are truly bed  
25 bound and don't have transportation,

1           that don't have anyone that can access  
2 medication for them, I would be happy to  
3 deliver it to their home if that were  
4 allowed and legal so maybe just some  
5 guidance on even an extreme situations,  
6 you know.

7           I don't think this is a scenario like  
8 I deliver in my traditional pharmacy  
9 downtown where we deliver everything,  
10 but just to have that option would be  
11 helpful.

12           The second and I think it's been  
13 discussed is, we, personally speaking  
14 for Capitol Wellness, we have two great  
15 technicians that are kind of  
16 underutilized. They can perform certain  
17 duties, data entry, but really beyond  
18 that, as far as the filling -- filling  
19 of the medication, they can't do now.  
20 The pharmacist is the only one in my  
21 understanding that can touch the product  
22 and you know, essentially stick a label  
23 on a box, if you will.

24           Sometimes that creates a logjam. We  
25 spend most of our time counseling

1 patients so if I'm in the back  
2 counseling a patient and we have three  
3 additional patients come in, everything  
4 is stopped waiting on me, where at a  
5 minimum, they could enter it, fill it,  
6 label it for me to check and review, as  
7 we do in the traditional pharmacy I  
8 guess. So in my mind, if they can fill,  
9 you know, a Percocet in a traditional  
10 pharmacy, I can count behind them and  
11 check it and then dispense it.

12 It would be helpful if they could do  
13 that in our world. There just seems to  
14 be this firewall between technicians and  
15 the product that I don't see any issue  
16 whatsoever with it professionally  
17 because I'm still checking behind it and  
18 the things we traditionally do. So  
19 that's another thing.

20 The -- another big one and I don't  
21 know, there's a fine line between we're  
22 really -- I don't know all the specifics  
23 in the law, but we're really prohibited  
24 from advertising. And I don't know that  
25 advertising is in a sense of you know,

1 we need to put up a billboard that we  
2 sell medical marijuana here, but it  
3 would help one, communicate with doctors  
4 and patients kind of what we do and what  
5 we can do.

6 We do that some for education now  
7 with physicians. We don't really have a  
8 way to reach the patients unless they  
9 call us. But the main reason there is a  
10 medical marijuana recommending facility  
11 adjacent to our location and we're  
12 commonly confused with them. So we're  
13 on Picardy off of Essen. They're on the  
14 corner of Picardy and Essen. You know  
15 they have some flag out with some  
16 marijuana paraphernalia type things.  
17 People regularly think that's us. We  
18 would like a way just to let them know  
19 that it's not.

20 I mean, for instance, our location  
21 just has on the outside, it just says  
22 "Capitol" and our logo. So especially  
23 with elderly folks, they're constantly  
24 confused with how to get to us, what we  
25 do, who we are. So again, I'm not

1 asking for anything specifically, more  
2 so just to start the conversation with  
3 how could we do this efficiently and  
4 professionally to communicate what we're  
5 doing with the general public in a  
6 professional way.

7 I don't think we want to, you know,  
8 have the blow up people dancing on the  
9 roads saying, you know, medical  
10 marijuana here, but it's really been a -  
11 - and I think its inhibited the growth  
12 statewide for folks. We still have  
13 physicians and patients that have  
14 literally no idea what it is that we do.  
15 In about six months now that we've been  
16 open, there have been some lives that  
17 have truly been changed so I can  
18 honestly say that I think we're going in  
19 the right direction.

20 We're taking it slowly and doing it  
21 very controlled and very well. These  
22 are just some things that I've seen in  
23 practice that I think would help every  
24 marijuana pharmacy without hurting the  
25 public in any way. Actually, quite the

1 opposite. But again, I'm not asking for  
2 anything specifically. Just maybe at  
3 some future meeting we could discuss it.

4 So I don't even know if this is the  
5 right forum for that but just to kind of  
6 get that down in the public comment.

7 MR. FINALET:

8 And you had a forth point, maybe?

9 MR. WOODARD:

10 Well, the fourth point and I'm  
11 skipping over, I see at the bottom,  
12 number 3, letter Q, Cannabis Metered  
13 Dose Inhaler. I don't know remotely  
14 what that's about. I will just say, one  
15 of the biggest issues we have is getting  
16 this product into a patient's system as  
17 quickly as possible for various reasons,  
18 whether it's acute pain, whether it's an  
19 anxiety attack secondary to PTSD.

20 That's still the fastest way to get this  
21 medication into someone's body, through  
22 the lungs.

23 So, you know, again, I'm not here  
24 saying we should, you know, have flower  
25 or vaporization. I don't know. This is

1 one thing that's come up, metered dose  
2 inhaler. I will just say from the  
3 clinical perspective, I couldn't support  
4 something like this more. I don't know  
5 what it looks like. I don't know if it's  
6 an ILERA and southern product or it's a  
7 GB -- well, it's not GB anymore,  
8 Wellcanna, an LSU product, but that's  
9 been a real issue with us is we need  
10 some mechanism to get instant relief for  
11 some patients.

12 That's one of the biggest complaints  
13 we've had is that, you know, we have the  
14 tinctures. They're faster than an oral  
15 product. They work. They work very  
16 well. There's still a 15 to 30 to an  
17 hour gap there so if someone's having an  
18 acute anxiety attack, I have nothing for  
19 them.

20 MR. FINALET:

21 And I think that was the purpose of  
22 that both legislatively and regulation.

23 MR. WOODARD:

24 So just to -- and this is me speaking  
25 personally as a pharmacist and on behalf

1 of Capitol, that's something that we  
2 support. There is a need for it.

3 MR. FINALET:

4 And to answer your question about if  
5 this was the proper forum, I don't think  
6 it's improper. You know you definitely  
7 addressed that one aspect of the inhaler  
8 which was appropriate. The other items  
9 are appropriate insofar as they'll be  
10 part of the comment review that the  
11 Board's going to make at the February  
12 meeting.

13 MR. WOODARD:

14 Okay.

15 MR. FINALET:

16 And my feeling is that the Board  
17 President's going to delegate that to  
18 Regulation Revision Committee.

19 MR. WOODARD:

20 Okay.

21 MR. FINALET:

22 And so there should be a very lively  
23 chain of meetings thereafter --

24 MR. WOODARD:

25 Right.

1 MR. FINALET:

2 -- on all these aspects. And as you  
3 know, the projects evolving and we  
4 expected it to evolve and frankly, want  
5 it to evolve to address a lot of the  
6 concerns you had about educating  
7 appropriately.

8 MR. WOODARD:

9 Right, right.

10 MR. FINALET:

11 And informing the public and getting  
12 the right patients to you.

13 MR. WOODARD:

14 And I think we've all -- I will say  
15 that speaking with people kind of from  
16 other states, speaking with folks at  
17 Pennington, speaking with folks at LSU,  
18 I think we did it the right way. It's  
19 much, you know, much different than in  
20 California or Colorado model, but it's  
21 well controlled and we can actually use  
22 that to our benefit in a lot of ways. I  
23 mean we're talking about doing clinical  
24 trials now which is kind of  
25 groundbreaking.

1           But, you know, we've got to start  
2           and then I think it's, you know,  
3           postmortem review of what's working,  
4           what's not working and just speaking --  
5           we're in close contact with the other  
6           pharmacies in the state and it's kind of  
7           the same things that keep coming up. So  
8           I don't intend to be the spokesperson  
9           for everyone, but I'm happy to answer  
10          questions specifically, you know,  
11          patient based, what is working and  
12          what's not.

13         MR. FINALET:

14                 And I can tell you that the Board  
15                 will really want all of your input --

16         MR. WOODARD:

17                 Okay.

18         MR. FINALET:

19                 -- as to what you do because y'all  
20                 are on the front lines.

21         MR. WOODARD:

22                 Yeah.

23         MR. FINALET:

24                 Y'all know what is needed and then  
25                 they could figure out what we can work

1 with.

2 MR. WOODARD:

3 Perfect. So board meeting February  
4 at Xavier.

5 MR. FINALET:

6 At Xavier and I believe the starting  
7 time is 9:00.

8 MR. WOODARD:

9 And will the Regulations Committee be  
10 before that or after that?

11 MR. FINALET:

12 After that.

13 MR. WOODARD:

14 So they'll be --

15 MR. FINALET:

16 There is a Regulations Committee  
17 meeting in January 23rd I think. But  
18 that -- nothing marijuana related I  
19 don't think is on that agenda. But they  
20 wouldn't be discussing this anyway. The  
21 Board has to delegate it to the  
22 committee.

23 MR. WOODARD:

24 Okay.

25 MR. FINALET:

1           The committee does take up issues on  
2           their own. There's a process for it.

3           MR. WOODARD:

4           That's what Malcolm said. I haven't  
5           brought it up myself yet to be delegated  
6           that because I wasn't quite ready. But  
7           maybe at the Board, do I ask for it to  
8           be delegated?

9           MR. FINALET:

10           Well, what I'm going to suggest to  
11           Malcolm when he's preparing the  
12           comments, is you know, for the Board's  
13           Digest is to itemize your comments and  
14           concerns.

15           MR. WOODARD:

16           Okay.

17           MR. FINALET:

18           And that would give the Board  
19           President a vehicle to delegate that at  
20           that time.

21           MR. WOODARD:

22           Okay. Perfect.

23           MR. FINALET:

24           If you want to check before the  
25           meeting, you can always just submit a

1 request for that and then I'm not sure  
2 which part of the meeting it would be  
3 considered. It might be one of the  
4 actual agenda items or it might be part  
5 of the Executive Committee report.

6 MR. WOODARD:

7 Okay.

8 MR. FINALET:

9 I'm not sure. Why don't we do this.  
10 Malcolm gets back on the 2nd. You know,  
11 between now and then, maybe you shoot  
12 him an e-mail just asking that question.

13 MR. WOODARD:

14 And it's -- and he has told me that  
15 and given me that guidance that the  
16 proper procedure like you just said.  
17 It's got to go the Regulations  
18 Committee. That's where this will be  
19 hashed out. And that's really all we  
20 want is just to have the discussion.  
21 And I'd love for everyone to ask us  
22 questions because this was all so new  
23 for everyone, what's working.

24 I will say, professionally speaking,  
25 it's worked much more than I thought it

1           was. You know, we never really knew,  
2           you're going to flip the lights on if  
3           this is going to be like some, you know,  
4           shady, fly-by-night deal and it's just  
5           not that at all.

6           MR. FINALET:

7                     And I've heard that your particular  
8           location is doing very well.

9           MR. WOODARD:

10                    Yeah.

11           MR. FINALET:

12                    And I've hear good things about it.

13           MR. WOODARD:

14                    Okay. Thank you, Carlos. I think  
15           that's it.

16           MR. FINALET:

17                    Give Lisa my hello.

18           MR. WOODARD:

19                    I will.

20           MR. FINALET:

21                    I might come by soon.

22           MR. WOODARD:

23                    Thank you again for your help. I've  
24           talked to Kerry so I think we have a  
25           good plan.

1 MR. FINALET:

2 Good deal. Take care. Happy new  
3 year.

4 MR. WOODARD:

5 You too.

6 MR. FINALET:

7 Thank you.

8 (No public comments were received  
9 from 9:17 a.m. until 11:59 a.m.)

10 MR. FINALET:

11 The time is now 12:00 noon. This  
12 public hearing is adjourned.

13

14 (THE HEARING ADJOURNED AT 12:00 P.M.)

15

16

17

18

19

20

21

22

23

24

25

## 1                   C E R T I F I C A T E

2           This certification is valid only for a  
3 transcript accompanied by my original signature  
4 and official seal on this page.

5           I, SUSAN ERKEL, Certified Court Reporter, in  
6 and for the State of Louisiana, as the officer  
7 before whom this hearing was taken, do hereby  
8 certify that the foregoing 6 pages  
9 were reported by me in the voice-writing method,  
10 and was prepared and transcribed by me or under  
11 my personal direction and supervision, and is a  
12 true and correct transcript to the best of my  
13 ability and understanding;

14           That the transcript has been prepared in  
15 compliance with transcript format guidelines  
16 required by statute or by rules of the board, and  
17 that I am informed about the complete  
18 arrangement, financial or otherwise, with the  
19 person or entity making arrangements for  
20 deposition services;

21           That I have acted in compliance with the  
22 prohibition on contractual relationships, as  
23 defined by Louisiana Code of Civil Procedure  
24 Article 1434 and in rules and advisory opinions  
25 of the board;

1           That I have no actual knowledge of any  
2 prohibited employment or contractual  
3 relationship, direct or indirect, between a court  
4 reporting firm and any party litigant in this  
5 matter nor is there any such relationship between  
6 myself and a party litigant in this matter; and

7           That I am not related to counsel or to the  
8 parties herein, nor am I otherwise interested in  
9 the outcome of this matter.

10  
11  
12 \_\_\_\_\_  
13 SUSAN ERKEL

14 CERTIFIED COURT REPORTER

15 LICENSE NO. 24005  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

R E P O R T E R ' S P A G E

I, SUSAN ERKEL, Certified Court Reporter in and for the State of Louisiana, before whom this statement was taken, do hereby state on the Record:

That due to the interaction in the spontaneous discourse of this proceeding, dashes (--) have been used to indicate pauses, changes in thought, and/or talkovers;

That same is the proper method for a Court Reporter's transcription of proceedings, and that the dashes (--) do not indicate that words or phrases have been left out of this transcript;

That any words and/or names which could not be verified through reference material have been denoted with the phrase "(spelled phonetically)."

---

SUSAN ERKEL  
CERTIFIED COURT REPORTER  
LICENSE NO. 24005

A		box (1) 9:23 Brentwood (1) 3:7 bring (2) 8:4,12 brought (1) 19:5 building (5) 3:24;4:9,10,11,20 bullet (1) 8:11	17:7 comment (3) 7:12;13:6;15:10 comments (15) 5:3,18,20,25;6:2,16, 19,23,24;7:3,6,19; 19:12,13;22:8 Committee (7) 15:18;18:9,16,22; 19:1;20:5,18 committees (1) 5:10 commonly (1) 11:12 communicate (2) 11:3;12:4 Companies (1) 7:14 company (1) 8:21 complaints (1) 14:12 concerns (2) 16:6;19:14 confused (2) 11:12,24 connecting (1) 4:18 consider (1) 5:20 consideration (1) 6:17 considered (1) 20:3 constantly (1) 11:23 contact (1) 17:5 controlled (2) 12:21;16:21 convened (2) 4:24;5:17 conversation (1) 12:2 cooler (1) 4:5 Copies (1) 6:4 corner (1) 11:14 Counsel (1) 3:10 counseling (2) 9:25;10:2 count (1) 10:10 courtesy (1) 3:14 creates (1) 9:24 critical (1) 8:14	D
<p>absence (1) 3:10 access (1) 9:1 accordance (1) 4:21 Act (1) 4:22 Activity (1) 5:12 actual (1) 20:4 actually (3) 6:7;12:25;16:21 acute (2) 13:18;14:18 addition (1) 4:5 Additional (2) 4:15;10:3 address (1) 16:5 addressed (1) 15:7 adjacent (1) 11:11 adjourned (2) 22:12,14 Administrative (1) 4:22 advertising (2) 10:24,25 Affairs (1) 7:17 Again (5) 6:15;11:25;13:1,23; 21:23 agenda (5) 5:5;6:5;8:1;18:19; 20:4 Albertsons (1) 7:13 allowed (1) 9:4 always (1) 19:25 amendments (3) 5:24;6:8,20 Anderson (1) 7:10 anxiety (2) 13:19;14:18 anymore (1) 14:7 appropriate (2) 15:8,9 appropriately (1) 16:7 area (2) 4:15,19</p>	<p>Aron (1) 3:11 aspect (1) 15:7 aspects (1) 16:2 assembled (1) 3:5 Association (1) 7:8 attack (2) 13:19;14:18 available (3) 4:15;6:5,9</p>	<p>C California (1) 16:20 call (3) 3:13,18;11:9 can (11) 9:1,16,21;10:8,10; 11:5;12:17;16:21; 17:14,25;19:25 Cannabis (1) 13:12 Capitol (4) 7:24;9:14;11:22; 15:1 care (1) 22:2 Carlos (3) 3:8;7:23;21:14 Carol (1) 3:11 cell (1) 3:16 CEO (1) 7:11 certain (1) 9:16 Chain (2) 7:9;15:23 changed (1) 12:17 charge (1) 8:20 check (3) 10:6,11;19:24 checking (1) 10:17 clarify (1) 6:13 clinical (2) 14:3;16:23 close (1) 17:5 clothing (1) 4:16 Colorado (1) 16:20 comfort (1) 3:24 coming (1)</p>	<p>dancing (1) 12:8 data (1) 9:17 deadline (1) 6:19 deal (2) 21:4;22:2 debate (1) 6:14 December (3) 3:4;7:7,13 definitely (1) 15:6 delegate (3) 15:17;18:21;19:19 delegated (2) 19:5,8 deliver (3) 9:3,8,9 delivery (3) 8:18,20,21 desk (1) 6:6 determine (1) 5:23 devices (1) 3:16 different (1) 16:19 Digest (1) 19:13 direction (1) 12:19 Director (1) 7:16 discuss (2) 8:13;13:3 discussed (1) 9:13 discussing (1) 18:20 discussion (1) 20:20 dispense (1) 10:11 distributed (1) 5:11 doctors (1) 11:3 done (1) 8:8 door (3) 3:21,23;4:4 Dose (2) 13:13;14:1 down (1) 13:6 downtown (1) 9:9</p>	
	<p>B back (3) 4:10;10:1;20:10 based (1) 17:11 Baton (1) 3:7 bed (1) 8:24 begin (1) 6:23 behalf (1) 14:25 behind (2) 10:10,17 belong (1) 4:13 benefit (1) 16:22 beyond (1) 9:17 big (1) 10:20 biggest (2) 13:15;14:12 billboard (1) 11:1 blow (1) 12:8 Board (16) 3:6,9,11;4:13;5:5,9, 17,20;7:7;8:13;15:16; 17:14;18:3,21;19:7, 18 Boardroom (1) 3:5 Board's (5) 4:19;6:10,17;15:11; 19:12 body (1) 13:21 both (1) 14:22 bottom (1) 13:11 bound (1) 8:25</p>			

<b>Drive (1)</b> 3:7	<b>exit (1)</b> 3:20	<b>four (1)</b> 8:14	<b>hello (1)</b> 21:17	<b>items (2)</b> 15:8;20:4
<b>Drug (1)</b> 7:9	<b>expected (1)</b> 16:4	<b>fourth (1)</b> 13:10	<b>help (4)</b> 4:6;11:3;12:23; 21:23	<b>J</b>
<b>during (1)</b> 5:21	<b>extreme (1)</b> 9:5	<b>frankly (1)</b> 16:4	<b>helpful (2)</b> 9:11;10:12	<b>January (1)</b> 18:17
<b>duties (1)</b> 9:17	<b>F</b>	<b>Friday (1)</b> 3:3	<b>Highway (1)</b> 4:17	<b>Jefferson (1)</b> 4:17
<b>E</b>	<b>facility (1)</b> 11:10	<b>front (7)</b> 3:22;4:10,11,12,19; 6:7;17:20	<b>home (1)</b> 9:3	<b>K</b>
<b>edition (1)</b> 5:7	<b>far (1)</b> 9:18	<b>Further (2)</b> 3:17;5:8	<b>honestly (1)</b> 12:18	<b>keep (1)</b> 17:7
<b>educating (1)</b> 16:6	<b>faster (1)</b> 14:14	<b>future (2)</b> 8:12;13:3	<b>hour (1)</b> 14:17	<b>Kerry (1)</b> 21:24
<b>education (1)</b> 11:6	<b>fastest (1)</b> 13:20	<b>G</b>	<b>hurting (1)</b> 12:24	<b>kind (9)</b> 8:9,13,15;9:15; 11:4;13:5;16:15,24; 17:6
<b>effective (1)</b> 8:16	<b>February (3)</b> 5:22;15:11;18:3	<b>gap (1)</b> 14:17	<b>I</b>	<b>knew (1)</b> 21:1
<b>efficiently (1)</b> 12:3	<b>feel (1)</b> 8:9	<b>GB (2)</b> 14:7,7	<b>idea (1)</b> 12:14	<b>L</b>
<b>elderly (1)</b> 11:23	<b>feeling (1)</b> 15:16	<b>Geddes (1)</b> 7:16	<b>identify (2)</b> 6:24;7:1	<b>label (2)</b> 9:22;10:6
<b>electronic (3)</b> 3:16;5:12,13	<b>few (2)</b> 8:5,6	<b>General (2)</b> 3:10;12:5	<b>ILERA (1)</b> 14:6	<b>ladies (1)</b> 4:1
<b>else (1)</b> 3:14	<b>figure (1)</b> 17:25	<b>gentlemen (1)</b> 4:3	<b>improper (1)</b> 15:6	<b>language (1)</b> 6:13
<b>e-mail (1)</b> 20:12	<b>filed (1)</b> 5:9	<b>gets (1)</b> 20:10	<b>indicated (2)</b> 5:16;6:18	<b>Law (2)</b> 4:23;10:23
<b>emergency (1)</b> 3:20	<b>fill (2)</b> 10:5,8	<b>given (1)</b> 20:15	<b>informing (1)</b> 16:11	<b>laws (1)</b> 4:24
<b>ensure (1)</b> 4:7	<b>filling (2)</b> 9:18,18	<b>Good (4)</b> 3:3;21:12,25;22:2	<b>Inhaler (3)</b> 13:13;14:2;15:7	<b>legal (1)</b> 9:4
<b>enter (2)</b> 7:5;10:5	<b>FINALET (27)</b> 3:2,9;13:7;14:20; 15:3,15,21;16:1,10; 17:13,18,23;18:5,11, 15,25;19:9,17,23; 20:8;21:6,11,16,20; 22:1,6,10	<b>great (1)</b> 9:14	<b>inhibited (1)</b> 12:11	<b>legislative (2)</b> 5:10;7:17
<b>entered (1)</b> 3:23	<b>find (1)</b> 3:17	<b>groundbreaking (1)</b> 16:25	<b>input (1)</b> 17:15	<b>legislatively (1)</b> 14:22
<b>entry (1)</b> 9:17	<b>fine (1)</b> 10:21	<b>growth (2)</b> 8:16;12:11	<b>insofar (1)</b> 15:9	<b>letter (1)</b> 13:12
<b>especially (1)</b> 11:22	<b>firewall (1)</b> 10:14	<b>guess (3)</b> 7:22;8:11;10:8	<b>instance (1)</b> 11:20	<b>Library (1)</b> 6:9
<b>Essen (2)</b> 11:13,14	<b>first (4)</b> 5:9;7:25;8:6,17	<b>guest (1)</b> 6:3	<b>instant (1)</b> 14:10	<b>licensees (1)</b> 5:15
<b>essentially (1)</b> 9:22	<b>flag (1)</b> 11:15	<b>guidance (2)</b> 9:5;20:15	<b>intend (1)</b> 17:8	<b>Licensing (1)</b> 8:1
<b>established (1)</b> 8:23	<b>flip (1)</b> 21:2	<b>H</b>	<b>Intent (2)</b> 5:6;6:14	<b>lights (1)</b> 21:2
<b>establishing (1)</b> 8:7	<b>flower (1)</b> 13:24	<b>happy (3)</b> 9:2;17:9;22:2	<b>Interested (1)</b> 5:14	<b>line (1)</b> 10:21
<b>even (3)</b> 8:3;9:5;13:4	<b>fly-by-night (1)</b> 21:4	<b>hashed (1)</b> 20:19	<b>interpretation (1)</b> 6:13	<b>lines (1)</b> 17:20
<b>event (1)</b> 6:4	<b>folks (4)</b> 11:23;12:12;16:16, 17	<b>hear (1)</b> 21:12	<b>into (4)</b> 3:22;7:5;13:16,21	<b>Lisa (1)</b> 21:17
<b>everyone (4)</b> 3:14;17:9;20:21,23	<b>forth (1)</b> 13:8	<b>heard (1)</b> 21:7	<b>issue (2)</b> 10:15;14:9	<b>List (1)</b> 5:14
<b>evolve (2)</b> 16:4,5	<b>forum (2)</b> 13:5;15:5	<b>hearing (10)</b> 3:12,13;4:21,24; 5:2,5,17;6:16;22:12, 14	<b>issues (4)</b> 6:14;8:14;13:15; 19:1	<b>listed (1)</b> 5:4
<b>evolving (1)</b> 16:3		<b>held (1)</b> 4:21	<b>item (1)</b> 8:1	<b>literally (1)</b> 12:14
<b>exactly (2)</b> 8:2,18			<b>itemize (1)</b> 19:13	
<b>Executive (1)</b> 20:5				

<p><b>lively (1)</b> 15:22</p> <p><b>lives (1)</b> 12:16</p> <p><b>lobby (3)</b> 3:22,25;4:2</p> <p><b>located (2)</b> 3:7,25</p> <p><b>location (3)</b> 11:11,20;21:8</p> <p><b>logjam (1)</b> 9:24</p> <p><b>logo (1)</b> 11:22</p> <p><b>looks (1)</b> 14:5</p> <p><b>lot (3)</b> 4:18;16:5,22</p> <p><b>Louisiana (4)</b> 3:6,8;5:8;6:11</p> <p><b>love (1)</b> 20:21</p> <p><b>LSU (2)</b> 14:8;16:17</p> <p><b>lungs (1)</b> 13:22</p>	<p><b>mind (2)</b> 4:7;10:8</p> <p><b>minimum (1)</b> 10:5</p> <p><b>model (1)</b> 16:20</p> <p><b>moderate (1)</b> 3:12</p> <p><b>months (3)</b> 8:6,8;12:15</p> <p><b>more (3)</b> 12:1;14:4;20:25</p> <p><b>morning (1)</b> 3:3</p> <p><b>most (1)</b> 9:25</p> <p><b>much (3)</b> 16:19,19;20:25</p> <p><b>myself (1)</b> 19:5</p>	<p>9:20</p> <p><b>Open (2)</b> 4:23;12:16</p> <p><b>opening (1)</b> 8:7</p> <p><b>opposite (2)</b> 4:1;13:1</p> <p><b>option (1)</b> 9:10</p> <p><b>oral (3)</b> 7:4,18;14:14</p> <p><b>order (1)</b> 3:13</p> <p><b>organization (1)</b> 6:25</p> <p><b>out (3)</b> 11:15;17:25;20:19</p> <p><b>outside (3)</b> 3:19;4:3;11:21</p> <p><b>over (2)</b> 8:6;13:11</p> <p><b>oversight (1)</b> 5:10</p> <p><b>own (1)</b> 19:2</p>	<p><b>perform (1)</b> 9:16</p> <p><b>Perlis (1)</b> 4:16</p> <p><b>personally (2)</b> 9:13;14:25</p> <p><b>perspective (1)</b> 14:3</p> <p><b>pertains (1)</b> 8:3</p> <p><b>Pharmacies (3)</b> 8:2,17;17:6</p> <p><b>Pharmacist (4)</b> 7:15;8:20;9:20; 14:25</p> <p><b>Pharmacy (7)</b> 3:6,9;7:16;9:8;10:7, 10:12;24</p> <p><b>phones (1)</b> 3:16</p> <p><b>physicians (2)</b> 11:7;12:13</p> <p><b>Picardy (2)</b> 11:13,14</p> <p><b>plan (1)</b> 21:25</p> <p><b>please (5)</b> 3:15,18;4:6,7;7:1</p> <p><b>PM (1)</b> 22:14</p> <p><b>point (2)</b> 13:8,10</p> <p><b>points (1)</b> 8:11</p> <p><b>possible (2)</b> 6:1;13:17</p> <p><b>posted (1)</b> 5:1</p> <p><b>postmortem (1)</b> 17:3</p> <p><b>practice (1)</b> 12:23</p> <p><b>prepared (1)</b> 6:22</p> <p><b>preparing (1)</b> 19:11</p> <p><b>President (3)</b> 3:11;7:11;19:19</p> <p><b>President's (1)</b> 15:17</p> <p><b>Prior (1)</b> 6:2</p> <p><b>procedure (1)</b> 20:16</p> <p><b>Procedures (1)</b> 4:22</p> <p><b>process (1)</b> 19:2</p> <p><b>product (6)</b> 9:21;10:15;13:16; 14:6,8,15</p> <p><b>professional (1)</b> 12:6</p>	<p><b>professionally (3)</b> 10:16;12:4;20:24</p> <p><b>prohibit (1)</b> 8:15</p> <p><b>prohibited (1)</b> 10:23</p> <p><b>projects (4)</b> 5:4,7,19;16:3</p> <p><b>proper (2)</b> 15:5;20:16</p> <p><b>properly (1)</b> 5:1</p> <p><b>proposed (3)</b> 5:24;6:8,20</p> <p><b>PTSD (1)</b> 13:19</p> <p><b>Public (13)</b> 3:13;4:25;5:3,17, 18:6;9:7;19:12;5,25; 13:6;16:11;22:8,12</p> <p><b>published (1)</b> 5:6</p> <p><b>purpose (3)</b> 5:2;6:15;14:21</p> <p><b>pursuant (1)</b> 4:25</p> <p><b>put (1)</b> 11:1</p>
<b>M</b>	<b>N</b>	<b>P</b>	<b>Q</b>	
<p><b>main (1)</b> 11:9</p> <p><b>making (1)</b> 6:2</p> <p><b>Malcolm (3)</b> 19:4,11;20:10</p> <p><b>Marijuana (8)</b> 8:1,17;11:2,10,16; 12:10,24;18:18</p> <p><b>may (2)</b> 6:12;7:1</p> <p><b>maybe (6)</b> 8:11;9:4;13:2,8; 19:7;20:11</p> <p><b>mean (2)</b> 11:20;16:23</p> <p><b>mechanism (2)</b> 8:19;14:10</p> <p><b>medical (3)</b> 11:2,10;12:9</p> <p><b>medication (3)</b> 9:2,19;13:21</p> <p><b>meeting (9)</b> 3:19;5:22;8:12; 13:3;15:12;18:3,17; 19:25;20:2</p> <p><b>Meetings (2)</b> 4:23;15:23</p> <p><b>Members (1)</b> 8:13</p> <p><b>Metered (2)</b> 13:12;14:1</p> <p><b>might (4)</b> 7:22;20:3,4;21:21</p>	<p><b>necessary (2)</b> 3:17;5:24</p> <p><b>need (3)</b> 11:1;14:9;15:2</p> <p><b>needed (1)</b> 17:24</p> <p><b>new (2)</b> 20:22;22:2</p> <p><b>next (1)</b> 5:22</p> <p><b>noon (2)</b> 6:21;22:11</p> <p><b>notice (4)</b> 4:25,25;5:12;7:25</p> <p><b>noticed (1)</b> 8:6</p> <p><b>Notices (4)</b> 5:6,16;6:5,18</p> <p><b>November (3)</b> 5:7,11,13</p> <p><b>number (1)</b> 13:12</p>	<p><b>paid (1)</b> 13:18</p> <p><b>paraphernalia (1)</b> 11:16</p> <p><b>park (1)</b> 4:8</p> <p><b>parking (4)</b> 4:12,15,18,19</p> <p><b>part (3)</b> 15:10;20:2,4</p> <p><b>particular (1)</b> 21:7</p> <p><b>Parties (1)</b> 5:14</p> <p><b>past (1)</b> 4:2</p> <p><b>path (1)</b> 3:21</p> <p><b>patient (2)</b> 10:2;17:11</p> <p><b>patients (8)</b> 8:22;10:1,3;11:4,8; 12:13;14:11;16:12</p> <p><b>patient's (1)</b> 13:16</p> <p><b>peace (1)</b> 4:7</p> <p><b>Pennington (1)</b> 16:17</p> <p><b>People (3)</b> 11:17;12:8;16:15</p> <p><b>Percocet (1)</b> 10:9</p> <p><b>Perfect (2)</b> 18:3;19:22</p>	<p><b>quickly (1)</b> 13:17</p> <p><b>quite (2)</b> 12:25;19:6</p>	
	<b>O</b>		<b>R</b>	
	<p><b>off (1)</b> 11:13</p> <p><b>offered (1)</b> 5:21</p> <p><b>Office (1)</b> 7:7</p> <p><b>one (12)</b> 4:8,11,12;7:7;9:20; 10:20;11:3;13:14; 14:1,12;15:7;20:3</p> <p><b>only (1)</b></p>		<p><b>rather (1)</b> 6:6</p> <p><b>reach (1)</b> 11:8</p> <p><b>ready (1)</b> 19:6</p> <p><b>real (1)</b> 14:9</p> <p><b>really (8)</b> 9:17;10:22,23;11:7; 12:10;17:15;20:19; 21:1</p> <p><b>rear (1)</b> 4:16</p> <p><b>reason (1)</b> 11:9</p> <p><b>reasons (1)</b> 13:17</p> <p><b>receive (4)</b> 5:3,18;6:16,22</p> <p><b>received (1)</b> 22:8</p> <p><b>receptionist's (1)</b> 4:2</p> <p><b>recommending (1)</b></p>	

11:10 <b>record (2)</b> 7:5,23 <b>Register (3)</b> 5:8;6:3,11 <b>registration (1)</b> 6:6 <b>regular (1)</b> 4:14 <b>regularly (1)</b> 11:17 <b>regulation (2)</b> 14:22;15:18 <b>Regulations (3)</b> 18:9,16;20:17 <b>regulatory (4)</b> 5:4,19;7:2,17 <b>related (1)</b> 18:18 <b>relationship (1)</b> 8:24 <b>relief (1)</b> 14:10 <b>remotely (1)</b> 13:13 <b>reply (1)</b> 5:25 <b>report (1)</b> 20:5 <b>reports (1)</b> 5:9 <b>represent (1)</b> 7:1 <b>representative (2)</b> 7:10,15 <b>representing (1)</b> 7:24 <b>request (1)</b> 20:1 <b>requested (1)</b> 3:12 <b>required (1)</b> 4:23 <b>restrooms (1)</b> 3:25 <b>review (3)</b> 10:6;15:10;17:3 <b>Revision (1)</b> 15:18 <b>revisions (1)</b> 5:23 <b>right (9)</b> 6:7;8:4;12:19;13:5; 15:25;16:9,9,12,18 <b>roads (1)</b> 12:9 <b>Robert (1)</b> 7:15 <b>room (5)</b> 3:15,19,21;4:4,6 <b>Rouge (1)</b> 3:8 <b>rule (2)</b>	5:24;6:8 <b>Rulemaking (1)</b> 5:12 <b>rules (1)</b> 6:20 <b>running (2)</b> 8:7,16	4:9,12 <b>speaking (7)</b> 9:13;14:24;16:15, 16,17;17:4;20:24 <b>specifically (5)</b> 7:9,14;12:1;13:2; 17:10 <b>specifics (1)</b> 10:22 <b>spend (1)</b> 9:25 <b>spokesperson (1)</b> 17:8 <b>stairway (1)</b> 4:18 <b>start (2)</b> 12:2;17:1 <b>starting (1)</b> 18:6 <b>state (1)</b> 17:6 <b>statements (2)</b> 7:4,18 <b>states (1)</b> 16:16 <b>statewide (1)</b> 12:12 <b>step (1)</b> 3:19 <b>Steven (1)</b> 7:10 <b>stick (1)</b> 9:22 <b>still (4)</b> 10:17;12:12;13:20; 14:16 <b>stopped (1)</b> 10:4 <b>store (1)</b> 4:16 <b>Stores (1)</b> 7:9 <b>submit (1)</b> 19:25 <b>submitted (2)</b> 7:6,12 <b>submitting (1)</b> 7:3 <b>suggest (1)</b> 19:10 <b>support (2)</b> 14:3;15:2 <b>sure (3)</b> 8:2;20:1,9 <b>system (1)</b> 13:16	<b>technicians (2)</b> 9:15;10:14 <b>telephone (1)</b> 3:18 <b>testimony (7)</b> 5:3,18,21;6:17,19, 23;7:3 <b>thereafter (2)</b> 6:1;15:23 <b>third-party (1)</b> 8:21 <b>thought (1)</b> 20:25 <b>three (3)</b> 4:9;8:14;10:2 <b>tinctures (1)</b> 14:14 <b>TJ (1)</b> 7:23 <b>Today (5)</b> 3:3;5:21;6:2,15,21 <b>today's (3)</b> 5:2,5;6:4 <b>told (1)</b> 20:14 <b>topic (1)</b> 7:2 <b>touch (1)</b> 9:21 <b>tow (1)</b> 4:13 <b>traditional (3)</b> 9:8;10:7,9 <b>traditionally (1)</b> 10:18 <b>transportation (1)</b> 8:25 <b>trials (1)</b> 16:24 <b>trucks (1)</b> 4:14 <b>truly (2)</b> 8:24;12:17 <b>two (2)</b> 7:5;9:14 <b>type (1)</b> 11:16	13:25 <b>various (1)</b> 13:17 <b>vehicle (1)</b> 19:19 <b>venue (1)</b> 8:4 <b>visitors (1)</b> 4:14
	<b>S</b>			<b>W</b>
	<b>safety (1)</b> 3:20 <b>same (1)</b> 17:7 <b>saying (2)</b> 12:9;13:24 <b>scenario (1)</b> 9:7 <b>second (2)</b> 7:12;9:12 <b>secondary (1)</b> 13:19 <b>section (1)</b> 6:9 <b>seems (1)</b> 10:13 <b>sell (1)</b> 11:2 <b>sense (1)</b> 10:25 <b>serve (1)</b> 3:9 <b>several (2)</b> 8:8,22 <b>shady (1)</b> 21:4 <b>shoot (1)</b> 20:11 <b>side (1)</b> 4:1 <b>sign (1)</b> 6:3 <b>silence (1)</b> 3:15 <b>situations (1)</b> 9:5 <b>six (1)</b> 12:15 <b>skipping (1)</b> 13:11 <b>slowly (1)</b> 12:20 <b>Solutions (1)</b> 7:25 <b>someone's (2)</b> 13:21;14:17 <b>Sometimes (1)</b> 9:24 <b>soon (2)</b> 5:25;21:21 <b>southern (1)</b> 14:6 <b>spaces (2)</b>	<b>talked (1)</b> 21:24 <b>talking (1)</b> 16:23	<b>T</b>	<b>waiting (1)</b> 10:4 <b>water (1)</b> 4:5 <b>way (6)</b> 11:8,18;12:6,25; 13:20;16:18 <b>ways (1)</b> 16:22 <b>website (2)</b> 6:10,11 <b>Wellcanna (1)</b> 14:8 <b>Wellness (2)</b> 7:25;9:14 <b>what's (6)</b> 8:9,10;17:3,4,12; 20:23 <b>whatsoever (1)</b> 10:16 <b>window (1)</b> 4:3 <b>without (1)</b> 12:24 <b>WOODARD (25)</b> 7:21,24;13:9;14:23; 15:13,19,24;16:8,13; 17:16,21;18:2,8,13, 23;19:3,15,21;20:6, 13;21:9,13,18,22;22:4 <b>work (3)</b> 14:15,15;17:25 <b>worked (1)</b> 20:25 <b>working (6)</b> 8:9,10;17:3,4,11; 20:23 <b>world (1)</b> 10:13 <b>written (2)</b> 7:6,12
			<b>U</b>	<b>X</b>
			<b>underutilized (1)</b> 9:16 <b>unless (1)</b> 11:8 <b>up (8)</b> 8:5,12;11:1;12:8; 14:1;17:7;19:1,5 <b>use (1)</b> 16:21	<b>Y</b>
			<b>V</b>	<b>y'all (2)</b> 17:19,24
			<b>vaporization (1)</b>	

<b>year (1)</b> 22:3				
<b>1</b>				
<b>11:59 (1)</b> 22:9 <b>12:00 (3)</b> 6:21;22:11,14 <b>15 (1)</b> 14:16 <b>17 (2)</b> 5:4,19				
<b>2</b>				
<b>2019 (5)</b> 3:4;5:7,13;7:8,13 <b>2020 (1)</b> 5:22 <b>23 (1)</b> 7:7 <b>23rd (1)</b> 18:17 <b>26 (1)</b> 7:13 <b>27 (1)</b> 3:4 <b>2nd (1)</b> 20:10				
<b>3</b>				
<b>3 (1)</b> 13:12 <b>30 (1)</b> 14:16 <b>3388 (1)</b> 3:7				
<b>5</b>				
<b>5 (1)</b> 5:22				
<b>8</b>				
<b>8 (1)</b> 5:11				
<b>9</b>				
<b>9 (1)</b> 5:13 <b>9:00 (2)</b> 3:4;18:7 <b>9:17 (1)</b> 22:9				



NATIONAL ASSOCIATION OF  
CHAIN DRUG STORES



December 20, 2019

Mr. Malcolm J. Broussard  
Executive Director  
Louisiana Board of Pharmacy  
3388 Brentwood Drive  
Baton Rouge, LA 70809-1700

By Fax: 225-925-6649  
By Email: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Dear Mr. Broussard:

On behalf of our members operating in Louisiana, the National Association of Chain Drug Stores(NACDS) appreciates the opportunity to comment on several regulatory projects. We are writing to express our concerns with projects related to pharmacy immunizations and dispensing of prescription refills. Additionally, we acknowledge and appreciate the Board's efforts to reduce unnecessary and onerous regulations that provide little value from a safety perspective and modernize pharmacy practice for the benefit of patients.

NACDS represents traditional drug stores, supermarkets, and mass merchants with pharmacies. In Louisiana, NACDS members operate 588 pharmacies that employ over 37,700 people. Chains operate over 40,000 pharmacies, and NACDS' over 80 chain member companies include regional chains, with a minimum of four stores, and national companies. Nationally, they fill over 3 billion prescriptions yearly and help patients use medicines correctly and safely, while offering innovative services that improve patient health and healthcare affordability. NACDS members also include more than 900 supplier partners and over 70 international members representing 21 countries. For more information, please visit [nacds.org](http://nacds.org).

#### COMMENTS AND RECOMMENDED AMENDMENTS

##### Project 2019-2 ~ Pharmacy Immunizations

As the face of neighborhood health care, community pharmacies and pharmacists provide accessible and cost-effective health services, including immunizations, to their local communities. Highly educated to provide patient care services, pharmacists are well-suited to help states increase their vaccination rates and further reduce the incidence of vaccine preventable diseases.

##### Reporting to the State Immunization Registry

As members of the healthcare team, pharmacists are committed to improving and promoting the health of their patients and communicating with physicians to demonstrate this commitment. NACDS members observe various timeline requirements across the country in terms of reporting the administration of vaccinations. The frequency of reporting vaccine administration by pharmacists to a state department of health or registry varies from 7 days in Rhode Island to 30 days in Ohio. The most common requirement is 14 days, as seen in Nevada, North Dakota, New York, and Texas.

Given these variations, we strongly recommend amending the following language:

**F. 2. The immunizing pharmacist or his designee shall report the immunization to the state immunization registry within seven days~~72 hours~~ of the administration of the immunization.**

In addition to the adjustment in reporting requirement timeline, we seek confirmation that the transmission of data is acceptable through an automated electronic transmission.

**Pharmacist Administering Immunizations in Locations other than a Pharmacy**

We seek clarification of the following subsection that we believe was intended to focus on pharmacists providing immunization services at locations other than pharmacies, or planned immunizing events at a pharmacy location. Currently, patients receiving immunizations are instructed to remain at the location for 15 minutes. This ensures the pharmacist is available to respond in the rare instance of an adverse reaction.

Additionally, pharmacy-based immunizations have contributed to a marked increase in vaccination rates across the country. If the intent of the board is to encompass pharmacy-based immunizations within the usual course of business as governed by this amendment, we fear there may be an unintended impact on vaccination rates, and therefore, public health. As many pharmacies provide immunizations within their usual workflow, it would not be uncommon for a patient to present for a needed vaccination at the open or near the close of business. In many pharmacies, the pharmacist would be working without technician support at this time due to limited workload and demand during these hours. The current language of the draft amendments would impede this patient from receiving a vaccination as there would be no additional staffing. Amending the language to indicate that a pharmacist should have adequate time to provide a vaccination would reduce this concern.

With this in mind, we strongly recommend amending the following language:

**H. ~~Pharmacies hosting immunization activities, as well as~~ Pharmacists administering immunizations in a location other than a pharmacy, or outside of the usual pharmacy workflow, shall comply with the following minimum standards:**

- 1. There shall be sufficient time~~staffing available~~ for the pharmacist to administer the immunization and monitor the patient in line with recommended guidelines~~afterward without distraction from other responsibilities~~.**
- 2. To facilitate emergency management of anaphylactic reactions, there shall be adequate supplies of medication and equipment, as well as pre-determined procedures for the arrangement of emergency medical services.**

**Project 2019-8 ~ Dispensing of Prescription Refills**

The issue of poor medication adherence by patients is a well-documented problem in the United States. The New England Healthcare Institute reports that poor adherence costs the U.S. healthcare system \$290 billion annually and results in avoidable and costly health complications, worsening of disease progression, increased emergency room visits, and hospital stays.

Pharmacies have useful tools and programs that can be implemented to help their patients be better adherent to their medication regimen. With the prior consent or approval of the patient or caregiver, these programs provide resources to improve medication adherence. The overall goal is to provide patients or caregivers options to approve refills without having to contact the pharmacy each time prior to picking up chronic prescription(s). Patients or caregivers should be able to approve refills for one or more chronic medications by opting into an adherence program offered by their pharmacy. They also may opt-out for any individual medications, if desired. For example, according to one recent study on this issue, patients enrolled in an automated prescription refill intervention



program obtained their refilled medications at higher rates than patients in the control group, indicating that the program had a positive impact on patients' adherence.<sup>1</sup> There are clearly public health benefits to facilitating use of adherence programs.

The proposed language changes may impede community pharmacies' ability to use various tools and programs to improve adherence. We are concerned that the proposed rule could be interpreted to require community pharmacies to obtain patient or caregiver consent *each* time prior to the pharmacy beginning the refilling process. It is common practice for community pharmacies to obtain patient or caregiver consent or approval prior to enrolling patients into adherence programs, and also to dis-enroll patients from these programs upon the patient's or caregiver's request. However, community pharmacies do not otherwise call to reconfirm consent prior to initiating the filling process each time they refill a prescription. Doing so would create unnecessary work for pharmacy staff and would inconvenience patients or caregivers who already provided consent or approval upon enrollment in pharmacy adherence programs or through the use of other adherence tools available from pharmacies. We seek clarification that a patient or caregiver may be granted the ability to approve the overall process of refilling prescriptions for chronic medications to avoid excessive outreach from the pharmacy and to preserve the benefits of adherence provided by such programs.

We are unclear what public health goal is achieved by imposing such strict limitations on adherence programs. As such, we do not see the public health benefit in regulating these programs (especially in the limiting manner outlined.)


We strongly recommend the following language changes:


B. Refill Request. Prescription refills authorized by the prescriber shall not be dispensed in the absence of a patient or caregiver's request or approval. A patient or caregiver may request or approve a single prescription refill or multiple, ongoing prescription refills, and the request or approval may apply to one prescribed medication or multiple prescribed medications. This prohibition shall not apply to refills authorized by the prescriber which are to be dispensed to a patient residing in a long term care facility.

#### Conclusion

NACDS thanks you for your consideration of our concerns and recommendations related to pharmacy immunizations and dispensing of prescription refills. Pharmacists are committed to the improving and promoting the health and welfare of their patients through preventive services, such as administration of immunizations, and programs to achieve optimal use of medications. If you have questions, please contact Mary Staples via email at [mstaples@nacds.org](mailto:mstaples@nacds.org) or by phone at 817-442-1155.

Sincerely,

  
Steven C. Anderson, IOM, CAE  
President and Chief Executive Officer



<sup>1</sup> Jiang, JZ, N Khandelwal, SG Frazee, and J Nadas. "PHP54 STUDY THE IMPACT OF AUTOREFILL PROGRAM ON MEDICATION ADHERENCE." *Value in Health* 13, no. 3 (2010): A91. doi:10.1016/S1098-3015(10)72434-7.

December 24, 2019

EXHIBIT  
tabbies  
2

Mr. Malcolm J. Broussard  
Executive Director  
Louisiana Board of Pharmacy  
3388 Brentwood Drive  
Baton Rouge, LA 70809-1700



Dear Mr. Broussard:

On behalf of Albertsons Companies, which operates 16 pharmacies in the state of Louisiana I am writing in response to the recently proposed rules, which will be heard on December 27, 2019. First and foremost, I want to thank the regulation committee and full board for all the hard work and hours that have been dedicated to streamlining and strengthening the regulations of Louisiana. I have a few concerns, which I would like to express to help shed light on a few areas where the regulations could prove problematic.

**2019-2 Pharmacy Immunizations:**

Our company fully supports timely reporting to the immunization registry by pharmacies. This is a valuable resource for all healthcare providers to increase access to life saving immunizations, as well as providing a framework to ensure immunizations are provided on the correct schedule. However, the requirement of reporting to the registry in 72 hours for all instances, can prove to be difficult in certain circumstances. There are varying timeline requirements across the country from 7 days to 30 days. To ensure the records are submitted accurately and not in haste, I respectfully request the timeline be extended from 72 hours to seven days.

I recommend amending the language in the following way:

*F. 2. The immunizing pharmacist or his designee shall report the immunization to the state immunization registry within seven days ~~72 hours~~ of the administration of the immunization.*

**2019-15 Drug Disposal by Pharmacies:**

These sections outline the instances where it is appropriate for a pharmacy to accept a return of medications. Based on my previous communication with you by email dated November 21, 2019 (attached), I would like to draw attention to section 2749 that states a pharmacy shall accept controlled substances previously dispensed by the pharmacy and may accept products dispensed by other pharmacies. In your response you stated this language may have been a drafting error. I would ask that the language of section 2749 be reviewed and reflect the option a pharmacy has in participating in drug disposal pursuant to sections 1519, 2503, and 2517.

Thank you very much for the opportunity to address these concerns. If you should have a question or concern, please reach out to me at 208-513-3470 or [rob.geddes@albertsons.com](mailto:rob.geddes@albertsons.com).

Sincerely,



Rob Geddes, PharmD  
Director, Pharmacy Legislative and Regulatory Affairs



December 2, 2019

Malcolm J Broussard, Executive Director  
Louisiana Board of Pharmacy  
3388 Brentwood Drive  
Baton Rouge, LA 70809-1700  
Cc via email: mbroussard@pharmacy.la.gov

Re: Rule § 2425 Telepharmacy Dispensing Sites

To Mr. Broussard:

On behalf of TelePharm I would like to thank you for the opportunity to comment on the proposed rule changes for telepharmacy dispensing sites. We applaud the Louisiana Board of Pharmacy (LABP) for taking the initiative of improving access to pharmacy services for patients living in Louisiana through the revision of the telepharmacy rules.

We support the LABP's current proposed rule changes to decrease telepharmacy mileage restrictions and to remove the provision which requires a telepharmacy dispensing site to permanently close or convert to a community pharmacy permit if another pharmacy opens within the mileage radius. The requirement to permanently close if another pharmacy opens within the mileage radius has served as a near prohibition as it created too much risk for a pharmacy that wished to open a telepharmacy site. Removal of this provision and decreasing the mileage restriction will both have a significant, positive impact on patient care as telepharmacy dispensing sites will connect more patients to enhanced pharmacy services.

Nationwide, telepharmacy dispensing sites have been shown to increase access to pharmacists and pharmacy services for patients who live in medically underserved areas without compromising patient safety. The proposed revisions to this rule will further this endeavor for residents who live throughout the state of Louisiana.

Thank you for your time and consideration on this matter. I can be reached at [jessica.adams@telepharm.com](mailto:jessica.adams@telepharm.com) or on my cell at (512)426-6868 for any questions.

Sincerely,

A handwritten signature in black ink that reads 'Jessica Adams'.

Jessica Adams, PharmD  
Manager, Regulatory Affairs



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-1B ~ Licensing of Marijuana Pharmacies  
at  
December 27, 2019 Public Hearing

1. TJ Woodard, PharmD on behalf of Capitol Wellness Solutions

Offered no comments or testimony about the proposed rule amendment.

Requested and granted an opportunity to present concerns relative to other parts of the rule for marijuana pharmacies:

- Some of their patients are home-bound and are unable to travel to the pharmacy. Some do not have caregivers or others who may retrieve their medications. Dr. Woodard would be willing to deliver prescriptions to his patients and believes some of the other marijuana pharmacies would be willing to do the same. He requested the Board consider some type of rule amendment that would allow deliveries of medication to patients.
- He believes the rule unnecessarily restricts what pharmacy technicians may do in marijuana pharmacies, resulting in under-utilization of those personnel. On occasion, that has caused delays in processing patient prescriptions.
- He requested the Board consider a modification of the advertising restrictions relative to the pharmacy location, to allow the pharmacy to inform consumers of their business. He related this location is adjacent to a facility hosting physician recommenders of marijuana products, and his pharmacy is commonly mistaken as part of that facility.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-2 ~ Pharmacy Immunizations  
at  
December 27, 2019 Public Hearing

1. Steven C. Anderson, CEO, on behalf of National Association of Chain Drug Stores

- Noted that timeframes for reporting of immunizations varies across the states, ranging from 7 days to 30 days, with the most common at 14 days. Requested an amendment of §521.F.2, to replace the proposed 72-hour reporting requirement with a 7-day reporting requirement.
- Requested confirmation that a reporting process using an automated electronic transmission would be acceptable.
- Requested amendments to §521.H, as noted here:
  - H. ~~Pharmacies hosting immunization activities, as well as~~ Pharmacists administering immunizations in a location other than a pharmacy, or outside the usual pharmacy workflow, shall comply with the following minimum standards:
    1. There shall be sufficient ~~staffing available time~~ for the pharmacist to administer the immunization and monitor the patient ~~afterward without distraction from other responsibilities in line with recommended guidelines.~~
    2. To facilitate emergency management of anaphylactic reactions, there shall be adequate supplies of medication and equipment, as well as pre-determined procedures for the arrangement of emergency medical services.

Noted their concern that proposed language would prevent patients arriving at the opening or near the close of business from receiving immunizations since the pharmacist may be operating without technician support at those times. Suggested that substituting 'time' for 'staffing' would address the concern and not impede vaccination rates in pharmacies.

2. Rob Geddes, PharmD, on behalf of Albertsons Companies

Noted that timeframes for reporting of immunizations varies across the states, ranging from 7 days to 30 days. Requested an amendment of §521.F.2, to replace the proposed 72-hour reporting requirement with a 7-day reporting requirement.

# Louisiana Administrative Code

## Title 46 – Professional and Occupational Standards

### Part LIII: Pharmacists

#### Chapter 5. Pharmacists

##### Subchapter B. Professional Practice Procedures

#### §521. Prescription Orders to Administer Medications

A. – E.2. ...

F. Vaccines.

1. The pharmacist shall maintain and furnish the following information to the practitioner within twenty-four hours of the administration:
  - ~~1.~~ a. name and address of the patient;
  - ~~2.~~ b. age of the patient, if under fourteen years of age;
  - ~~3.~~ c. name of the patient's primary care physician as provided by the patient or patient's agent;
  4. d. name, manufacturer, and lot number of the vaccine administered;
  - ~~5.~~ e. amount administered;
  - ~~6.~~ f. date of vaccine administration;
  7. g. site of vaccine administration;
  - ~~8.~~ h. route of administration; and
  9. i. name, address, and telephone number of the pharmacist administering the vaccine.
2. The immunizing pharmacist or his designee shall report the immunization to the state immunization registry within 72 hours of the administration of the immunization.

G. ...

H. Pharmacies hosting immunization activities, as well as pharmacists administering immunizations in a location other than a pharmacy, shall comply with the following minimum standards:

1. There shall be sufficient staffing available for the pharmacist to administer the immunization and monitor the patient afterward without distraction from other responsibilities.
2. To facilitate emergency management of anaphylactic reactions, there shall be adequate supplies of medication and equipment, as well as pre-determined procedures for the arrangement of emergency medical services.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 14:708 (October 1988), effective January 1, 1989, amended LR 29:2085 (October 2003), effective January 1, 2004, amended LR 34:1409 (July 2008), amended by the Department of Health, Board of Pharmacy, LR



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-3 ~ Investigational Drugs  
at  
December 27, 2019 Public Hearing

*No comments or testimony received.*



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-4 ~ Telepharmacy Dispensing Sites  
at  
December 27, 2019 Public Hearing

1. Jessica Adams, PharmD, on behalf of TelePharm

Expressed support for proposed revisions; did not request any amendments.



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-5 ~ Correctional Center Pharmacy  
at  
December 27, 2019 Public Hearing

*No comments or testimony received.*



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-7 ~ Veterinary Hospital Pharmacy  
at  
December 27, 2019 Public Hearing

*No comments or testimony received.*



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-8 ~ Dispensing of Prescription Refills  
at  
December 27, 2019 Public Hearing

1. Steven C. Anderson, CEO, on behalf of National Association of Chain Drug Stores

- Expressed concern for potential interpretation of rule that would require patient approval or consent for every prescription dispensed in lieu of allowing patient to approve some or all prescriptions. Requested amendment of §2519.B, as noted here:
  - B. Refill Requests. Prescription refills authorized by the prescriber shall not be dispensed in the absence of a patient or caregiver's request or approval. A patient or caregiver may request or approve a single prescription refill or multiple, ongoing prescription refills, and the request or approval may apply to one prescribed medication or multiple prescribed medications. This prohibition shall not apply to refills authorized by the prescriber which are to be dispensed to a patient residing in a long term care facility.

## Louisiana Administrative Code

### Title 46 – Professional and Occupational Standards

#### Part LIII – Pharmacists

#### Chapter 25. Prescriptions, Drugs, and Devices

#### §2519. Prescription Refills; Medication Synchronization and Refill Consolidation

- A. ...
- B. Refill Requests. Prescription refills authorized by the prescriber shall not be dispensed in the absence of a patient or caregiver's request or approval. This prohibition shall not apply to refills authorized by the prescriber which are to be dispensed to a patient residing in a long term care facility.
- ~~B.~~ C. Controlled Dangerous Substances.
  - 1. The refilling of a prescription for a drug listed in Schedule II is prohibited.
  - 2. A prescription for a drug listed in Schedule III, IV, or V may be refilled up to five times, if so indicated at the time issued.
- ~~C.~~ D. Medication Synchronization and Refill Consolidation. These terms refer to a service which a pharmacist may perform for his patient, at the request of the patient, wherein he may proactively adjust the medication dispensing quantity and/or the refill schedule of a prescription in order to manage the patient's medication therapy, with the goal of improved medication adherence by the patient.
  - 1. For the performance of this service, the pharmacist may adjust the dispensing quantity and/or the refill schedule originally ordered by the prescriber; however, the pharmacist shall not exceed the total quantity prescribed [dispensing quantity multiplied by the total number of fills authorized (original plus refills)], or what is otherwise allowed by law.
  - 2. With respect to prescriptions for controlled substances where refills have been authorized, pharmacists may utilize partial fills, as described in § Section 2747.C.5 of the board's rules this Part, but may not exceed the dispensing quantity noted on the original prescription.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 14:708 (October 1988), effective January 1, 1989, amended LR 29:2104 (October 2003), effective January 1, 2004, amended LR 33:1133 (June 2007), amended LR 42:1519 (September 2016), amended by the Department of Health, Board of Pharmacy, LR



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-9 ~ Delays of Licensure Examinations  
at  
December 27, 2019 Public Hearing

*No comments or testimony received.*



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-10 ~ License Transfer for Pharmacy Technicians  
at  
December 27, 2019 Public Hearing

*No comments or testimony received.*



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-11 ~ Continuing Education Records  
at  
December 27, 2019 Public Hearing

*No comments or testimony received.*



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-12 ~ Partial Fills of Schedule II Prescriptions  
at  
December 27, 2019 Public Hearing

*No comments or testimony received.*



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-13 ~ Controlled Substance License for Third Party Logistics Providers  
at  
December 27, 2019 Public Hearing

*No comments or testimony received.*



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-14 ~ Rulemaking Procedures  
at  
December 27, 2019 Public Hearing

*No comments or testimony received.*



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-15 ~ Drug Disposal by Pharmacies  
at  
December 27, 2019 Public Hearing

1. Rob Geddes, PharmD, on behalf of Albertsons Companies

Noted that Sections 1503, 2503, and 2517 appear to give pharmacies an option whether to accept returns of prescription drugs, but that Section 2749 appears to require pharmacies to accept returns of controlled substances instead of providing an option. Staff agrees there is a drafting error in that section and it should be revised to provide the same option as appears in the other sections, as noted here:

**§2749. Disposal of Controlled Substances**

A. – C. ...

- D. When a patient or his designee wishes to return previously dispensed controlled dangerous substances to a pharmacy for ~~destruction~~ disposal, the pharmacy shall ~~accept such products previously dispensed by that pharmacy and may accept such products previously dispensed by another pharmacy, but only for destruction~~ inform the patient or his designee of the disposal mechanisms available to him. In the event the pharmacy elects to accept such previously dispensed products for disposal, the pharmacy shall comply with the following requirements:
1. From the time of receipt of such products until the time of ~~destruction~~ disposal, the pharmacy shall quarantine such products to keep them separate from its active dispensing stock and shall take appropriate security measures to prevent the theft or diversion of such products.
  2. The pharmacy shall comply with the provisions of 21 CFR §1317 or its successor for the pharmacy's disposal of controlled substances.

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:972.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 34:2157 (October 2008), amended by the Department of Health, Board of Pharmacy, LR.

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

\* \* \*

§1503. Definitions

- A. As used in this Chapter, the following terms shall have the meaning ascribed to them in this Section: CFR – Code of Federal Regulations

\* \* \*

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 14:708 (October 1988), effective January 1, 1989, amended LR 29:2093 (October 2003), effective January 1, 2004, amended LR 33:1132 (June 2007), amended LR 39:1282 (May 2013), amended LR 40:2256 (November 2014), effective January 1, 2015, amended LR 41:2147 (October 2015), amended by the Department of Health, Board of Pharmacy, LR

\* \* \*

§1519. Drug Returns; Drug Disposal

- A. In a hospital with a permitted hospital pharmacy on site, unused drugs may be returned to the pharmacy for re-dispensing in accordance with good professional practice standards.
- B. When a patient or his designee wishes to return previously dispensed prescription drugs to a pharmacy for disposal, the pharmacy shall inform the patient or his designee of the disposal mechanisms available to him. In the event the pharmacy elects to accept such previously dispensed products for disposal, the pharmacy shall comply with the following requirements:
  - 1. From the time of receipt of such products until the time of disposal, the pharmacy shall quarantine such products to keep them separate from its active dispensing stock and shall take appropriate security measures to prevent the theft or diversion of such products.
  - 2. The pharmacy shall comply with the provisions of 21 CFR §1317 or its successor for the pharmacy’s disposal of controlled substances and other non-hazardous waste pharmaceuticals.
  - 3. The pharmacy shall comply with the provisions of 40 CFR §261 or its successor for the pharmacy’s disposal of hazardous waste pharmaceuticals.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 29:2094 (October 2003), effective January 1, 2004, amended by the Department of Health, Board of Pharmacy, LR.

\* \* \*

§2503. Drug Returns; Drug Disposal

- A. Unless otherwise allowed by law, drugs dispensed on prescription to a patient shall not be accepted for return, exchange, or re-dispensing by any pharmacist or pharmacy after such drugs have been removed from the pharmacy premises where they were dispensed.
- B. When a patient or his designee wishes to return previously dispensed prescription drugs to a pharmacy for disposal, the pharmacy shall inform the patient or his designee of the disposal mechanisms available to him. In the event the pharmacy elects to accept such previously dispensed products for disposal, the pharmacy shall comply with the following requirements:
  - 1. From the time of receipt of such products until the time of disposal, the pharmacy shall quarantine such products to keep them separate from its active dispensing stock and shall take appropriate security measures to prevent the theft or diversion of such products.
  - 2. The pharmacy shall comply with the provisions of 21 CFR §1317 or its successor for the pharmacy’s disposal of controlled substances and other non-hazardous waste pharmaceuticals.
  - 3. The pharmacy shall comply with the provisions of 40 CFR §261 or its successor for the pharmacy’s disposal of hazardous waste pharmaceuticals.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 14:708 (October 1988), effective January 1, 1989, amended LR 29:2102 (October 2003), effective January 1, 2004, amended by the Department of Health, Board of Pharmacy, LR

\* \* \*

**§2517. Prescription Dispensing; Equivalent Drug Product Interchange; Drug Returns; Drug Disposal**

A. – C. ...

D. When a patient or his designee wishes to return previously dispensed prescription drugs to a pharmacy for disposal, the pharmacy shall inform the patient or his designee of the disposal mechanisms available to him. In the event the pharmacy elects to accept such previously dispensed products for disposal, the pharmacy shall comply with the following requirements:

1. From the time of receipt of such products until the time of disposal, the pharmacy shall quarantine such products to keep them separate from its active dispensing stock and shall take appropriate security measures to prevent the theft or diversion of such products.
2. The pharmacy shall comply with the provisions of 21 CFR §1317 or its successor for the pharmacy's disposal of controlled substances and other non-hazardous waste pharmaceuticals.
3. The pharmacy shall comply with the provisions of 40 CFR §261 or its successor for the pharmacy's disposal of hazardous waste pharmaceuticals.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 14:708 (October 1988), effective January 1, 1989, amended LR 29:2104 (October 2003), effective January 1, 2004, amended by the Department of Health, Board of Pharmacy, LR 43:2162 (November 2017), amended LR

\* \* \*

**§2701. Definitions**

A. Words not defined in this Chapter shall have their common usage and meaning as stated in the Merriam-Webster's Collegiate Dictionary – Tenth Edition, as revised, and other similarly accepted reference texts. As used in this Chapter, the following terms shall have the meaning ascribed to them in this Section unless the context clearly indicates otherwise.

\* \* \*

CFR – Code of Federal Regulations

\* \* \*

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:972.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 34:2127 (October 2008), amended by the Department of Health, Board of Pharmacy, LR

\* \* \*

**§2749. Disposal of Controlled Substances**

A. – C. ...

D. When a patient or his designee wishes to return previously dispensed controlled dangerous substances to a pharmacy for destruction, the pharmacy shall accept such products previously dispensed by that pharmacy and may accept such products previously dispensed by another pharmacy, but only for destruction.

1. From the time of receipt of such products until the time of destruction, the pharmacy shall quarantine such products to keep them separate from its active dispensing stock and shall take appropriate security measures to prevent the theft or diversion of such products.
2. The pharmacy shall comply with the provisions of 21 CFR §1317 or its successor for the pharmacy's disposal of controlled substances.

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:972.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 34:2157 (October 2008), amended by the Department of Health, Board of Pharmacy, LR.



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-16 ~ Pharmacy Compounding  
at  
December 27, 2019 Public Hearing

*No comments or testimony received.*



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-17 ~ Pharmacy Records  
at  
December 27, 2019 Public Hearing

*No comments or testimony received.*



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2019-18 ~ Cannabis Metered Dose Inhaler  
at  
December 27, 2019 Public Hearing

1. TJ Woodard, PharmD on behalf of Capitol Wellness Solutions

Offered support for the concept, noting some patients need a dosage form which provides a more rapid onset of action via the lungs than is available through tinctures or other oral dosage forms. He did not request any amendments of the proposed rule.

1 HLS 20-  
2 Regular Session, 2020  
3 House Bill No. \_\_\_\_\_  
4 By Representative

5

6 CONTROLLED SUBSTANCES: Adds Clonazolam and Flualprazolam to Schedule I and  
7 Solriamfetol to Schedule IV.

8

9 AN ACT

10

11 To amend and reenact R.S. 40:964, relative to the composition of various schedules of controlled  
12 substances.

13 Be it enacted by the Legislature of Louisiana:

14 Section 1. R.S. 40:964 is hereby amended and reenacted to read as follows:

15 §964. Composition of schedules

16 \* \* \*

17 Schedule I

18 \* \* \*

19 D. Depressants.

20 Unless specifically excepted or unless listed in another schedule, any  
21 material, compound, mixture, or preparation which contains any quantity of  
22 the following substances having a depressant effect on the central nervous  
23 system, including its salts, isomers, and salts of isomers whenever the

24 existence of such salts, isomers, and salts of isomers is possible within the  
25 specific chemical designation:

26 (1)– (5) ...

27 (6) Clonazepam

28 (7) Flualprazolam

29 \* \* \*

30 Schedule IV


31 \* \* \*

32 D. Stimulants

33 \* \* \*

34 (14) Solriamfetol (2-amino-3-phenylpropyl carbamate; benzenepropanol, beta-  
35 amino-, carbamate (ester))

36 Section 2. The Louisiana State Law Institute is hereby authorized and directed to  
37 alphabetize the entries in the Depressants section of Schedule I.



1 HLS 20-  
2 Regular Session, 2020  
3 House / Senate Bill No. \_\_\_\_\_  
4 By Representative / Senator

5

6 PHARMACISTS: Provides relative to pharmacy collaborative drug therapy management and  
7 pharmacist prescriptive authority.

8

9 AN ACT

10

11 To amend and reenact R.S. 37:1164(39), relative to pharmacy collaborative drug therapy  
12 management, and to enact R.S. 37:1220, relative to pharmacist prescriptive authority.

13 Be it enacted by the Legislature of Louisiana:

14 Section 1. R.S. 37:1164(39) is hereby amended and reenacted to read as follows:

15 §1164. Definitions

16 As used in this Chapter, the following terms have the meaning ascribed to them  
17 by this Section:

18 \* \* \*

19 (39) (a) ~~“Pharmacy collaborative drug therapy management practice” means that practice~~  
20 ~~whereby a pharmacist or pharmacists have, on a voluntary basis, agreed to~~  
21 ~~manage the disease-specific drug therapy of a patient under written protocol,~~  
22 ~~working in conjunction with a physician licensed to practice medicine by the~~  
23 ~~Louisiana State Board of Medical Examiners. Pharmacy collaborative drug~~  
24 ~~therapy management does not include the substitution by the pharmacist of a~~

25 ~~product that is not an equivalent drug product to the product originally prescribed~~  
26 ~~by the physician or practitioner without the explicit consent of the physician or~~  
27 ~~practitioner. Any pharmacy collaborative drug therapy management protocol~~  
28 ~~shall adhere to rules and regulations promulgated by the board~~ the practice of  
29 pharmacy whereby one or more pharmacists have jointly agreed to work in  
30 conjunction with one or more practitioners to provide delegated patient care  
31 services pursuant to a written agreement subject to rules promulgated by the  
32 board.

33 ~~(b) (i) The Louisiana State Board of Medical Examiners and the Louisiana Board of~~  
34 ~~Pharmacy shall initiate the rulemaking process in accordance with the~~  
35 ~~provisions of the Administrative Procedure Act by publishing their respective~~  
36 ~~notices of intent no later than one hundred twenty days following the effective~~  
37 ~~date of this Subparagraph.~~

38 ~~(ii) If both boards have not initiated the rulemaking process in accordance with the~~  
39 ~~provisions of the Administrative Procedure Act by publishing their respective~~  
40 ~~notices of intent by one hundred twenty days following the effective date of~~  
41 ~~this Subparagraph, then the boards shall appoint a committee composed of~~  
42 ~~three physicians and three pharmacists, the physicians by the Louisiana State~~  
43 ~~Board of Medical Examiners and the pharmacists by the Louisiana Board of~~  
44 ~~Pharmacy. The committee shall complete the drafting process no later than~~  
45 ~~one hundred eighty days following the effective date of this Subparagraph.~~

46 ~~(iii) If the boards have not initiated the rulemaking process in accordance with the~~  
47 ~~provisions of the Administrative Procedure Act by publishing their respective~~  
48 ~~notices of intent by one hundred eighty days following the effective date of this~~

49 ~~Subparagraph, then the Louisiana Board of Pharmacy shall have the authority~~  
50 ~~to promulgate the rule required in R.S. 37:1164(39) independently of the~~  
51 ~~Louisiana State Board of Medical Examiners.~~

52 \* \* \*

53 Section 2. R.S. 37:1220 is hereby enacted to read as follows:

54 §1220. Pharmacist prescriptive authority

55 A. A pharmacist may prescribe drugs or devices in accordance with the product's  
56 labeling, as approved by the federal food and drug administration or its  
57 successor, subject to the following limitations:

58 (1) When the initiation of treatment is:

59 (a) Limited to conditions that do not require a new diagnosis;

60 (b) Based on a test that is used to guide clinical decision making that is  
61 waived under the federal Clinical Laboratory Improvement  
62 Amendment of 1988 (42 USC §263a) or its successor; or

63 (c) In circumstances where the patient faces an immediate health risk.

64 (2) In the event the secretary of the state health department determines a  
65 public health crisis exists that requires immediate access to specific drugs  
66 or devices.

67 (3) A pharmacist may discontinue a medication or device based on his  
68 judgment that the treatment in question poses a health risk to the patient.

69 (4) The pharmacist shall:

70 (a) Communicate the prescription and its justification to the patient's  
71 primary care practitioner through the most reliable method available;

72 and

73 (b) Assure the patient without a primary care home is directed to a  
74 primary care practitioner for follow-up.


75 (5) The pharmacist shall not provide continuing treatment absent a  
76 collaborative practice agreement as defined in this Chapter.

77 B. A pharmacist may order and interpret laboratory assessments as described by  
78 rules promulgated by the board.

79 C. The board shall promulgate rules in accordance with the Administrative  
80 Procedure Act to implement the provisions of this Section.

81 Section 3. The Louisiana State Law Institute is hereby authorized and directed to  
82 alphabetize the entries in R.S. 37:1164.

83



**Louisiana Administrative Code**

**Title 46 – Professional and Occupational Standards**

**Part LIII: Pharmacists**

**Chapter 30. Pharmacy Benefit Managers**

**§3001. Definitions**

- A. The following terms shall have the meaning ascribed to them in this Section:
1. “Audited financial statement” – the financial statement and related disclosures prepared by an independent certified public accountant in accordance with United States Generally Accepted Accounting Principles (GAAP) of the specific entity or licensee intending to operate or operating in Louisiana.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1253.

HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR

**§3003. Pharmacy Benefit Manager Permit**

- A. A pharmacy benefit manager, as defined at R.S. 40:2863, shall obtain and maintain a pharmacy benefit manager permit from the board prior to conducting business in Louisiana if it administers, develops, maintains, performs, or provides one or more of the pharmacy services enumerated in R.S. 40:2868 in the state or that affects one or more beneficiaries of a pharmacy benefit management plan, as defined at R.S. 40:2863, administered by the pharmacy benefit manager.
- B. A pharmacy benefit manager permit shall authorize the permit holder to administer pharmacy benefit management services.
- C. The board shall not issue a pharmacy benefit manager permit to any person or other entity which has not yet registered with the Louisiana Secretary of State to conduct business within the state.
- D. A pharmacy benefit manager permit is not transferable from the original owner. The permit shall not be subject to sale, assignment or other transfer, voluntary or involuntary. Moreover, in the event the ownership of the pharmacy benefit manager changes by 50 percent or more after the initial issuance of the permit, the ownership will be deemed sufficiently different as to require a new pharmacy benefit manager permit. The continued operation of a pharmacy benefit manager permit after its ownership has changed by more than 50 percent shall constitute sufficient basis for the board to issue a finding for the operation of a pharmacy benefit manager without a valid permit, in violation of R.S. 40:2865.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1253.

HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR

**§3005. Permitting Procedures**

- A. Application for Initial Issuance of Permit
  1. The board shall develop an application form suitable for the pharmacy benefit manager permit. The board may revise that application form on its own initiative in order to collect the information it deems necessary to properly evaluate an applicant.
  2. The application shall include copies of the following documents:
    - a. Governance documents, including Articles of Incorporation, Articles of Association, partnership agreements, trade name certificates, trust agreements, shareholder agreements, and all amendments to such documents.
    - b. The applicant’s standard generic contract template which it uses for contracts entered into by the applicant and pharmacies or pharmacy services administrative organizations in this state in the administration of pharmacy benefits for healthcare insurers, providers, or payors.
    - c. An audited financial statement for the applicant’s previous fiscal year.

- 53 3. The board shall not process applications received by facsimile, or that are incomplete, or  
 54 submitted with the incorrect fee.  
 55 4. Once received by the board, an application for the permit shall expire one year thereafter.  
 56 5. In the event any information contained in the application or accompanying documents changes  
 57 after being submitted to the board and before the issuance of the permit, the applicant shall  
 58 immediately notify the board in writing and provide corrected information.  
 59 6. The applicant may be required to personally appear before the board or any of its committees prior  
 60 to any decision on the permit application.  
 61 7. Upon approval of the application, the board shall issue the pharmacy benefit manager permit to the  
 62 applicant.  
 63 B. Application for Renewal of Permit  
 64 1. All pharmacy benefit manager permits shall expire two years after the date of its initial issuance  
 65 and the renewals shall expire every two years thereafter on that anniversary date.  
 66 2. The board shall not process applications received by facsimile, or that are incomplete.  
 67 3. In the event the pharmacy benefit manager does not submit a properly completed renewal  
 68 application to the board prior to the expiration of the permit, the permit shall be rendered null and  
 69 void. A pharmacy benefit manager shall not operate with an expired permit. The continued  
 70 operation of a pharmacy benefit manager with an expired permit shall constitute sufficient basis  
 71 for the board to issue a finding for the operation of a pharmacy benefit manager without a valid  
 72 permit, in violation of R.S. 40:2865.  
 73 4. A pharmacy benefit manager permit not renewed by 30 days after the expiration date shall be  
 74 automatically terminated by the board.  
 75 C. Application for Reinstatement of Terminated, Suspended, or Revoked Permit  
 76 1. The applicant shall complete the application form for this specific purpose supplied by the board  
 77 2. Upon the receipt of a properly completed application form, the board staff shall refer the  
 78 application to the board's reinstatement committee for its consideration and shall notify the  
 79 applicant of the time and place for the committee meeting.  
 80 D. Maintenance of Permit  
 81 1. A pharmacy benefit manager permit shall be valid for the entity to whom it is issued and shall not  
 82 be subject to sale, assignment or other transfer, voluntary or involuntary.  
 83 2. Upon receipt of a written request and payment of the fee authorized in R.S. 37:1184, the board  
 84 shall issue a duplicate or replacement permit to the applicant; however, such duplicate or  
 85 replacement permit shall not serve or be used as an additional or second permit.  
 86 E. Permanent Closure of Permit  
 87 1. In the event the pharmacy benefit manager contemplates permanent closure of the pharmacy  
 88 benefit manager business, the owner of the permit shall notify the board, in writing, 10 days prior  
 89 to the anticipated date of closure and surrender its permit.  
 90 2. The notice required in this Subsection shall include an acknowledgement of the firm's obligation  
 91 to maintain copies of all records for all patients and pharmacies in Louisiana for a minimum of  
 92 two years following the date of closure and surrender of its permit, and further, the point of  
 93 contact for all inquiries and requests for such records during that two year period of time  
 94

95 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1253.

96 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR

### 97 §3007. Reporting Requirements


- 98 A. Initial Report  
 99 1. An application for the initial issuance of a pharmacy benefit manager permit shall include an  
 100 audited financial statement for the applicant's previous fiscal year  
 101 B. Annual Reports  
 102 1. A pharmacy benefit manager shall submit an audited financial statement no later than 90 days  
 103 after the end of their fiscal year.  
 104

105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122

2. A pharmacy benefit manager shall submit an operational activity report no later than 90 days after the end of their fiscal year including but not limited to the following information:
  - a. A list of the insurers, providers, or payors with which the pharmacy benefit manager had an agreement during the preceding fiscal year, to include names and addresses.
  - b. The total number of contracts with entities doing business in the state.
  - c. A list of any acquisitions of Louisiana pharmacies or other entities completed during the previous fiscal year.
  - d. The average number of days to pay after submission of a clean claim, both nationally and in Louisiana, for the previous fiscal year.
  - e. The average number of days to pay after re-submission of a clean claim, both nationally and in Louisiana, for the previous fiscal year.
  - f. The claim denial rate as a percentage of total claims, both nationally and in Louisiana.
  - g. The total revenues or fees associated with Louisiana operations during the previous fiscal year.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1253.

HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR



**Louisiana Administrative Code**

**Title 46 – Professional and Occupational Standards**

**Part LIII: Pharmacists**


**Chapter 7. Pharmacy Interns**

**§709. Scope of Practice**

- A. ~~A~~ pharmacy interns may ~~perform any duty of a pharmacist~~ engage in the practice of pharmacy provided he is ~~under the supervision of~~ supervised by a pharmacist.
- B. ~~The ratio of pharmacy interns to pharmacists shall be 1:1. However, the ratio of pharmacy interns on rotation with a board approved college of pharmacy to pharmacists shall be no more than 3:1.~~
- C. A pharmacy intern may not:
  - 1. present or identify himself as a pharmacist; or
  - 2. ~~sign or initial any document which is required to be signed or initialed by a pharmacist unless a preceptor cosigns the document;~~
  - 3. independently supervise pharmacy technicians or pharmacy technician candidates; ~~or~~
  - 4. ~~administer immunizations unless properly credentialed as required by the board.~~

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 36:755 (April 2010), amended by the Department of Health, Board of Pharmacy, LR



## Louisiana Administrative Code

### Title 46 – Professional and Occupational Standards

#### Part LIII: Pharmacists

#### Chapter 9. Pharmacy Technicians

##### §903. Pharmacy Technician Candidates

A. – B. ...

C. Practical Experience

1. – 3. ...

4. The candidate's registration shall evidence his authority to earn practical experience in a pharmacy, under the supervision of a pharmacist, in satisfaction of the requirements for pharmacy technician certification.

- a. In the event the registration was issued to an applicant enrolled in a nationally-accredited and board-approved training program, the candidate shall earn the amount of experience prescribed by the curriculum of that program, which may include hours earned in a consultant pharmacy practice which does not hold a pharmacy permit; or
- b. In the event the registration was issued to an applicant by any other method, the candidate shall earn at least ~~600~~ 400 hours of practical experience in a pharmacy in Louisiana, provided however, that a candidate may receive board credit for a maximum of 50 hours per week.

C.5. – D.2.b. ...

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1212.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 30:2485 (November 2004), effective January 1, 2005, amended LR 39:1777 (July 2013), amended by the Department of Health, Board of Pharmacy, LR 43:2496 (December 2017), effective January 1, 2018, repromulgated LR 44:49 (January 2018), amended LR

##### §905. Pharmacy Technician Certificate

A. Qualifications

1. – 2. ...

3. An applicant shall demonstrate one of the following educational competencies:

- a. In the event the applicant obtained their technician candidate registration on the basis of their enrollment in a nationally-accredited and board-approved pharmacy technician training program, the applicant shall demonstrate successful completion of that training program, or in the alternative, another nationally-accredited and board-approved pharmacy technician training program.
- b. In the event the applicant obtained their technician candidate registration by any other method, the applicant shall demonstrate the acquisition of at least ~~600~~ 400 hours of practical experience under the supervision of a pharmacist, using a [form](#) supplied by the board.

A.4. – B.6. ...

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1212.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 30:2486 (November 2004), effective January 1, 2005, amended LR 38:1235 (May 2012), LR 39:1777 (July 2013), amended by the Department of Health, Board of Pharmacy, LR 43:2497 (December 2017), effective January 1, 2018, amended LR

**Louisiana Administrative Code**

**Title 46 – Professional and Occupational Standards**

**Part LIII: Pharmacists**

**Chapter 24. Limited Service Providers**

**Subchapter E. Marijuana Pharmacy**

**§2441. Definitions**

A. As used in this Subchapter, the following terms shall have the meaning ascribed to them in this Section:

\* \* \*

~~*Marijuana* – all parts of plants of the genus *Cannabis*, whether growing or not, the seeds thereof, the resin extracted from any part of such plant, and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks (except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination~~ Repealed.

\* \* \*

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046.

HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 43:1538 (August 2017), amended LR 45:1473 (October 2019), amended LR

**§2443. Marijuana Products**

A. – D.1.c. ...

~~d. No single container shall contain more than a one-month supply of marijuana.~~ Repealed.

D.1.e – E.4.f. ...

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046.

HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 43:1540 (August 2017), amended LR 45:1473 (October 2019), amended LR

\* \* \*

**§2451. Operation of Marijuana Pharmacy**

A. – M. ...

N. No marijuana pharmacy shall ~~sell anything other than marijuana products; however, the pharmacy may elect to sell over the counter (OTC) medications, durable medical equipment (DME), and other retail products from the same premises but outside the prescription department~~ acquire, possess or dispense any controlled substance other than medical marijuana products authorized by R.S. 40:1046.

O. – U. ...

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046.

HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 43:1547 (August 2017), amended LR

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII – Pharmacists

Chapter 29. Prescription Monitoring Program

§2901. Definitions

A. As used in this Chapter, the following terms shall have the meaning ascribed to them unless the context clearly indicates otherwise:

Drugs of Concern – drugs other than controlled substances as defined by rule whose use requires tracking for public health purposes or which demonstrate a potential for abuse, including any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, esters, ethers, isomers, and salts of isomers [whenever the existence of such salts, esters, ethers, isomers, and salts of isomers is possible within the specific chemical designation]:

- a. butalbital when in combination with at least 325 milligrams of acetaminophen per dosage unit.
b. naloxone.
c. elbasvir / grazoprevir.
d. glecaprevir / pibrentasvir.
e. ledipasvir / sofosbuvir.
f. ombitasvir / paretaprevir / ritonavir / dasabuvir.
g. sofosbuvir.
h. sofosbuvir / velpatasvir.
i. sofosbuvir / velpatasvir / voxilaprevir.
j. gabapentin.
k. promethazine in oral liquid formulations.

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1011.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1345 (July 2007), amended LR 36:755 (April 2010), effective September 1, 2010, amended LR 39:314 (February 2013), amended LR 40:1096 (June 2014), amended LR 41:684 (April 2015), amended by the Department of Health, Board of Pharmacy, LR 45:42 (January 2019), amended LR



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Executive Committee

2  
3 *Title:* PMP – Advisory Council

Policy No. V.A.2

4  
5 Approved: 02-19-2019

Revised:

6  
7  
8 1. The membership of the prescription monitoring program (PMP) advisory council  
9 and its functions are found at R.S. 40:1005 and LAC 46:LIII.2909.

10  
11 A. The members of the council serve at the pleasure of their respective  
12 appointing authorities, eleven of whom shall constitute a quorum for the  
13 transaction of all business.

14  
15 i. The member organization shall identify their appointee to the  
16 council and shall notify the Board of Pharmacy office of the date of  
17 their appointment and any subsequent changes to that  
18 appointment.

19  
20 ii. The member organization shall identify any designee of their  
21 appointee and shall notify the Board of Pharmacy office of the date  
22 of the designee's appointment and any subsequent changes or  
23 additional designees.

24  
25 B. PMP staff shall develop and maintain a roster of council members. The  
26 roster shall identify the organizations enumerated within the legislation,  
27 their appointees, designees, and staff representatives. The roster shall  
28 include the mailing address as well as email address for all persons listed  
29 on the roster.

30  
31 i. The Board staff shall reply timely to requests for council  
32 membership information from the Senate & Governmental Affairs  
33 Committee or any other governmental agency or private entity.

34  
35 2. The council members shall elect a chairman and vice chairman. The term of  
36 office for each officer shall be one year. Members shall elect their officers during  
37 the July meeting each year. Officers elected shall serve until their successor is  
38 elected. The presiding officer shall conduct all meetings in conformance with the  
39 Open Meetings Law and Robert's Rules of Order.

40  
41 A. The chairman shall preside at all council meetings, and may accept other  
42 assignments as authorized by the council.

43  
44 B. In the absence of the chairman, the vice chairman shall preside at council  
45 meetings, and may accept other assignments as authorized by the  
46 council.

47  
48 C. In the absence of the chair and vice chair, the chair shall designate the  
49 presiding officer for the council meeting.

50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98

3. The council is required to meet at least four times every year, and the Board is responsible for fixing the time and place for the council meetings.
  - A. As expressed by the membership the council has established a preference for its meetings to occur on the second Wednesday of the first month of each calendar quarter [*January, April, July, and October*], to convene at 1:00 p.m. on those days. Council meetings are held at the Board office unless specified otherwise.
  - B. PMP staff shall prepare and distribute meeting notices at least 14 days prior to a scheduled meeting of the council. The meeting notice shall include the following documents: (1) meeting agenda, (2) draft minutes from the previous meeting, and (3) such other documents as may be appropriate to assist the members in preparing for the consideration of agenda items.
  - C. PMP staff shall prepare draft minutes of council meetings no later than 14 days after the council meeting for review by an administrative officer.
4. The council shall provide information and advice regarding the development and operation of the program, including but not limited to the following:
  - A. Which controlled substances should be monitored;
  - B. Which drugs of concern demonstrate a potential for abuse and should be monitored;
  - C. Design and implementation of educational courses for program participants;
  - D. The methodology to be used for analysis and interpretation of prescription monitoring information;
  - E. Design and implementation of a program evaluation component;
  - F. Identification of potential additional members to the advisory council.
5. The standard agenda sequence for council meetings, which may be modified as deemed appropriate by the council chair, shall be as follows:
  - A. Call to order
  - B. Quorum call
  - C. Call for additional agenda items and adoption of agenda
  - D. Consideration of minutes from previous meeting

99	E.	Opportunity for public comment
100		
101	F.	Review of program operation
102		
103	G.	Calendar notes
104		
105	H.	Adjourn
106		

DRAFT

2  
3 *Title:* Criminal Background Check (CBC)

Policy No. III.J

4  
5 *Approved:*

Revised:

6  
7  
8 *Legal Authorities*

- 9
- 10 1. The statutory authority for the Board to obtain criminal history record information  
 11 is found at:
- 12 A. R.S. 37:1216 with respect to applicants for any designation deemed  
 13 necessary to engage in the practice of pharmacy; and
- 14 B. R.S. 40:973.1 with respect to applicants for a state controlled dangerous  
 15 substance license.
- 16
- 17 2. The regulatory authority for the Board to obtain criminal history record  
 18 information from applicants for a state controlled dangerous substance license is  
 19 found at LAC 46:LIII.2707.A.4.
- 20
- 21 3. Criminal history record information (CHRI) is defined in the *Code of Federal*  
 22 *Regulations* as information collected by criminal justice agencies on individuals  
 23 consisting of identifiable descriptions and notations of arrests, detentions,  
 24 indictments, information, or other formal criminal charges, and any disposition  
 25 arising therefrom, including acquittal, sentencing, correctional supervision, and  
 26 release [28 CFR 20.3]. 28 CFR 20.21 further states information is considered  
 27 CHRI if it confirms the existence or nonexistence of CHRI. CHRI is also  
 28 described by the Federal Bureau of Investigation (FBI) Criminal Justice  
 29 Information Services (CJIS) Security Policy 4.1.1 as a subset of criminal justice  
 30 information (CJI) and is sometimes referred to as “restricted data”. Information is  
 31 considered CHRI if it is transferred or reproduced directly from CHRI received as  
 32 a result of a national FBI check and associated with the subject of the record.  
 33 This includes information such as conviction/disposition data as well as  
 34 identifiers used to index records regardless of format.
- 35
- 36 4. The Louisiana State Police Bureau of Criminal Identification and Information  
 37 (LSP Bureau) is the state’s designated repository that stores CHRI in the  
 38 Louisiana Computerized Criminal History (LACCH) database. As indicated in the  
 39 authorizing statutes cited above, the Board will not accept CBC reports from any  
 40 other source.

41  
42 *Purpose*

- 43
- 44 5. The Board’s purpose for obtaining CHRI is to assist in its determination of the  
 45 applicant’s fitness for practice.
- 46  
47  
48  
49

50 Policies

- 51
- 52 6. Noncriminal justice agencies are prohibited from using CHRI for any purpose  
53 other than that for which it was requested. CHRI may be used solely for the  
54 purpose for which the record was requested and shall not be shared with any  
55 other agency or entity, even if the agency or entity is authorized to receive CHRI  
56 pursuant to its own statutes. When CHRI is needed for a subsequent authorized  
57 use, a new record request including fingerprints must be submitted to obtain the  
58 most possible current and accurate information.
- 59
- 60 7. The Board will obtain, maintain, handle, transport, and store CHRI by using only  
61 hard copy paper format.
- 62
- 63 8. The Board's Executive Director shall execute the Civil Agency User Agreement  
64 with the LSP Bureau. The user agreement identifies the requesting agency,  
65 identifies the purpose for which CHRI is requested, and identifies the specific  
66 statutory authorization granting access to the information. The user agreement  
67 is subject to cancellation by either party with 14 days written notice. The LSP  
68 Bureau may immediately suspend service for violation or for investigation of  
69 apparent/alleged violations of the user agreement or requirements for access.  
70 Further, the user agreement shall identify the following designations:
- 71 A. Local Agency Security Officer (LASO): Pursuant to CJIS Security Policy  
72 3.2.9, the LASO will act as liaison with the LSP Bureau and the La.  
73 Division of Administration's Office of Technology Services (OTS) to  
74 ensure the agency is in compliance with security procedures. This  
75 individual must be knowledgeable in CHRI policies and mandates rules  
76 and regulations as well as knowledge of IT security procedures. LASOs  
77 are designated as the point of contact on security-related issues for their  
78 respective agencies and LASOs are responsible for instituting the CJIS  
79 System Agency (CSA) incident response reporting procedures at their  
80 agency as needed.
- 81 B. Noncriminal Agency Coordinator (NAC): The NAC will act as the primary  
82 contact person for that agency. The NAC should complete LSP Bureau  
83 training requirements and shall serve as liaison between the agency and  
84 the LSP Bureau. The NAC will ensure all employees with access or  
85 potential access to CHRI successfully complete the appropriate level of  
86 CJIS Security Awareness Training and will maintain that certification as  
87 long as the employee may have access to CHRI. The NAC is responsible  
88 for maintaining an updated Authorized Personnel List on file with the LSP  
89 Bureau. The Authorized Personnel List contains those individuals whom  
90 the agency has identified as authorized to access, handle, and/or destroy  
91 CHRI. The authorizations are based solely on the agency's  
92 determination, but should be limited to the minimum number of personnel  
93 necessary. All personnel who view, handle, uses, disseminate, or dispose  
94 of CHRI must appear on the list. Anyone included on this list must  
95 undergo the appropriate level of CJIS Security Awareness Training. The  
96 NAC should inform the LSP Bureau of changes in the agency head or any  
97 relevant business information (agency name changes, mailing/physical  
98 address changes, etc.). Changes must be made as they occur. A change

99 in an agency's authorization may invalidate the entire User Agreement; if  
100 the NAC becomes aware of a change in the authorization for access (e.g.,  
101 new state statute, etc.), he/she shall contact the LSP Bureau immediately  
102 to update the User Agreement and, if necessary, submit the new  
103 authorization to LSP Bureau.

104  
105 9. The Board has identified all licensing staff, compliance staff, prescription  
106 monitoring program staff, student workers, executive staff, Board members, and  
107 information technology staff and/or contractors as authorized personnel.

108 A. No person who has been convicted of a felony may be granted access to  
109 CHRI without the explicit consent of the LSP Bureau or the CJIS System  
110 Officer (CSO).

111  
112 10. All authorized persons must complete CJIS Security Awareness training as well  
113 as any agency-specific training on CHRI security and handling based on the  
114 agency's required policies and procedures. The NAC is responsible for ensuring  
115 agency personnel receive such training within six months of employment and  
116 every two years thereafter. Training levels are based on the level of access  
117 each individual will have to the information. The NAC is responsible for setting  
118 up user accounts for all personnel who must be certified. Training shall be  
119 completed based on the assigned levels noted here:

120 A. Level 1 Security Awareness Training (CSP 5.2.1.1) – Student workers

121 B. Level 2 Security Awareness Training (CSP 5.2.1.2) – Board members

122 C. Level 3 Security Awareness Training (CSP 5.2.1.3) – Board staff

123 D. Level 4 Security Awareness Training (CSP 5.2.1.4) – Information  
124 technology staff and/or contractors for IT support

125  
126 11. Authorized personnel training must be logged on the NCJA Training  
127 Documentation Form and the documentation must be available for inspection by  
128 auditors.

129  
130 12. Any persons within the office that are not listed on the Authorized Personnel List  
131 must be escorted through any portion of the building within which CHRI is  
132 processed, accessed, or stored by authorized personnel.

133  
134 13. The retention and destruction of CHRI shall be based on the Board's record  
135 retention policy and shall comply with all applicable federal and state laws.  
136 Formal procedures for the secure disposal or destruction of physical media shall  
137 minimize the risk of sensitive information compromised by unauthorized  
138 individuals. Physical media (paper documents) shall be destroyed by shredding  
139 or incineration. Disposal or destruction shall be accomplished and witnessed by  
140 authorized personnel.

141  
142 14. Federal and state civil and criminal penalties may apply to the misuse of CHRI.  
143 CHRI shall be used solely for the purpose requested and shall not be  
144 disseminated outside the Board. The exchange of CHRI is subject to immediate  
145 cancellation if disseminated beyond the Board or if used for any reason other  
146 than that authorized by Louisiana law. Further, depending on the nature of the  
147 offense and the identity of the offender, federal or state crimes may be charged

148 for the willful and unauthorized disclosure of CHRI.

- 149
- 150 15. All unauthorized disclosure is to be reported to LSP Bureau using the forms
- 151 designated by that agency.
- 152 A. Unauthorized disclosures by members of the staff shall result in
- 153 disciplinary action, which could include termination of employment.
- 154 B. Unauthorized disclosures by board members shall be reported to the
- 155 Office of the Inspector General.

156 Procedures

- 157
- 158 16. Upon receipt of the following applications for a credential issued by the Board,
- 159 staff will provide a criminal background check (CBC) packet to the applicant,
- 160 unless the applicant has previously completed the CBC process for the Board
- 161 and the resulting report was received within the five year period prior to the date
- 162 of the application (two years with respect to an applicant for a therapeutic
- 163 marijuana designation):
- 164 A. Application for New Pharmacist License
- 165 B. Application for New Pharmacy Intern Registration
- 166 C. Application for New Pharmacy Technician Certificate
- 167 D. Application for New Pharmacy Technician Candidate Registration
- 168 E. Application for New Pharmacy Permit
- 169 (1) For persons holding 20% or more ownership interest at the direct or
- 170 indirect level; and
- 171 (2) For the pharmacist-in-charge.
- 172 F. Application for Reinstatement of Pharmacist License or Pharmacy
- 173 Technician Certificate, but only when the credential has been lapsed more
- 174 than five years.
- 175 G. Application for New Controlled Dangerous Substance License for any
- 176 person not holding a primary credential issued by a professional licensing
- 177 agency in Louisiana.
- 178 H. Application for New Therapeutic Marijuana Designation.
- 179
- 180 17. The National Crime Prevention and Privacy Compact Council (Compact Council)
- 181 outlines rights provided to applicants who are the subject of a national
- 182 fingerprint-based criminal history record check for a noncriminal justice purpose.
- 183 These rights are detailed in the Agency Privacy Requirements for Noncriminal
- 184 Justice Applicants. The Board must notify applicants of their privacy rights by
- 185 providing applicants with a copy of the Noncriminal Justice Applicant's Privacy
- 186 Rights document. This notification shall be included in each CBC packet
- 187 provided to applicants.
- 188
- 189 18. Completed CBC packets submitted by applicants to the Board shall be opened
- 190 at a secure reception area, out of public view, and then forwarded to the
- 191 licensing staff for preparation and delivery to the LSP Bureau.
- 192
- 193 19. Any CHRI received by the Board office shall immediately be marked "NOT
- 194 PUBLIC RECORD". Information is considered CHRI if it is transferred or
- 195 reproduced directly from CHRI received as a result of a national FBI check and

196 associated with the subject of the record. This includes information such as  
197 conviction/disposition data as well as identifiers used to index records regardless  
198 of format.

200 20. Items marked "NOT PUBLIC RECORD" shall not be shared or discussed with  
201 any individual not listed on the Authorized Personnel List.

203 21. Items marked "NOT PUBLIC RECORD" shall be stored in the file of the licensee  
204 or applicant and maintained in the secured portion of the office building

206 22. Authorized staff will transport CBC packets, in paper format, to and from the La.  
207 State Police headquarters on a weekly basis.

209 23. Authorized staff will transport CBC reports from the La. State Police  
210 headquarters on a weekly basis.

212 24. At no time during the transport of CBC packets or CBC reports may those  
213 materials be left unattended in the authorized personnel's vehicle.

215 25. With respect to applicants who fail to disclose arrests on their application, Board  
216 staff shall send such applicants a letter outlining the date, arresting agency, and  
217 charge. This letter shall be marked "NOT PUBLIC RECORD" prior to mailing  
218 and a copy will be placed in their file. This information may not be mailed to any  
219 address other than the mailing address provided by the applicant; and further,  
220 this information may only be shared with the applicant by mail or by personal  
221 appearance at the Board office.

223 26. Applicants or licensees who want to obtain a copy of the CBC report shall be  
224 offered one of the following options:

225 A. Pursuant to La. R.S. 15:588, an individual may obtain a certified copy of  
226 his personal criminal history as maintained by the LSP Bureau.  
227 Individuals must submit a "Right to Review Authorization Form" and a  
228 "Right to Review Disclosure Form" along with fingerprints and the  
229 appropriate fees to the LSP Bureau. Individuals may use this record to  
230 identify, if applicable, the date of an arrest, the identity of the arresting  
231 agency, and disposition information. This criminal history record may only  
232 be given to the individual, his authorized representative, or his attorney.

233 B. The U.S. Dept. of Justice Order 556-73, also known as Departmental  
234 Order, establishes rules and regulations for individuals to obtain a copy of  
235 their Identity History Summary for review or proof that one does not exist.  
236 The individual may submit fingerprints, an Applicant Information Form,  
237 and payment directly to the FBI according to the procedures in 28 CFR  
238 16.34.

239

**Louisiana Revised Statutes of 1950**  
**Title 37 – Professions and Occupations**  
**Chapter 14 – Pharmacy Practice Act**

**§1184. Fees**

Notwithstanding any other provision of this Chapter, the fees and costs established by the board in accordance with R.S. 37:1182(A) shall not be less than the following schedule:

	Minimum
(1) ...	
<b>(2) Licenses, permits, certification, registrations and examinations for pharmacists</b>	
(a)(i) <del>Annual</del> renewal fee for license, <u>per year</u>	\$100.00
(ii) Pharmacy education support fee, <u>per year</u>	\$100.00
(b) Delinquent fee in addition to renewal fee, <u>per year</u>	\$50.00
(c) – (i) ...	
<b>(3) Licenses, permits, certification, registration, and any other designations for pharmacy locations</b>	
(a)(i) ...	
(ii) Pharmacy education support fee, <u>per year</u>	\$100.00
(b) – (c)	
(d) Pharmacy permit renewal fee, <u>per year</u>	\$125.00
(e) Delinquent permit renewal fee, <u>per year</u>	\$62.50
(f) Pharmacy CDS permit fee, <u>per year</u>	\$25.00
(g) Delinquent pharmacy CDS permit fee, <u>per year</u>	\$12.50
(h) ...	
(i) Automated medication system registration, <u>per year</u>	\$150.00
(j) Emergency drug kits for long-term care facilities, <u>per year</u>	\$25.00
<b>(4) Certification and examination for pharmacy technicians</b>	
(a) ...	
(b) <del>Annual</del> renewal certification fee, <u>per year</u>	\$50.00
(c) – (d) ...	
(e) Delinquent certificate renewal fee, <u>per year</u>	\$25.00
(f) ...	
(5) ...	

**§1207. Renewal of license, registration, and certification; expiration; reinstatement**

- A. (1) Each person licensed, registered, or certified by the board shall apply for renewal ~~annually~~ at a time designated by the board and pay a fee specified by the board. A person who desires to continue in the practice of pharmacy or assist in the practice of pharmacy in this state shall file with the board an application in such form and contain such data as the board may require, and complete such other requirements as deemed necessary by the board, for renewal.
- (2) (a) (i) The board shall assess on each ~~annual~~ pharmacist license renewal as required by this Section an additional fee of one hundred dollars per year to be designated as the “pharmacy education support fee.” This fee shall be dedicated and allocated as specified in this Paragraph to an accredited school of pharmacy of a public university in this state. The board shall include on each license renewal form issued to a pharmacist an optional election whereby the person may elect not to remit the one hundred dollar pharmacy education support fee.

A(2)(a)(ii) – D. ...

**§1208. Waiver of licensure or certification renewal while in military service**

Upon written request of any licensed pharmacist or certified technician serving in active duty in the military

52 service of the United States or any of its allies, the board may waive the requirement for the ~~annual~~ renewal of  
53 pharmacist license or technician certificate, including the ~~annual~~ renewal fees.  
54

55 **§1209. Waiver of renewal fee when licensed fifty years; award**

56 The board, in recognition of contributions to the practice of pharmacy, shall waive the ~~annual~~ renewal fee  
57 requirement for ~~annual~~ renewal of licensure for licensed pharmacists who have been duly registered and licensed to  
58 practice in Louisiana for not less than fifty years; in lieu thereof the board shall award to such pharmacists an honorary  
59 gold-embossed certificate. Such pharmacists desiring to continue to practice pharmacy shall file the ~~annual~~ renewal  
60 application and shall meet all other requirements for active licensure.  
61

62 **§1230. Renewal of permits; expiration; reinstatement**

- 63 A. (1) Each pharmacy issued a permit by the board shall apply for renewal ~~annually~~, at the time designated  
64 by the board and pay a fee specified by the board.  
65 (2) (a) (i) The board shall assess on each ~~annual~~ pharmacy permit renewal required by this Section an  
66 additional fee of one hundred dollars per year to be designated as the “pharmacy education  
67 support fee.” This fee shall be dedicated and allocated as specified in this Paragraph to an  
68 accredited school of pharmacy of a public university in this state. The board shall include on  
69 each permit renewal form issued to a pharmacy an optional election whereby the pharmacy  
70 may elect not to remit the one hundred dollar pharmacy education support fee.

71 A(2)(a)(ii) – D. ...  
72

73 **§1232. Nonresident pharmacy**

- 74 A. ...  
75 B. A nonresident pharmacy granted a nonresident pharmacy permit by the board shall disclose to the  
76 board the location, names, and titles of all principal corporate officers, as well as the owner’s managing  
77 officer and pharmacist-in-charge. A report containing this information shall be made to the board ~~on an~~  
78 ~~annual basis~~ with each renewal application and within thirty business days after any change of office,  
79 corporate officer, or within ten business days of the departure of the prior owner’s managing officer or  
80 pharmacist in charge.  
81 C. – E. ...  
82

83 **§1253. Pharmacy benefit managers; permit; ~~annual~~ report; fees**

- 84 A. ...  
85 B. The board may promulgate rules and regulations to specify the ~~annual~~ reporting requirements for the  
86 pharmacy benefit manager.  
87

**Louisiana Revised Statutes of 1950**

**Title 37 – Professions and Occupations**

**Chapter 14 – Pharmacy Practice Act**

**§1184. Fees**

Notwithstanding any other provision of this Chapter, the fees and costs established by the board in accordance with R.S. 37:1182(A) shall not be less than the following schedule:

	Minimum
(1) ...	
<b>(2) Licenses, permits, certification, registrations and examinations for pharmacists</b>	
(a)(i) <del>Annual</del> renewal fee for license, <u>per year</u>	\$100.00
(ii) Pharmacy education support fee, <u>per year</u>	\$100.00
(b) Delinquent fee in addition to renewal fee, <u>per year</u>	\$50.00
(c) – (i) ...	
<b>(3) Licenses, permits, certification, registration, and any other designations for pharmacy locations</b>	
(a)(i) ...	
(ii) Pharmacy education support fee, <u>per year</u>	\$100.00
(b) – (c)	
(d) Pharmacy permit renewal fee, <u>per year</u>	\$125.00
(e) Delinquent permit renewal fee, <u>per year</u>	\$62.50
(f) Pharmacy CDS permit fee, <u>per year</u>	\$25.00
(g) Delinquent pharmacy CDS permit fee, <u>per year</u>	\$12.50
(h) ...	
(i) Automated medication system registration, <u>per year</u>	\$150.00
(j) Emergency drug kits for long-term care facilities, <u>per year</u>	\$25.00
<b>(4) Certification and examination for pharmacy technicians</b>	
(a) ...	
(b) <del>Annual</del> renewal certification fee, <u>per year</u>	\$50.00
(c) – (d) ...	
(e) Delinquent certificate renewal fee, <u>per year</u>	\$25.00
(f) ...	
<b>(5) ...</b>	
<b>(6) Permits for pharmacy benefit managers</b>	
(a) <u>Application fee for initial permit</u>	<u>\$500.00</u>
(b) <u>Permit renewal fee, per year</u>	<u>\$500.00</u>

**§1207. Renewal of license, registration, and certification; expiration; reinstatement**

- A. (1) Each person licensed, registered, or certified by the board shall apply for renewal ~~annually~~ at a time designated by the board and pay a fee specified by the board. A person who desires to continue in the practice of pharmacy or assist in the practice of pharmacy in this state shall file with the board an application in such form and contain such data as the board may require, and complete such other requirements as deemed necessary by the board, for renewal.
- (2) (a) (i) The board shall assess on each ~~annual~~ pharmacist license renewal as required by this Section an additional fee of one hundred dollars per year to be designated as the “pharmacy education support fee.” This fee shall be dedicated and allocated as specified in this Paragraph to an accredited school of pharmacy of a public university in this state. The board shall include on each license renewal form issued to a pharmacist an optional election whereby the person may elect not to remit the one hundred dollar pharmacy education support fee.

A(2)(a)(ii) – D. ...

52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90

**§1208. Waiver of licensure or certification renewal while in military service**

Upon written request of any licensed pharmacist or certified technician serving in active duty in the military service of the United States or any of its allies, the board may waive the requirement for the ~~annual~~ renewal of pharmacist license or technician certificate, including the ~~annual~~ renewal fees.

**§1209. Waiver of renewal fee when licensed fifty years; award**

The board, in recognition of contributions to the practice of pharmacy, shall waive the ~~annual~~ renewal fee requirement for ~~annual~~ renewal of licensure for licensed pharmacists who have been duly registered and licensed to practice in Louisiana for not less than fifty years; in lieu thereof the board shall award to such pharmacists an honorary gold-embossed certificate. Such pharmacists desiring to continue to practice pharmacy shall file the ~~annual~~ renewal application and shall meet all other requirements for active licensure.

**§1230. Renewal of permits; expiration; reinstatement**

- A. (1) Each pharmacy issued a permit by the board shall apply for renewal ~~annually~~, at the time designated by the board and pay a fee specified by the board.
- (2) (a) (i) The board shall assess on each ~~annual~~ pharmacy permit renewal required by this Section an additional fee of one hundred dollars per year to be designated as the “pharmacy education support fee.” This fee shall be dedicated and allocated as specified in this Paragraph to an accredited school of pharmacy of a public university in this state. The board shall include on each permit renewal form issued to a pharmacy an optional election whereby the pharmacy may elect not to remit the one hundred dollar pharmacy education support fee.

A(2)(a)(ii) – D. ...

**§1232. Nonresident pharmacy**

- A. ...
- B. A nonresident pharmacy granted a nonresident pharmacy permit by the board shall disclose to the board the location, names, and titles of all principal corporate officers, as well as the owner’s managing officer and pharmacist-in-charge. A report containing this information shall be made to the board ~~on an annual basis~~ with each renewal application and within thirty business days after any change of office, corporate officer, or within ten business days of the departure of the prior owner’s managing officer or pharmacist in charge.
- C. – E. ...

**§1253. Pharmacy benefit managers; permit; ~~annual~~ report; fees**

- A. ...
- B. The board may promulgate rules and regulations to specify the ~~annual~~ reporting requirements for the pharmacy benefit manager.



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Report of Assistant Executive Director



LOUISIANA  
BOARD *of*  
PHARMACY

# PRESCRIPTION MONITORING PROGRAM (PMP)

BOARD MEETING – FEBRUARY 05, 2020

**PMP User Stats for 2019Q4 (10/01/2019 - 12/31/2019)**

PMP Role Title - Healthcare Provider	Number of Providers <u>Eligible</u> for PMP Access (as of 12/31/2019)	Number of Providers with PMP <u>Active Access Privileges</u> (as of 12/31/2019)	Number of PMP Requests by Providers through <u>AWARxE™</u> During 2019Q4	Number of PMP Requests by Providers through <u>GATEWAY™</u> During 2019Q4
Physician (MD, DO)	13,140	8,760	410,385	2,465,798
Nurse Practitioner (APRN)	3,670	2,831	105,607	395,803
Dentist (DDS)	2,262	1,533	5,585	931
Physician Assistant (PA)	999	727	23,308	48,377
Optometrist (OD)	361	152	17	0
Podiatrist (DPM)	164	110	651	0
Medical Psychologist (MP)	91	80	5,418	0
Medical Intern/Resident	1,194	1,065	4,473	0
Prescriber's Delegate	NA	2,633	196,239	NA
Pharmacist (PST)	9,301	4,405	473,182	1,565,226
Pharmacist's Delegate	NA	1,021	47,088	NA
<b>Totals</b>	<b>31,182</b>	<b>23,317</b>	<b>1,271,953</b>	<b>4,476,135</b>

**PMP User Stats for 2019Q3 (07/01/2019 - 09/30/2019)**

PMP Role Title - Healthcare Provider	Number of Providers <u>Eligible</u> for PMP Access (as of 09/30/2019)	Number of Providers with PMP <u>Active Access Privileges</u> (as of 09/30/2019)	Number of PMP Requests by Providers through <u>AWARxE™</u> During 2019Q3	Number of PMP Requests by Providers through <u>GATEWAY™</u> During 2019Q3
Physician (MD, DO)	13,125	8,878	424,703	2,343,919
Nurse Practitioner (APRN)	3,576	2,802	101,701	412,022
Dentist (DDS)	2,256	1,553	6,384	1,069
Physician Assistant (PA)	984	728	24,838	50,895
Optometrist (OD)	364	153	7	0
Podiatrist (DPM)	165	112	438	0
Medical Psychologist (MP)	89	83	6,059	0
Medical Intern/Resident	1,299	1,113	4,146	0
Prescriber's Delegate	NA	2,522	206,613	NA
Pharmacist (PST)	9,231	4,351	523,925	721,397
Pharmacist's Delegate	NA	990	50,325	NA
<b>Totals</b>	<b>31,089</b>	<b>23,285</b>	<b>1,349,139</b>	<b>3,529,302</b>


### PMP User Stats for 2019Q2 (04/01/2019 - 06/30/2019)

PMP Role Title - Healthcare Provider	Number of Providers <u>Eligible</u> for PMP Access (as of 06/30/2019)	Number of Providers with PMP <u>Active</u> Access Privileges (as of 06/30/2019)	Number of PMP Requests by Providers through <u>AWARxE™</u> During 2019Q2	Number of PMP Requests by Providers through <u>GATEWAY™</u> During 2019Q2
Physician (MD, DO)	13,149	8,767	401,705	2,023,067
Nurse Practitioner (APRN)	3,435	2,675	94,087	317,520
Dentist (DDS)	2,224	1,531	6,249	657
Physician Assistant (PA)	928	688	30,021	34,675
Optometrist (OD)	360	154	7	0
Podiatrist (DPM)	163	111	520	0
Medical Psychologist (MP)	91	83	5,469	0
Medical Intern/Resident	1,047	1,029	2,790	0
Prescriber's Delegate	NA	2,368	204,522	NA
Pharmacist (PST)	9,255	4,246	522,828	364,003
Pharmacist's Delegate	NA	926	41,913	NA
Totals	30,652	22,578	1,310,111	2,739,922

### PMP User Stats for 2019Q1 (01/01/2019 - 03/31/2019)


PMP Role Title - Healthcare Provider	Number of Providers <u>Eligible</u> for PMP Access (as of 03/31/2019)	Number of Providers with PMP <u>Active</u> Access Privileges (as of 03/31/2019)	Number of PMP Requests by Providers through <u>AWARxE™</u> During 2019Q1	Number of PMP Requests by Providers through <u>GATEWAY™</u> During 2019Q1
Physician (MD, DO)	13,047	8,748	373,300	1,483,241
Nurse Practitioner (APRN)	3,322	2,575	88,031	60,903
Dentist (DDS)	2,226	1,525	5,479	22
Physician Assistant (PA)	895	668	27,013	7,354
Optometrist (OD)	359	155	15	0
Podiatrist (DPM)	163	112	348	0
Medical Psychologist (MP)	91	81	4,708	0
Medical Intern/Resident	1,157	1,017	2,763	288
Prescriber's Delegate	NA	2,239	199,711	NA
Pharmacist (PST)	8,894	4,189	504,328	349,849
Pharmacist's Delegate	NA	854	38,361	NA
Totals	30,154	22,163	1,244,057	1,901,657

# Louisiana Prescriber & Pharmacist Searches through AWARe and Gateway



# NUMBER OF ELIGIBLE PRESCRIPTION TRANSACTIONS REPORTED TO THE PMP

**Total Reported: 139,648,718**  
**(01/01/2008 through 12/31/2019)**



Quick Slicers:




2012 2013 2014 2015 2016 2017 2018 **2019** 2020

**State Rx per Capita**  
**2.322**

**Prescriptions**  
**10,812,250**

Quantity Dispensed	EACH (TABLETS, KITS, ETC..)	477,674K
	GRAMS (SOLIDS)	3,043K
	MILLILITERS (LIQUIDS)	71,565K
	UNSPECIFIED	1,005K

**Days Supply**  
**254,332,044**







YoY Prescriptions (#) by Drug Schedule

Schedule 2	2019	4,911,637
Schedule 3	2019	739,370
Schedule 4	2019	4,332,705
Schedule 5	2019	504,187
Unscheduled	2019	312,886
Unspecified	2019	11,465

YoY Prescriptions (#) by Drug Classes

Opioid	2019	4,405,993
Benzo	2019	2,395,139
Anxiolytic, Hypnotics, Se..	2019	946,594
Other	2019	3,064,524



Last Updated @  
1/7/2020 2:23:22 PM

**State Rx per Capita**  
**2.437**


**Prescriptions**  
**34,083,188**

Quick Slicers:



Quantity Dispensed	Quantity
EACH (TABLETS, KITS, ETC..)	1,550,632K
GRAMS (SOLIDS)	10,008K
MILLILITERS (LIQUIDS)	249,049K
UNSPECIFIED	1,221K

**Days Supply**  
**799,120,679**




**YoY Prescriptions (#) by Drug Schedule**

Schedule	Year	Prescriptions (#)
Schedule 2	2017	5,485,011
	2018	5,139,446
	2019	4,911,637
Schedule 3	2017	739,595
	2018	724,749
	2019	739,370
Schedule 4	2017	4,829,516
	2018	4,576,650
	2019	4,332,705
Schedule 5	2017	592,095


**YoY Prescriptions (#) by Drug Classes**

Class	Year	Prescriptions (#)
Opioid	2017	5,343,093
	2018	4,786,446
	2019	4,405,993
Benzo	2017	2,605,822
	2018	2,497,602
	2019	2,395,139
Anxiolytic, Hypnotics, Sedatives	2017	1,031,301
	2018	997,847
	2019	946,594
Other	2017	2,987,123


Prescriptions >= 90 MME vs. All




Rx by Patient Demographic Environment




New vs. Refill Prescriptions




Opioids vs. Non Opioids (%)




# Hydrocodone / APAP Dispensing by Number of Prescriptions



# Hydrocodone / APAP Dispensing by Number of Dosage Units



# Hydrocodone / APAP Dispensing by Number of Patients



# Dispensations - Drugs

Metrics related to dispensations based on drugs and drug class.  
Use the drop downs to customize the report to your needs.






Prescriptions: **10,812,250**  
**Opioid 40.8%**  
**Non-Opioid 59.2%**



Quick Filters:

Year: **2019**  
 Month: **(All)**

Drug: Schedule **(All)**    Drug: AHFS Class **(All)**    Drug: Opioid? **(All)**  
 Patient: State **(All)**    Patient: County **(All)**  
 Prescriber: Speciality Lvl 2 **(All)**    Prescriber: Out of State? **(All)**  
 Drug: Act. Ingr. **(All)**    Drug: Unit **(All)**    Drug: Dosage Type **(All)**  
 Patient: Age Band **(All)**  
 Prescriber: PDMP Role **(All)**



Select Category: **None**

Select Drug Name: **Generic Name**

You can modify the table to the right by changing the parameters above.

Drug Name	Patients	Prescriptions	Quantity	Days Supply	Total MME
HYDROCODONE BITARTRATE/ACETAMI...	664,058	1,801,041	96,016,555	28,319,520	783,882,367
DEXTROAMPHETAMINE SULF-SACCHA..	155,816	1,117,099	50,219,511	33,546,302	0
ALPRAZOLAM	186,744	976,213	51,730,599	26,635,143	0
TRAMADOL HCL	283,201	793,809	44,253,343	13,718,414	227,004,366
ZOLPIDEM TARTRATE	98,307	610,164	19,404,693	19,374,186	0
OXYCODONE HCL/ACETAMINOPHEN	209,456	598,848	36,129,430	10,472,010	483,729,841
CLONAZEPAM	102,296	593,000	30,765,840	17,437,223	0
LISDEXAMFETAMINE DIMESYLATE	75,298	442,563	13,420,139	13,329,092	0
LORAZEPAM	92,695	328,578	14,363,199	7,483,692	0
METHYLPHENIDATE HCL	54,259	294,198	12,061,758	8,813,643	0
DIAZEPAM	93,534	251,335	10,198,716	5,176,051	0
PHENTERMINE HCL	80,925	227,719	7,026,364	6,876,836	0
PREGABALIN	39,133	208,129	15,082,806	6,732,778	0
BUPRENORPHINE HCL/NALOXONE HCL	20,862	206,712	8,685,267	4,246,105	0

Last Time Updated:  
1/7/2020 3:40:29 PM

# Dispensations - Drugs

Metrics related to dispensations based on drugs and drug class.  
Use the drop downs to customize the report to your needs.

Quick Filters:

Year:

Month:




Prescriptions: **10,812,250**

Opioid: **40.8%**

Non-Opioid: **59.2%**

Drug: Schedule 
 Drug: AHFS Class 
 Drug: Opioid? 
 Patient: State 
 Patient: County 
 Prescriber: Speciality Lvl 2 
 Prescriber: Out of State?

Drug: Act. Ingr. 
 Drug: Unit 
 Drug: Dosage Type 
 Patient: Age Band 
 Prescriber: PDMP Role



Select Category:

Select Drug Name:

You can modify the table to the right by changing the parameters above.

Drug Name	Patients	Prescriptions	Quantity	Days Supply	Total MME
HYDROCODONE-ACETAMINOPHEN 10-...	204,019	834,110	58,141,268	17,985,784	581,412,678
TRAMADOL HCL 50 MG TABLET	281,605	779,589	43,779,656	13,314,239	218,898,280
HYDROCODONE-ACETAMINOPHEN 5-3...	311,011	487,930	13,117,369	4,211,861	65,586,843
HYDROCODONE-ACETAMINOPHEN 7.5-...	224,436	440,088	17,443,189	5,840,044	130,823,918
ZOLPIDEM TARTRATE 10 MG TABLET	68,571	439,123	14,040,965	14,038,263	0
ALPRAZOLAM 0.5 MG TABLET	88,790	406,163	20,620,332	10,970,427	0
OXYCODONE-ACETAMINOPHEN 10-325...	72,631	304,841	23,158,244	6,743,167	347,373,665
ALPRAZOLAM 1 MG TABLET	45,545	295,380	17,816,774	8,408,206	0
CLONAZEPAM 0.5 MG TABLET	58,971	268,227	12,948,939	7,703,069	0
CLONAZEPAM 1 MG TABLET	43,065	261,598	14,335,354	7,836,309	0
DEXTROAMP-AMPHETAMIN 30 MG TAB	35,489	261,223	14,244,951	7,830,514	0
DEXTROAMP-AMPHETAMIN 20 MG TAB	41,867	244,498	13,748,309	7,359,201	0
PHENTERMINE 37.5 MG TABLET	74,343	201,687	6,120,727	6,090,577	0
ALPRAZOLAM 0.25 MG TABLET	56,466	190,042	8,480,530	4,826,232	0

Last Time Updated:  
1/7/2020 3:40:29 PM

# NABP PMP InterConnect®

## PMP Interstate Data Sharing

As of January 1, 2020, the Louisiana PMP is sharing with 29 states and the U.S. Military Health System (MHS) – Department of Defense (DOD)

Alabama	Kansas	North Carolina
Alaska	Maine	North Dakota
Arizona	Massachusetts	Oklahoma
Arkansas	MHS-DOD	Pennsylvania
Connecticut	Michigan	South Carolina
Delaware	Minnesota	South Dakota
D.C.	Mississippi	Tennessee
Florida	Montana	Texas
Georgia	Nevada	Virginia
Idaho	New Mexico	West Virginia

# LAW ENFORCEMENT REQUESTS

**Total Number of Law Enforcement  
Requests Processed: 11,206  
01/01/2009 through 12/31/2019**



## Requests for Full Exemption from PMP Reporting February 5, 2020

In accordance with LA.R.S:40.4.X-A.1006.C. The board may issue an exemption from the reporting requirement to a dispenser whose practice activities are inconsistent with the intent of the program. The board may rescind any previously issued exemption without the need for an informal or formal hearing.

Permit	Permit Type	Name	Scope of Practice	DEA	City	State
8029	NR	BioMatrix Specialty Pharmacy of Maryland	Specialty Pharmacy	Yes	Columbia	MD
6364	NR	Crescent Healthcare	Retail Pharmacy	Yes	Santa Fe Springs	CA
7946	NR	Doc Lane's Veterinary Pharmacy, LLC	Veterinary Only Compounding Pharmacy	Yes	Lexington	KY
7994	NR	Entirelypets Pharmacy	Veterinary Pharmacy	No	Union City	CA
8012	HOS	Intensive Specialty Hospital	Inpatient Hospital Pharmacy	Yes	Shreveport	LA
8011	HOS	KPC Promise Hospital of Baton Rouge, LLC	Long Term Acute Care Hospital	Yes	Baton Rouge	LA
8003	NR	LibraSun Pharmacy	Diabetic supplies and some topicals used for pain or neuropathy	Yes	Oakland Park	FL
7980	IR	Ochsner LSU Health Shreveport	Outpatient Investigational Pharmacy	Yes	Shreveport	LA
7986	NR	OSRX, Inc.	Community Compounding Pharmacy	Yes	Missoula	MT
7988	HOS	Our Lady of the Lake Children's Hospital Pharmacy	Inpatient Pharmacy	Yes	Baton Rouge	LA
7960	NR	PANTHERx Specialty Pharmacy	Specialty Pharmacy	Yes	Pittsburgh	PA
7574	NR	Pet Supplies Delivered	Veterinary Pharmacy	No	La Vista	NE
7971	NR	PharmD on Demand Inc.	Non-Dispensing and Remote Order Entry/Verification Services for Inpatient Hospitals	Yes	Watkinsville	GA

Permit	Permit Type	Name	Scope of Practice	DEA	City	State
7977	NR	RareMed Solutions	Non-Commercial Pharmacy	Yes	Pittsburgh	PA
6823	NR	Solutions Rx Pharmacy	Retail/ Independent/ Compounding	Yes	Birmingham	AL
7455	IR	Tulane University Health Sciences Pharmacy	340B Pharmacy for the Louisiana Center for Bleeding & Clotting Disorders	No	New Orleans	LA
8002	NR	Veterinary Internet Company Retail Pharmacy	Veterinary Mail Order	No	Union Grove	AL

**Staff Recommendation**

Approve the proposed waivers conditioned upon execution of the standard Consent Agreement:

**EXEMPTION TO PRESCRIPTION MONITORING PROGRAM REPORTING REQUIREMENTS  
CONSENT AGREEMENT**

WHEREAS, in order to facilitate the pharmacy's request for an exemption to the reporting requirements to the Louisiana Board of Pharmacy's Prescription Monitoring Program (PMP) as required by law, the Pharmacy indicated below agrees to the following terms:

- (1) The Pharmacy shall not be authorized to dispense any controlled dangerous substances (CDS) or *drugs of concern*, with the exception of a hospital pharmacy permit's inpatient dispensing, as identified by the Louisiana Board of Pharmacy (Board) by regulation.
- (2) Upon the first instance of receipt of evidence by the Board indicating the Pharmacy dispensed CDS or drugs of concern, the Pharmacy agrees to the following sanction:  
***The Pharmacy agrees to pay a fine of \$5,000.00 and reimburse the Board \$250.00 in administrative hearing costs, with total payment due the Board of \$5,250.00, due by certified check or money order within 30 days of notice of this prohibited activity.***
- (3) Upon the second instance of receipt of evidence indicating the Pharmacy dispensed CDS or drugs of concern, the Pharmacy agrees to pay the above sanction, the termination of this exemption and the resumption of its reporting to the PMP.
- (4) The Pharmacy shall post a copy of this agreement adjacent or attached to its pharmacy permit.

By signing this Consent Agreement, Respondent agrees that the Board has jurisdiction in this matter and waives all rights to informal conference, to Notice of Hearing, to a formal Administrative Hearing, and to judicial review of this Consent Agreement.



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Report of General Counsel



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Report of Executive Director



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



February 5, 2020

## Agenda Item 11-L: Report of Executive Director

1. Meeting Activity
2. Reports
3. Examinations
4. Operations
5. State Activities
6. Regional & National Activities
7. International Activities

### 1. Meeting Activity

In addition to Board and committee meetings, I have also participated in or attended the following meetings since the last Board meeting.

Nov. 18	Drug Policy Board
Dec. 6	CLEAR Workshop on Sexual Misconduct Investigations
Dec. 12-13	Cannabis & Hemp Symposium @ Southern Univ. Law Center
Jan. 14	dotPharmacy Executive Board ( <i>via webinar</i> )
Jan. 15	La. Hospital Association – Medical Marijuana Policy Workgroup
	La. Pharmacy Congress

### 2. Reports

#### A. Internal Reports (posted in the Library)

1. Credentials Division
  - a. Census Report
  - b. Licensure Activity Report
  - c. Pending Applications Report
  - d. Exceptions Report
2. Compliance Division
  - a. Census Report – Practitioner Recovery Program & Disciplinary Status
  - b. Complaint Investigation Policy Monitor

#### B. External Reports

Since the last Board meeting, we have filed the following reports on your behalf:

1. La. Office of the Governor – Boards & Commissions
  - a. Annual Report
2. La. Office of the Governor – Drug Policy Board / HOPE Advisory Council
  - a. Naloxone Dispensing Report
3. La. Div. of Administration – Office of the Commissioner
  - a. Quarterly Report of Legal Judgments [Act 2018-627]
  - b. Annual Report for Sexual Harassment Complaints [Act 2018-270]
4. La. Div. of Administration – Boards & Commissions
  - a. Annual LaTrac Report of Board Activity [Act 2009-12]
  - b. Quarterly Report of Member Expense Reimbursements
  - c. Ad hoc reports of personnel salaries, meeting notices, and budgets
5. La. Div. of Administration – Facility Planning & Control
  - a. Semiannual Report of Leased Office Space [Act 2016-66]

6. La. Div. of Administration – Property Assistance Agency
  - a. Annual Inventory of Property & Equipment
  - b. Annual Asset Certification Report
  - c. Monthly Agency Fleet Mileage Report
7. La. Div. of Administration – Office of Group Benefits
  - a. Annual Designations of Master User & Agency Coordinator
  - b. Ad hoc reports of non-discrimination testing
8. La. Div. of Administration – Office of Risk Management
  - a. Annual Agency Driver Authorization Report
  - b. Annual Loss Prevention Compliance Audit
  - c. Semiannual Property Exposure Report
  - d. Quarterly Risk Exposure Report
  - e. Quarterly Property Safety & Maintenance Inspections
  - f. Monthly Loss Claims Report
  - g. Monthly Report re Transitional Return to Work
9. La. Div. of Administration – Office of State Procurement
  - a. Monthly Report on Status of Professional Contracts [Act 2015-87]
  - b. Ad hoc reports on contractor performance review
10. La. Div. of Administration – Office of State Register
  - a. Ad hoc notices for rulemaking projects
11. La. Div. of Administration – Office of Statewide Reporting & Accounting Policy
  - a. Comprehensive Annual Financial Report
  - b. Annual Report of Taxable Compensation
  - c. Quarterly Report of Accounts Receivable [Act 1995-745]
12. La. Dept. of Children & Family Services
  - a. Ad hoc rosters for credential renewals for pharmacists and technicians
13. La. Dept. of Culture, Recreation, & Tourism – State Library of Louisiana
  - a. Annual Publications Report Form
  - b. Semiannual Roster & Agency Inventory of Agency Publications
  - c. Ad hoc document publication reports
14. La. Dept. of Economic Development
  - a. Ad hoc rulemaking notices
15. La. Dept. of Health – Bureau of Health Services Financing
  - a. Monthly Report of Pharmacy Openings & Closures
16. La. Dept. of Health – Office of Public Health
  - a. Semi-annual Report of Active MA Registrations
17. La. Dept. of Insurance
  - a. Annual Report of Investigation Referrals [Act 2009-251]
18. La. Dept. of Justice – Office of the Attorney General
  - a. Quarterly Report of Private Legal Fees Paid [Act 2006-611]
  - b. Quarterly Report of Legal Judgments [Act 2018-627]
  - c. Ad hoc notices for emergency rules
19. La. Dept. of Revenue
  - a. Quarterly Employer's Return of State Withholding Tax
  - b. Ad hoc rosters for credential renewals for pharmacists and technicians
20. La. Dept. of State – Division of Archives
  - a. Annual Report of Records Officer Designation
21. La. Dept. of State Civil Service
  - a. Annual Confirmation of Agency EEO Policy
  - b. Annual Report of Performance Evaluations
  - c. Ad hoc Payroll Comparison Report
22. La. Dept. of Treasury – Cash Management Review Board
  - a. Quarterly Report of Agency Bank Accounts [Act 2016-587]
23. La. Board of Regents – ULM College of Pharmacy
  - a. Annual Report of Pharmacy Education Support Fees Collected
24. La. State Employees Retirement System
  - a. Monthly Report of Employer & Employee Contributions

25. La. Workforce Commission
  - a. Quarterly Report of Employer's Unemployment Tax
26. La. House of Representatives – Office of the Speaker
  - a. Annual Report of Rulemaking Activity
  - b. Ad hoc notices for rulemaking projects
27. La. House of Representatives – Poynter Legislative Research Library
  - a. Annual Filing of Legislative Reports
28. La. House of Representatives – Committee on Appropriations
  - a. Quarterly Report of Legal Judgments [Act 2018-627]
29. La. House of Representatives – Committee on Commerce
  - a. Annual Report of Licensed Ex-Offenders [Act 2017-262]
30. La. House of Representatives – Committee on House & Governmental Affairs
  - a. Quarterly Report of Board Complaints [Act 2018-655]
31. La. House of Representatives – Committee on Health & Welfare
  - a. Annual LaTrac Report on Board Activity [Act 2009-12]
  - b. Annual Report on Rulemaking Activity
  - c. Annual Notice of Budget Adoption
  - d. Comprehensive Annual Financial Report
  - e. Ad hoc notices for rulemaking projects
32. La. Senate – Office of the President
  - a. Annual Report on Rulemaking Activity
  - b. Ad hoc notices for rulemaking projects
33. La. Senate – Committee on Finance
  - a. Quarterly Report on Legal Judgments [Act 2018-627]
34. La. Senate – Committee on Health & Welfare
  - a. Annual LaTrac Report on Board Activity [Act 2009-12]
  - b. Annual Report on Rulemaking Activity
  - c. Annual Notice of Budget Adoption
  - d. Comprehensive Annual Financial Report
  - e. Ad hoc notices for rulemaking projects
35. La. Senate – Committee on Senate & Governmental Affairs
  - a. Annual Report on Boards & Commissions
  - b. Quarterly Report of Board Complaints [Act 2018-655]
36. La. Legislature – Legislative Auditor
  - a. Comprehensive Annual Financial Statement
  - b. Annual Inventory of Property & Equipment
  - c. Annual Asset Certification Report
  - d. Annual Notice of Budget Adoption
37. La. Legislature – Legislative Fiscal Office
  - a. Annual Notice of Budget Adoption
  - b. Annual LaTrac Report of Board Activity [Act 2009-12]
  - c. Ad hoc impact statements for rulemaking projects
38. La. Legislature – Joint Legislative Committee on the Budget
  - a. Annual Notice of Budget Adoption
  - b. Annual LaTrac Report of Board Activity [Act 2009-12]
39. U.S. Dept. of Commerce – Census Bureau
  - a. Annual Survey of Public Employment & Payroll
40. U.S. Dept. of Health & Human Services – Office of Public Health
  - a. Quarterly Report to ESAR-VHP
41. U.S. Dept. of Labor – Bureau of Labor Statistics
  - a. Monthly Survey of Current Employment Statistics
42. U. S. Dept. of Treasury – Internal Revenue Service
  - a. Annual Filings (Forms 1094, 1095-C, 1096, 1099, W-2, & W-3)
  - b. Quarterly Report of Form 941 – Employer's Federal Tax Return

(cont.)

### 3. **Examinations**

#### A. Pharmacists

1. MPJE – the results for the third trimester of 2019 are not yet available.
2. NAPLEX – the results for the third trimester of 2019 are not yet available.

#### B. Technicians

1. NHA – the results for the fourth quarter of 2019 are available.
2. PTCB – the results for the second half of 2019 are available.

### 4. **Operations**

#### A. Credentials Division

As of January 23, 2020, we had 72,041 active credentials under management by the Board. That number reflects a 2.9% increase from the beginning of this fiscal year on July 1, 2019. About 65% of the credentials (46,746) reside in the Pharmacy Program with the balance in the CDS Program.

We opened the renewal cycle for pharmacists and pharmacies on November 1; we sent renewal reminder notices on October 31.

- PST: We placed 9,350 licenses in renewal. Of that number, 8,689 (92.93%) renewed timely. Of the number renewing timely, 95.68% did so online, with the remaining 375 pharmacists using the paper application form.
- PHY: We placed 2,029 permits in renewal. Of that number, 1,945 (95.86%) renewed timely. Of the number renewing timely, 87.71% did so online, with the remaining 239 pharmacies using the paper application form.
- CDS-PHY: We placed 1,311 licenses in renewal. Of that number, 1,269 (96.8%) renewed timely. Of the number renewing timely, 94.48% did so online, with the remaining 70 pharmacies using the paper application form.

#### B. Compliance Division

Our 7 pharmacist compliance officers are responsible for inspecting all the pharmacies and other facilities holding controlled substances (CDS). The census reports available for this meeting reflect 1,425 pharmacies within the state, as well as 324 DME permits, and an additional 533 various types of facilities and persons for CDS visits, including hospitals, researchers, animal euthanasia technicians, etc.

In addition to their routine site visits, the compliance officers are also responsible for investigating complaints filed with the Board. We began this fiscal year with 179 cases pending from the prior fiscal year. We have opened 226 new cases and closed 225, leaving 180 cases still open for this fiscal year. Of the 126 cases closed, 66% were disposed of through staff activities and the balance through committee and Board action.

#### C. Administrative Division

The administrative team continues our work on three major projects – developing a revision of the record retention policy for ultimate approval by the state archives which will include provisions for disposing of scanned documents and other aspects of electronic document management (which will then allow for the imaging of existing records), researching the integration of electronic documents with our licensure information system, and transitioning more credentials to both online renewal and online original applications.

We have a personnel change to report. We determined it appropriate to discharge our previous receptionist, and then transferred one of the administrative coordinators from the PMP office to the front office. Ms. Robbi Lewis is now our receptionist.

#### D. Marijuana Pharmacies

As you may recall, the enabling legislation adopted in 2015 limits the number of

marijuana pharmacy permits in the state to a maximum of ten active permits. The Board's rules for marijuana pharmacies adopted in August 2017 identified the nine regions of the state used by the state health department, allocated one marijuana pharmacy permit to each of those nine regions, and included a provision that the 10<sup>th</sup> permit may be awarded by the Board when it is convinced of the need for it. Following the conclusion of the competitive application process identified in its rules, the Board awarded the first nine marijuana pharmacy permits in April 2018.

To facilitate the Board's determination of need for a 10<sup>th</sup> permit, we have initiated a data collection process to document patient need as indicated by the ZIP code of the patients with medical cannabis transactions reported by the marijuana pharmacies to the PMP database. A copy of the graphical report including transactions from August 6 through December 31, 2019 has been posted in the Boardroom Library.

## 5. **State Activities**

- A. La. Dept. of Health – Office of Public Health  
The agency published an *Emergency Rule* on November 7 to amend their rules to implement the registration of industrial hemp derived cannabidiol products as authorized by Act 164 of the 2019 Legislature.
- B. Legislative Oversight Committee  
The House Committee on Ways and Means and the Senate Committee on Revenue and Fiscal Affairs conducted a joint legislative oversight hearing on November 6 relative to an *Emergency Rule* published on September 11 by the Dept. of Revenue's Office of Alcohol & Tobacco Control (ATC) relative to industrial hemp-derived cannabidiol products intended for consumption or topical use. The House Committee on Ways and Means found the emergency rule unacceptable with respect to ATC's regulatory authority over any hemp derived products that do not contain cannabidiol, and further, limited the agency's authority to industrial hemp derived cannabidiol products intended for consumption or topical use.
- C. La. Dept. of Agriculture & Forestry  
The agency published a *Potpourri Notice* in the November 2019 edition of the *Louisiana Register*, indicating their intent to make substantive changes to the original *Notice of Intent* in the October 2019 edition of the *Louisiana Register* relative to the establishment of their industrial hemp program. The public hearing was conducted on December 20, and public comments on the substantive changes were due the same day.
- D. La. Dept. of Revenue – Office of Alcohol & Tobacco Control  
The agency published an *Emergency Rule* on November 27 relative to industrial-hemp derived cannabidiol products. This third iteration of emergency rules on this topic was published to remedy the previous edition published on September 11 which was ruled unacceptable by the legislative oversight committee on November 6. The rule provides a regulatory structure for the retail sale of such products at both wholesale and retail levels.
- E. La. State Board of Medical Examiners  
The agency published a *Notice of Intent* in the December 2019 edition of the *Louisiana Register* to amend its rules relative to medical marijuana, to conform those rules to Act 284 of the 2019 Legislature by removing the physician domiciliary requirement as well as the board's annual reporting requirement to the state legislature, along with other technical changes. The deadline for public comments was January 20.
- F. La. State Board of Optometry Examiners  
The agency published a *Rule* in the January 2020 edition of the Louisiana Register which affects prescriptions for spectacles and contact lenses and also imposes a mandatory requirement to review patient information in the PMP database when prescribing opioids. The rule lists specific data elements that must be present in prescriptions for both spectacles and contact lenses, provides an expiration date of 18 months for spectacle prescriptions and 12 months for contact lens prescriptions, and further, prohibits the

substitution of either spectacle or contact lens prescriptions for the other. The Rule also implements the provisions of recent legislation requiring prescribers of opioids to review patient information in the PMP database, with the same exceptions in the Rule as are in the law.

- G. La. Dept. of Health – Office of Behavioral Health & Bureau of Health Services Financing  
The agencies published a *Rule* in the January 2020 edition of the *Louisiana Register* which extends coverage for medication-assisted treatment provided in opioid treatment programs, including methadone, to all Medicaid-eligible adults and children with opioid use disorder.
- H. La. Dept. of Health – Bureau of Health Services Financing  
The agency published a *Rule* in the January 2020 edition of the *Louisiana Register* enabling the communication of “Dispense as Written” instructions in electronic prescriptions. *“Limits on payments for multiple source drugs shall not be applicable when the prescriber certifies that the brand name drug is medically necessary ... in his own handwriting or via an electronic prescription. Such certification shall be written directly on the prescription, on a separate sheet which is dated and attached to the prescription, or submitted electronically. A standard phrase such as ‘brand necessary’ indicating the medical necessity of the brand will be acceptable.”* [LAC 50:XXIX.949.D.1]
- I. Regular Session of 2020 Legislature  
The session will convene at 12:00 noon on Monday, March 9, 2020 and must adjourn no later than 6:00 pm on Monday, June 1, 2020. The deadline to request the pre-filing of legislation is Wednesday, February 26, and the deadline to request the filing of all legislation is Monday, March 30. The initial report has been posted in the Boardroom Library. We will publish interim reports periodically during the session.

## 6. **Regional & National Activities**

- A. National Association of Boards of Pharmacy (NABP)  
The annual meeting of this association is one of the three meetings for which certain of your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board’s travel policy as well as the state’s travel policy in PPM-49.  
For your planning purposes, the association will hold its 116<sup>th</sup> Annual Meeting on May 14-16, 2020 in Baltimore, MD. Registration details will be provided when they are available.
- B. NABP-AACP District 6  
The annual meeting of this association is one of the three meetings for which certain of your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board’s travel policy as well as the state’s travel policy in PPM-49.  
For your planning purposes, Districts 6, 7, and 8 will meet together again on October 11-13, 2020 at the Civana Spa, Resort & Sanctuary in Carefree, AZ. Registration details will be provided when they are available.
- C. MALTAGON  
The annual meeting of this association is one of the three meetings for which certain of your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board’s travel policy as well as the state’s travel policy in PPM-49.  
For your planning purposes, the Alabama Board of Pharmacy will host next year’s conference The Lodge Hotel in Gulf Shores, AL on Oct. 4-6, 2020. Registration details will be provided when they are available.  
As a gentle reminder, the Louisiana Board is scheduled to host the conference in 2021. We should be prepared to provide the date and venue for that meeting during the 2020 conference.

## 7. ***International Activities***

### A. International Pharmaceutical Federation (FIP)

FIP has announced that future congresses will be held Sep. 13-17, 2020 in Seville, Spain; Aug. 29 – Sep. 2, 2021 in Brisbane, Australia; and Sep. 25-29, 2022 in Capetown, South Africa.

### B. World Health Professions Alliance (WHPA)

WHPA has announced their 6<sup>th</sup> World Health Professions Regulation Conference will be held May 16, 2020 in Geneva, Switzerland. Presentations will revolve around two key topics: the value of strong regulatory bodies to deliver quality care, and the importance of continuing professional development (CPD).

### C. dotPharmacy Verified Websites Program

dotPharmacy is a generic top level domain (gTLD) on the Internet. Although it is owned by NABP, the dotPharmacy domain is governed by a global collaboration including the International Pharmaceutical Federation (FIP) and the National Association of Pharmacy Regulatory Authorities (NAPRA – Canada) and endorsed by multiple global partners, including the World Health Organization (WHO), Interpol, and the Pharmaceutical Group of the European Union (PGEU). dotPharmacy is different from most TLDs in that authority to host a website on dotPharmacy is restricted to applicants whose legitimacy has been verified by NABP or one of its global partners. The vision for dotPharmacy is to create an online pharmacy community where patients can go to safely order prescription drugs, knowing the sites have already been verified as legitimate pharmacies that are licensed by the appropriate pharmacy regulatory authority. In addition to pharmacies, the plan is to create a presence for a number of related organizations, including professional membership organizations, colleges of pharmacy, boards of pharmacy, drug manufacturers, and consumer-oriented drug information organizations. dotPharmacy began accepting applications for website registrations in June 2015.

In December 2019, there were 580 registered domains held by pharmacy organizations representing approximately 60% of the physical pharmacy locations in the U.S. Although most of the domains are based in the U.S., 62 domains are based in other countries around the world, including Canada, the Netherlands, Germany, Malta, and the United Kingdom. Discussions and negotiations are underway with pharmacy regulatory authorities in Australia, Brazil, China, India, New Zealand, Scotland, South Africa, and Turkey. More information, including a list of registered domains, is available at [www.safe.pharmacy](http://www.safe.pharmacy).

NABP verification of websites through the dotPharmacy program enables pharmacy websites to comply with e-business requirements established by Google, Bing, Yahoo, Twitter, Snap, Visa, and MasterCard.

The Louisiana Board has two website addresses in the dotPharmacy domain: [www.laboard.pharmacy](http://www.laboard.pharmacy) and [www.la.pharmacy](http://www.la.pharmacy). The domain name fees for these websites have been waived by NABP. For now, visitors to these sites are automatically re-directed to the Board's website at [www.pharmacy.la.gov](http://www.pharmacy.la.gov).

Respectfully submitted,  
Malcolm J Broussard  
Executive Director

Louisiana Board of Pharmacy  
Pharmacy Program - Census Report

		<u>6/30/2018</u>	<u>6/30/2019</u>	<u>1/23/2020</u>
PST.VI	LA	14	9	13
	NR	20	17	15
	<i>Total</i>	34	26	28
PST-GVI	LA	24	20	16
	NR	8	6	7
	<i>Total</i>	32	26	23
PST-M	LA	0	0	0
	NR	8	8	8
	<i>Total</i>	8	8	8
PST-MS	LA		3	5
	NR		2	5
	<i>Total</i>		5	10
PST-G	LA	194	186	180
	NR	27	31	30
	<i>Total</i>	221	217	210
PST	LA	5,690	5,795	5,640
	NR	3,090	3,230	3,119
	<i>Total</i>	8,780	9,025	8,759
	<b>Active PST</b>	<b>9,009</b>	<b>9,255</b>	<b>9,038</b>
PNT	LA	910	892	903
	NR	158	200	228
	<i>Total</i>	1,068	1,092	1,131
PNT-FPG	Total	2	2	3
	<b>PNT</b>	<b>1,070</b>	<b>1,094</b>	<b>1,134</b>
CPT	LA	6,433	6,452	6,923
	NR	152	147	165
	<i>Total</i>	6,585	6,599	7,088
CPT-M	Total	1	1	2
CPT-MS	Total		1	3
	<b>Active CPT</b>	<b>6,586</b>	<b>6,601</b>	<b>7,093</b>
PTC	LA	1,931	1,544	1,663
	NR	69	51	53
	<b>PTC</b>	<b>2,000</b>	<b>1,595</b>	<b>1,716</b>

Louisiana Board of Pharmacy  
Pharmacy Program - Census Report

		<u>6/30/2018</u>	<u>6/30/2019</u>	<u>1/23/2020</u>
PHY	CH	10	9	9
	HOS	163	161	163
	HOX	6	5	5
	IN	11	11	10
	INX	11	11	11
	IR	584	597	612
	IRX	6	8	9
	NR	534	561	561
	NRN	8	10	10
	NRP	2	1	1
	NU	13	13	12
	PE	0	0	0
	PEN	0	0	0
	PEX	3	4	4
	RC	630	596	572
	RPP	1	2	2
	SAT	6	6	7
	SPL	0	0	0
	TDS	0	0	0
	TM		8	9
	<b>PHY</b>	<b>1,988</b>	<b>2,003</b>	<b>1,997</b>

AMS	AMS	498	116	145
	AMS-X	372	345	368
	<b>AMS</b>	<b>870</b>	<b>461</b>	<b>513</b>

EDK	EDK	435	374	420
	EDK-X	11	6	8
	<b>EDK</b>	<b>446</b>	<b>380</b>	<b>428</b>

DME	LA	205	339	338
	NR	437	301	293
	<b>DME</b>	<b>642</b>	<b>640</b>	<b>631</b>

CDTM	69	78	79
------	----	----	----

MAR	3,073	3,161	3,270
-----	-------	-------	-------

PMP	15,835	19,686	21,205
-----	--------	--------	--------

SWP	45	41	50
-----	----	----	----

TMD	71	127	147
-----	----	-----	-----

<b>TOTAL</b>	<b>41,770</b>	<b>45,174</b>	<b>47,298</b>
--------------	---------------	---------------	---------------

Louisiana Board of Pharmacy  
CDS Program - Census Report

<i>Classification</i>	<u>6/30/2018</u>	<u>6/30/2019</u>	<u>1/23/2020</u>
ACS Animal Control Shelter	0	0	0
AMS Automated Medication System	35	40	46
AMX Automated Medication System - Exempt	2	2	2
APN Advanced Practice Registered Nurse	2,975	3,434	3,682
ASC Ambulatory Surgical Center	0	0	0
CRX Correctional Center	0	0	0
DDS Dentist	2,174	2,224	2,256
DET Drug Detection Canine - Private Agency	0	6	6
DEX Drug Detection Canine - Law Enforcement	8	0	0
DIS Distributor	290	285	287
DPM Podiatrist	158	163	165
DVM Veterinarian	1,188	1,216	1,280
DYS Dialysis Center	0	0	0
EMC Emergency Center	0	0	0
EMS Emergency Medical Service	0	0	0
ETC Animal Euthanasia Tech - Cert	3	3	3
ETL Animal Euthanasia Tech - Lead	26	25	24
HOS Hospital	301	297	299
HOX Hospital - Exempt	5	5	5
INT Intern or Resident	318	1,047	1,197
LAB Analytical Laboratory	8	8	8
LAX Analytical Laboratory - Exempt	4	4	5
MD Physician	12,824	13,138	13,137
MDT Physician via Telemedicine	2	11	16
MED Medical Clinic	0	0	0
MFR Manufacturer	45	47	44
MP Medical Psychologist	91	91	92
OD Optometrist	349	360	360
PA Physician's Assistant	783	928	999
PHX Pharmacy - Exempt	22	24	25
PHY Pharmacy	1,313	1,279	1,265
REP Sales Representative	0	0	0
RES Researcher	104	106	111
RHC Rural Health Clinic	0	0	0
RNT APRN via Telehealth	5	1	1
ROF Registered Outsourcing Facility	19	19	18
SAC Substance Abuse Clinic	6	6	6
SAX Substance Abuse Clinic - Exempt	0	0	0
MIS Other	<u>0</u>	<u>0</u>	<u>0</u>
<i>TOTAL</i>	<i>23,058</i>	<i>24,769</i>	<i>25,339</i>

*Highlighted credentials subject to inspection*

**Total Credentials Under Board Management**

Pharmacy Program	41,770	45,174	46,746
CDS Program	<u>23,058</u>	<u>24,769</u>	<u>25,295</u>
<b>TOTAL</b>	<b>64,828</b>	<b>69,943</b>	<b>72,041</b>

Louisiana Board of Pharmacy  
Pharmacy Program - Census Report

3/17/1995   6/30/1996   6/30/1997   6/30/1998   6/30/1999   6/30/2000   6/30/2001   6/30/2002

PST.VI   LA  
NR  
*Total*

PST-GVI   LA  
NR  
*Total*

PST-M   LA  
NR  
*Total*

PST-MS   LA  
NR  
*Total*

PST-G   LA  
NR  
*Total*

PST	LA	3,642	3,660	4,143	4,247	4,269	4,830	3,887	4,386
	NR	377	446	1,339	1,435	1,421	944	1,901	1,453
	<i>Total</i>	4,019	4,106	5,482	5,682	5,690	5,774	5,788	5,839

**Active PST**

PNT   LA  
NR  
*Total*

PNT-FPG	Total <b>PNT</b>							<b>957</b>	<b>976</b>
---------	---------------------	--	--	--	--	--	--	------------	------------

CPT   LA  
NR  
*Total*

CPT-M	Total <b>CPT</b>							<b>3,216</b>	<b>3,453</b>
-------	---------------------	--	--	--	--	--	--	--------------	--------------

PTC   LA  
NR  
**PTC**

								<b>2,896</b>	<b>2,372</b>
--	--	--	--	--	--	--	--	--------------	--------------

Louisiana Board of Pharmacy  
Pharmacy Program - Census Report

		<u>3/17/1995</u>	<u>6/30/1996</u>	<u>6/30/1997</u>	<u>6/30/1998</u>	<u>6/30/1999</u>	<u>6/30/2000</u>	<u>6/30/2001</u>	<u>6/30/2002</u>
PHY	CH	4	4	4	7	4	4	8	9
	HOS	177	174	171	175	172	171	171	174
	HOX								
	IN	46	45	38	39	19	19	19	18
	INX								
	IR	651	634	636	609	621	602	601	595
	IRX								
	NR	122	152	168	175	216	223	262	313
	NRN								
	NRP								
	NU	9	10	10	9	10	10	12	14
	PE	78	104	102	120	102	102	102	100
	PEN	13	12	12	12	12	12	12	13
	PEX								
	RC	464	473	471	493	505	520	530	535
	RPP								
	SAT								
	SPL								
	TDS								
TM									
	<b>PHY</b>	<b>1,564</b>	<b>1,608</b>	<b>1,612</b>	<b>1,639</b>	<b>1,661</b>	<b>1,663</b>	<b>1,717</b>	<b>1,771</b>
<hr/>									
AMS	AMS AMS-X <b>AMS</b>								<b>109</b>
<hr/>									
EDK	EDK EDK-X <b>EDK</b>							<b>468</b>	<b>461</b>
<hr/>									
DME	LA NR <b>DME</b>								
<hr/>									
CDTM									
MAR									
PMP									
SWP									
TMD									
<b>TOTAL</b>		<b>5,583</b>	<b>5,714</b>	<b>7,094</b>	<b>7,321</b>	<b>7,351</b>	<b>7,437</b>	<b>15,042</b>	<b>14,981</b>

Louisiana Board of Pharmacy  
Pharmacy Program - Census Report

6/30/2003   6/30/2004   6/30/2005   6/30/2006   6/30/2007   6/30/2008   6/30/2009   6/30/2010

PST.VI   LA  
NR  
*Total*

PST-GVI   LA  
NR  
*Total*

PST-M   LA  
NR  
*Total*

PST-MS   LA  
NR  
*Total*

PST-G   LA  
NR  
*Total*

PST	LA	4,435	4,486	4,532	4,460	4,522	4,612	4,750	4,860
	NR	1,455	1,484	1,686	1,915	1,975	1,964	2,029	2,098
	<i>Total</i>	<b>5,890</b>	<b>5,970</b>	<b>6,218</b>	<b>6,375</b>	<b>6,497</b>	<b>6,576</b>	<b>6,779</b>	<b>6,958</b>

*Active PST*

PNT	LA			980	1,079	1,074	1,035	965
	NR			109	117	67	84	153
	<i>Total</i>			<b>1,089</b>	<b>1,196</b>	<b>1,141</b>	<b>1,119</b>	<b>1,118</b>

PNT-FPG	Total								
	<i>PNT</i>	<b>929</b>	<b>995</b>	<b>1,154</b>	<b>1,089</b>	<b>1,196</b>	<b>1,141</b>	<b>1,119</b>	<b>1,118</b>

CPT	LA			4,552	4,587	4,780	4,733	5,363
	NR			163	152	144	109	144
	<i>Total</i>			<b>4,715</b>	<b>4,739</b>	<b>4,924</b>	<b>4,842</b>	<b>5,507</b>

CPT-M	Total							
	<i>CPT</i>			<b>4,715</b>	<b>4,739</b>	<b>4,924</b>	<b>4,842</b>	<b>5,507</b>

PTC	LA			1,081	1,389	1,446	1,510	1,679
	NR			32	32	23	32	35
	<i>PTC</i>			<b>1,113</b>	<b>1,421</b>	<b>1,469</b>	<b>1,542</b>	<b>1,714</b>

Louisiana Board of Pharmacy  
Pharmacy Program - Census Report

		<u>6/30/2003</u>	<u>6/30/2004</u>	<u>6/30/2005</u>	<u>6/30/2006</u>	<u>6/30/2007</u>	<u>6/30/2008</u>	<u>6/30/2009</u>	<u>6/30/2010</u>
PHY	CH	11	12	12	12	12	11	12	14
	HOS	179	181	181	167	164	167	167	165
	HOX								
	IN	19	27	36	35	36	37	37	27
	INX								
	IR	595	633	729	681	620	588	592	587
	IRX								
	NR	353	339	200	226	240	250	256	286
	NRN								
	NRP								
	NU	13	13	13	17	16	16	16	16
	PE	94	0	0	0	0	0	0	0
	PEN	13	0	0	0	0	0	0	0
	PEX								
	RC	541	555	473	430	491	534	545	562
	RPP								
	SAT								
	SPL								
	TDS								
TM									
	<b>PHY</b>	<b>1,818</b>	<b>1,760</b>	<b>1,644</b>	<b>1,568</b>	<b>1,579</b>	<b>1,603</b>	<b>1,625</b>	<b>1,657</b>
<hr/>									
AMS	AMS AMS-X <b>AMS</b>	<b>136</b>	<b>158</b>	<b>174</b>	<b>173</b>	<b>212</b>	<b>255</b>	<b>306</b>	<b>361</b>
<hr/>									
EDK	EDK EDK-X <b>EDK</b>	<b>474</b>	<b>444</b>	<b>471</b>	<b>428</b>	<b>412</b>	<b>439</b>	<b>388</b>	<b>503</b>
<hr/>									
DME	LA NR <b>DME</b>								
<hr/>									
CDTM									
MAR									
PMP									
SWP									
TMD									
<b>TOTAL</b>		<b>14,088</b>	<b>14,510</b>	<b>15,190</b>	<b>15,461</b>	<b>16,056</b>	<b>16,407</b>	<b>16,601</b>	<b>17,818</b>

Louisiana Board of Pharmacy  
Pharmacy Program - Census Report

		<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>	<u>6/30/2014</u>	<u>6/30/2015</u>	<u>6/30/2016</u>	<u>6/30/2017</u>	<u>6/30/2018</u>
PST.VI	LA	12	10	9	9	13	16	18	14
	NR	9	10	15	14	15	16	24	20
	<i>Total</i>	21	20	24	23	28	32	42	34
PST-GVI	LA		6	13	13	12	15	26	24
	NR		0	3	5	5	5	10	8
	<i>Total</i>		6	16	18	17	20	36	32
PST-M	LA	3	5	3	1	2	1	0	0
	NR	11	11	11	13	10	10	9	8
	<i>Total</i>	14	16	14	14	12	11	9	8
PST-MS	LA								
	NR								
	<i>Total</i>								
PST-G	LA	158	157	164	166	186	204	216	194
	NR	30	35	32	31	31	35	30	27
	<i>Total</i>	188	192	196	197	217	239	246	221
PST	LA	4,654	4,933	4,981	5,140	5,408	5,304	5,372	5,690
	NR	2,079	2,212	2,527	2,479	2,471	2,835	2,950	3,090
	<i>Total</i>	6,733	7,145	7,508	7,619	7,879	8,139	8,322	8,780
	<b>Active PST</b>	<b>6,935</b>	<b>7,353</b>	<b>7,718</b>	<b>7,830</b>	<b>8,108</b>	<b>8,389</b>	<b>8,577</b>	<b>9,009</b>
PNT	LA	907	938	942	948	952	957	946	910
	NR	137	128	128	127	143	127	145	158
	<i>Total</i>	1,044	1,066	1,070	1,075	1,095	1,084	1,091	1,068
PNT-FPG	Total	5	0	3	6	2	4	3	2
	<b>PNT</b>	<b>1,049</b>	<b>1,066</b>	<b>1,073</b>	<b>1,081</b>	<b>1,097</b>	<b>1,088</b>	<b>1,094</b>	<b>1,070</b>
CPT	LA	5,720	5,509	5,751	6,463	6,584	6,815	6,418	6,433
	NR	145	120	112	138	141	152	141	152
	<i>Total</i>	5,865	5,629	5,863	6,601	6,725	6,967	6,559	6,585
CPT-M	Total	1	0	1	2	1	2	2	1
	<b>CPT</b>	<b>5,866</b>	<b>5,629</b>	<b>5,864</b>	<b>6,603</b>	<b>6,726</b>	<b>6,969</b>	<b>6,561</b>	<b>6,586</b>
PTC	LA	1,574	1,665	1,658	1,870	1,929	1,813	1,971	1,931
	NR	35	39	37	37	52	48	54	69
	<b>PTC</b>	<b>1,609</b>	<b>1,704</b>	<b>1,695</b>	<b>1,907</b>	<b>1,981</b>	<b>1,861</b>	<b>2,025</b>	<b>2,000</b>

Louisiana Board of Pharmacy  
Pharmacy Program - Census Report

		<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>	<u>6/30/2014</u>	<u>6/30/2015</u>	<u>6/30/2016</u>	<u>6/30/2017</u>	<u>6/30/2018</u>
PHY	CH	12	12	12	12	12	12	11	10
	HOS	151	154	158	164	163	160	163	163
	HOX	19	18	14	11	8	7	6	6
	IN	14	10	12	12	11	11	12	11
	INX	11	14	13	11	10	10	11	11
	IR	570	568	558	583	588	576	577	584
	IRX	21	19	17	10	10	7	6	6
	NR	318	361	387	422	473	513	515	534
	NRN	0	0	0	9	9	8	7	8
	NRP	0	0	0	1	2	2	2	2
	NU	15	15	15	15	14	15	14	13
	PE	0	0	0	0	0	0	0	0
	PEN	0	0	0	0	0	0	0	0
	PEX			1	2	2	2	2	3
	RC	576	587	597	619	649	671	651	630
	RPP					0	0	0	1
	SAT				1	3	6	6	6
	SPL					0	0	0	0
	TDS					0	0	0	0
	TM								
	<b>PHY</b>	<b>1,707</b>	<b>1,758</b>	<b>1,784</b>	<b>1,871</b>	<b>1,951</b>	<b>2,000</b>	<b>1,983</b>	<b>1,988</b>
AMS	AMS	55	64	349	92	456	113	104	498
	AMS-X	301	302	289	359	356	367	335	372
	<b>AMS</b>	<b>356</b>	<b>366</b>	<b>638</b>	<b>451</b>	<b>812</b>	<b>480</b>	<b>439</b>	<b>870</b>
EDK	EDK	417	435	421	464	474	454	402	435
	EDK-X	13	13	10	10	10	10	9	11
	<b>EDK</b>	<b>430</b>	<b>448</b>	<b>431</b>	<b>474</b>	<b>484</b>	<b>464</b>	<b>411</b>	<b>446</b>
DME	LA		223	160	209	336	345	346	205
	NR			218	281	267	287	291	437
	<b>DME</b>			<b>378</b>	<b>490</b>	<b>603</b>	<b>622</b>	<b>637</b>	<b>642</b>
CDTM				41	41	52	59	66	69
MAR			1,617	2,037	2,383	2,603	2,820	3,073	
PMP									15,835
SWP		58	78	126	38	54	48	48	45
TMD									71
<b>TOTAL</b>		<b>18,031</b>	<b>18,651</b>	<b>21,405</b>	<b>813</b>	<b>824</b>	<b>817</b>	<b>768</b>	<b>41,770</b>

Louisiana Board of Pharmacy  
CDS Program - Census Report

<i>Classification</i>	<u>8/1/2006</u>	<u>6/30/2007</u>	<u>6/30/2008</u>	<u>6/30/2009</u>
ACS Animal Control Shelter				
AMS Automated Medication System				
AMX Automated Medication System - Exempt				
APN Advanced Practice Registered Nurse	220	346	479	607
ASC Ambulatory Surgical Center	94	94	101	106
CRX Correctional Center				
DDS Dentist	2,009	2,090	2,177	2,267
DET Drug Detection Canine - Private Agency	11	11	11	11
DEX Drug Detection Canine - Law Enforcement	8	9	9	9
DIS Distributor	236	285	322	363
DPM Podiatrist	146	147	153	161
DVM Veterinarian	817	870	936	1,000
DYS Dialysis Center	58	63	63	63
EMC Emergency Center	17	17	17	17
EMS Emergency Medical Service	56	57	58	63
ETC Animal Euthanasia Tech - Cert	29	31	39	44
ETL Animal Euthanasia Tech - Lead				
HOS Hospital	350	369	387	405
HOX Hospital - Exempt				
INT Intern or Resident				
LAB Analytical Laboratory	13	13	14	14
LAX Analytical Laboratory - Exempt				
MD Physician	12,754	13,195	13,876	14,599
MDT Physician via Telemedicine				
MED Medical Clinic	65	73	78	88
MFR Manufacturer	31	36	43	52
MP Medical Psychologist	30	37	44	50
OD Optometrist	196	230	253	269
PA Physician's Assistant	153	170	194	232
PHX Pharmacy - Exempt				
PHY Pharmacy				
REP Sales Representative	54	57	65	66
RES Researcher	91	100	110	119
RHC Rural Health Clinic	15	19	20	21
RNT APRN via Telehealth				
ROF Registered Outsourcing Facility				
SAC Substance Abuse Clinic	14	14	14	14
MIS Other	<u>80</u>	<u>74</u>	<u>73</u>	<u>58</u>
TOTAL	17,547	18,407	19,536	20,698

*Highlighted credentials subject to inspection*

Total Credentials Under Board Management

Pharmacy Program	18,031	18,651	21,405
CDS Program	<u>18,407</u>	<u>19,536</u>	<u>20,698</u>
<b>TOTAL</b>	<b>36,438</b>	<b>38,187</b>	<b>42,103</b>

Louisiana Board of Pharmacy  
CDS Program - Census Report

<i>Classification</i>	<u>6/30/2010</u>	<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>
ACS Animal Control Shelter	1	1	1	1
AMS Automated Medication System				
AMX Automated Medication System - Exempt				
APN Advanced Practice Registered Nurse	758	889	1,015	1,103
ASC Ambulatory Surgical Center	113	90	88	85
CRX Correctional Center		7	6	5
DDS Dentist	2,363	2,027	2,048	1,902
DET Drug Detection Canine - Private Agency	11	0	0	0
DEX Drug Detection Canine - Law Enforcement	11	14	12	10
DIS Distributor	400	279	288	273
DPM Podiatrist	165	139	136	118
DVM Veterinarian	1,065	922	901	852
DYS Dialysis Center	63	6	4	3
EMC Emergency Center	18	14	16	17
EMS Emergency Medical Service	66	54	50	45
ETC Animal Euthanasia Tech - Cert	49	16	7	6
ETL Animal Euthanasia Tech - Lead		12	20	21
HOS Hospital	438	280	267	263
HOX Hospital - Exempt		12	14	5
INT Intern or Resident				
LAB Analytical Laboratory	15	8	6	7
LAX Analytical Laboratory - Exempt		4	5	5
MD Physician	15,269	12,362	11,727	10,698
MDT Physician via Telemedicine				
MED Medical Clinic	102	80	86	82
MFR Manufacturer	58	48	50	45
MP Medical Psychologist	58	65	67	69
OD Optometrist	278	275	287	279
PA Physician's Assistant	272	294	326	344
PHX Pharmacy - Exempt		50	47	41
PHY Pharmacy		1,357	1,318	1,329
REP Sales Representative	88	29	20	7
RES Researcher	156	109	110	98
RHC Rural Health Clinic	23	17	12	11
RNT APRN via Telehealth				
ROF Registered Outsourcing Facility				
SAC Substance Abuse Clinic	17	7	9	9
MIS Other	<u>59</u>	<u>20</u>	<u>14</u>	<u>12</u>
<b>TOTAL</b>	<b>21,916</b>	<b>19,487</b>	<b>18,957</b>	<b>17,745</b>

*Highlighted credentials subject to inspection*

Total Credentials Under Board Management

Pharmacy Program	22,823	24,251	24,583	24,688
CDS Program	<u>21,916</u>	<u>19,487</u>	<u>18,957</u>	<u>17,745</u>
<b>TOTAL</b>	<b>44,739</b>	<b>43,738</b>	<b>43,540</b>	<b>42,433</b>

Louisiana Board of Pharmacy  
CDS Program - Census Report

<i>Classification</i>	<u>6/30/2014</u>	<u>6/30/2015</u>	<u>6/30/2016</u>	<u>6/30/2017</u>
ACS Animal Control Shelter	1	1	0	0
AMS Automated Medication System	26	29	22	28
AMX Automated Medication System - Exempt	2	1	0	0
APN Advanced Practice Registered Nurse	1,479	1,954	2,296	2,343
ASC Ambulatory Surgical Center	89	87	21	0
CRX Correctional Center	6	4	1	0
DDS Dentist	2,123	2,133	2,134	1,929
DET Drug Detection Canine - Private Agency	0	0	0	0
DEX Drug Detection Canine - Law Enforcement	11	12	9	8
DIS Distributor	324	319	301	284
DPM Podiatrist	133	142	152	136
DVM Veterinarian	1,002	1,045	1,085	1,007
DYS Dialysis Center	4	0	0	0
EMC Emergency Center	22	26	5	0
EMS Emergency Medical Service	50	49	16	0
ETC Animal Euthanasia Tech - Cert	6	5	5	1
ETL Animal Euthanasia Tech - Lead	23	23	22	24
HOS Hospital	272	271	289	278
HOX Hospital - Exempt	6	6	5	5
INT Intern or Resident				
LAB Analytical Laboratory	8	8	8	7
LAX Analytical Laboratory - Exempt	5	5	4	4
MD Physician	11,913	12,124	12,360	11,575
MDT Physician via Telemedicine	2	1	0	0
MED Medical Clinic	89	81	3	0
MFR Manufacturer	42	42	37	38
MP Medical Psychologist	78	82	86	84
OD Optometrist	309	316	326	297
PA Physician's Assistant	449	487	610	667
PHX Pharmacy - Exempt	30	24	21	20
PHY Pharmacy	1,357	1,379	1,367	1,339
REP Sales Representative	0	0	0	0
RES Researcher	113	113	108	100
RHC Rural Health Clinic	12	11	2	0
RNT APRN via Telehealth				
ROF Registered Outsourcing Facility		8	14	13
SAC Substance Abuse Clinic	9	10	7	6
MIS Other	<u>13</u>	<u>11</u>	<u>0</u>	<u>0</u>
<b>TOTAL</b>	<b>20,008</b>	<b>20,809</b>	<b>21,316</b>	<b>20,193</b>

*Highlighted credentials subject to inspection*

Total Credentials Under Board Management

Pharmacy Program	41,770	44,025	24,583	24,688
CDS Program	<u>20,008</u>	<u>20,809</u>	<u>21,316</u>	<u>20,193</u>
<b>TOTAL</b>	<b>61,778</b>	<b>64,834</b>	<b>45,899</b>	<b>44,881</b>

**New Credentials Issued**  
**FYE 2020 - 2nd Quarter**  
**October 1, 2019 - December 31, 2019**

Prefix	Subcategory	CredentialType	Total
AMS		Automated Medication System	8
AMS	X	Automated Medication System - Exempt	12
<b>Prefix Totals</b>			<b>20</b>
CDS	AMS	CDS License - Automated Medication System	3
CDS	APN	CDS License - APRN	103
CDS	DDS	CDS License - Dentist	21
CDS	DIS	CDS License - Distributor	5
CDS	DVM	CDS License - Veterinarian	22
CDS	HOS	CDS License - Hospital	6
CDS	INT	CDS License - Medical Intern or Resident	35
CDS	LAX	CDS License - Laboratory - Exempt	1
CDS	MD	CDS License - Physician	92
CDS	MDT	CDS License - Physician via Telemedicine	2
CDS	MP	CDS License - Medical Psychologist	2
CDS	OD	CDS License - Optometrist	2
CDS	PA	CDS License - Physician Assistant	28
CDS	PHX	CDS License - Pharmacy - Exempt	1
CDS	PHY	CDS License - Pharmacy	19
CDS	RES	CDS License - Researcher	3
<b>Prefix Totals</b>			<b>345</b>
CDTM		Collaborative Drug Therapy Management (V)	1
CPT		Certified Pharmacy Technician	78
DME		Durable Medical Equipment (DME) Provider	16
EDK		Emergency Drug Kit	10
MA		Medication Administration (V)	100
PHY	HOS	Pharmacy - Hospital Inpatient	4
PHY	IR	Pharmacy - Community ~ Independent	18
PHY	IRX	Pharmacy - Community - Exempt	1
PHY	NR	Pharmacy - Nonresident	14
PHY	RC	Pharmacy - Community ~ Chain	1
<b>Prefix Totals</b>			<b>38</b>
PIC		Pharmacist-in-Charge (V)	6
PMP	CDS	PMP - CDS Credential (V)	88
PMP	PHY	PMP - PHY Dispenser Account (V)	26
PMP	PST	PMP - Pharmacist (V)	9
<b>Prefix Totals</b>			<b>123</b>
PNT		Pharmacy Intern	163
PST		Pharmacist	66
PST	MS	Pharmacist - Military Spouse	1
<b>Prefix Totals</b>			<b>67</b>
PTC		Pharmacy Technician Candidate	274
SWP		Special Work Permit	13
TM	CPT	Therapeutic Marijuana Designation - CPT	2
TM	PST	Therapeutic Marijuana Designation - PST	5
<b>Prefix Totals</b>			<b>7</b>
<b>Grand Totals</b>			<b>1261</b>

## Pending Applications

### PHARMACY CREDENTIALS

Prefix	Subcat.	CredentialType	8/2/2018	11/2/2018	2/6/2019	5/13/2019	8/1/2019	11/1/2019	1/23/2020
AMS		Automated Medication System	5	5	8	9	7	7	6
CPT		Certified Pharmacy Technician	29	29	33	58	46	32	28
DME		Durable Medical Equipment	17	18	20	12	14	10	6
EDK		Emergency Drug Kit	4	5		7	2	2	3
PHY	CH	Pharmacy - Charitable	1	1	1				
PHY	HOS	Pharmacy - Hospital Inpatient	1	5	6	6	9	8	6
PHY	IN	Pharmacy - Institutional	1	1	1	1			3
PHY	IR	Pharmacy - Community ~ Independent	21	20	22	18	21	22	15
PHY	NR	Pharmacy - Nonresident	74	73	60	67	61	41	41
PHY	NRN	Pharmacy - Nonresident Nuclear	1						
PHY	NU	Pharmacy - Nuclear							1
PHY	PEN	Pharmacy - Penal	3	1					
PHY	RC	Pharmacy - Community ~ Chain	2	4	3	2	1	1	2
PHY	RPP	Pharmacy - Remote Processor	1	1					
PHY	SAT	Pharmacy - Hospital Off-Site Satellite		1	1	1	1	2	3
PHY	SPL	Pharmacy - Special Event				1	1	1	
PHY	TM	Pharmacy - Therapeutic Marijuana	9	8	6	2	1		
PIC		Pharmacist-in-Charge					1	0	1
PNT	FPG	Pharmacy Intern - Foreign Graduate	1	1	1				1
PNT		Pharmacy Intern	31	173	74	35	57	139	86
PST		Pharmacist	480	278	272	348	305	234	203
PTC		Pharmacy Technician Candidate	286	289	223	235	245	232	213
<b>Subtotal</b>			<b>967</b>	<b>913</b>	<b>731</b>	<b>802</b>	<b>772</b>	<b>731</b>	<b>618</b>

### CDS CREDENTIALS

Prefix	Subcat.	CredentialType	8/2/2018	11/2/2018	2/6/2019	5/13/2019	8/1/2019	11/1/2019	1/23/2020
CDS	AMS	CDS - Automated Medication System	4	1	1	1			
CDS	APN	CDS - APRN	17	14	14	11	10	9	11
CDS	DDS	CDS - Dentist	4	3	2	1			3
CDS	DET	CDS - Drug Detection / Canine	3	1				1	2
CDS	DIS	CDS - Distributor	6	17	15	14	13	2	3
CDS	DPM	CDS - Podiatrist	1						1
CDS	DVM	CDS - Veterinarian	5			4	1	3	1
CDS	ETC	CDS - Animal Euthanasia Tech, Certified		1					
CDS	ETL	CDS - Animal Euthanasia Tech, Lead	1	1	3	1			
CDS	HOS	CDS - Hospital	9	8	12	13	13	12	11
CDS	INT	CDS - Medical Intern or Resident	18	14	7	7	8	13	10
CDS	MD	CDS - Physician	27	34	24	18	20	8	9
CDS	MFR	CDS - Manufacturer	4	4					
CDS	MP	CDS - Medical Psychologist							
CDS	OD	CDS - Optometrist	1						
CDS	PA	CDS - Physician Assistant	10	11	8	11	14	6	3
CDS	PHY	CDS - Pharmacy	22	27	24	21	20	23	23
CDS	PHX	CDS - Pharmacy - Exempt	2	1	1				
CDS	RES	CDS - Researcher	5	2	2	3	5	17	16
CDS	RNT	CDS - APRN via Telehealth	1						
CDS	ROF	CDS - Registered Outsourcing Facility	2	1	3	2	1		
CDS	SAC	CDS - Substance Abuse Clinic	4	1	5	1	1		3
CDS	TM	CDS - Therapeutic Marijuana	9	8	6	2	1		
<b>Subtotal</b>			<b>155</b>	<b>149</b>	<b>127</b>	<b>110</b>	<b>107</b>	<b>94</b>	<b>96</b>

### OTHER CREDENTIALS

Prefix	Subcat.	CredentialType	8/2/2018	11/2/2018	2/6/2019	5/13/2019	8/1/2019	11/1/2019	1/23/2020
CDTM		Collaborative Drug Therapy Management						1	
LB		Law Book							
MA		Medication Administration	3	10	10	10	8	8	6
PMP		PMP - CDS Credential	206	143	342	310	310	287	144
PMP		PMP - MIS Credential							
PMP		PMP - PHY Credential		2	1				
PMP		PMP - PST Credential	210	5	345	2	2	1	
SWP		Special Work Permit	10	10	10	10	10	10	10
TM	CPT	Therapeutic Marijuana Designation - CPT	4	18	17	26	26	29	24
TM	OMO	Therapeutic Marijuana Designation - OMO	2						1
TM	PST	Therapeutic Marijuana Designation - PST	4	2	7	10	11	16	11
<b>Subtotal</b>			<b>439</b>	<b>190</b>	<b>732</b>	<b>368</b>	<b>367</b>	<b>352</b>	<b>196</b>

<b>TOTAL</b>	<b>1561</b>	<b>1252</b>	<b>1590</b>	<b>1280</b>	<b>1246</b>	<b>1177</b>	<b>910</b>
--------------	-------------	-------------	-------------	-------------	-------------	-------------	------------



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



February 5, 2020

## Agenda Item 11-L: Report of Executive Director

### Section 2 – A – 1 – D ~ Exceptions Report

#### 1. **PIC at Multiple Pharmacies**

Board Policy I.A.4 permits the Executive Director to approve requests from pharmacists wishing to serve as the Pharmacist-in-Charge (PIC) of more than one pharmacy at the same time. The decision to approve such a request requires the concurrence of the President, as well as notice to the Board at its next meeting. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

- On November 22, 2019 Mr. Aron and Mr. Fontenot concurred to grant a request from Colleen Ann Natali Savoie (PST.014950) for temporary dual PIC privileges at Prairieville Family General Hospital (PHY.008009-HOS) and Vermillion Behavioral Health Systems Pharmacy (PHY.005693-HOS). The dual PIC privilege is temporary and will expire on December 31, 2019.

#### 2. **Special Work Permits for military-trained applicants and their spouses**

LAC Title 46: LIII §904 authorizes the Board to provide preferential licensing procedures for military-trained applicants and their spouses. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

- *(None since previous report)*

#### 3. **Special Work Permits**

Board Policy I.A.7 permits the Executive Director to issue Special Work Permits to document the resurrection of expired non-renewable credentials and for other purposes as authorized by the Board. The decision to approve such a request requires the concurrence of the President, as well as notice to the Board at its next meeting. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

- On October 30, 2019, Mr. Aron and Mr. Finalet concurred to grant a request of Youzette Comise Davenport. She had previously obtained PTC.015919 which expired on July 19, 2011. She is PTCB-certified and was issued a Special Work Permit for two years to earn her hours of practical experience.
- On November 5, 2019, Mr. Aron and Mr. Finalet concurred to grant a request of Michelle Nicole Tarver. She had previously obtained PTC.022442 which expired on August 27, 2016. She is PTCB-certified and was issued a Special Work Permit for two years to earn her hours of practical experience.
- On November 14, 2019, Mr. Aron and Mr. Finalet concurred to grant a request of Kandrese Renee Nelson. She had previously obtained PTC.026106 which expired on October 11, 2019. She is ExCPT-certified and was issued a Special Work Permit for two years to earn her hours of practical experience.
- On December 9, 2019, Mr. Aron and Mr. Finalet concurred to grant a request of Jasmine Elaine Randle. She had previously obtained PTC.026402 which expired on June 28, 2019. She is ExCPT-certified and was issued a Special Work Permit for two years to earn her hours of practical experience.
- On December 12, 2019, Mr. Aron and Mr. Finalet concurred to grant a request of Stephen Paul Landry. He had previously obtained PTC.020564 which expired on April 8, 2015. He is PTCB-certified and was issued a Special Work Permit for two years to earn the

- required hours of practical experience.
- On December 19, 2019, Mr. Aron and Mr. Finalet concurred to grant a request of Jonathan David Sayles. He had previously obtained PTC.012101 which expired on January 6, 2008. He is PTCB-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.
  - On December 19, 2019, Mr. Aron and Mr. Finalet concurred to grant a request of Chrishawn Kieana Black. She had previously obtained PTC.020088 which expired on November 29, 2014. She is ExCPT-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.
  - On December 19, 2019, Mr. Aron and Mr. Finalet concurred to grant a request of Stephanie Marie Probst. She had previously obtained PTC.025628 which expired on June 19, 2019. She is PTCB-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.
  - On January 2, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Alexia Mone' Johnson. She had previously obtained PTC.024335 which expired on February 2, 2018. She is ExCPT-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.
  - On January 7, 2020, Mr. Aron and Mr. Finalet concurred to grant a request of Keiara LaJerica Jenkins. She had previously obtained PTC.015571 which expired on March 21, 2011. She is PTCB-certified and was issued a Special Work Permit for two years to earn the required hours of practical experience.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Compliance Division Census Report

February 5, 2020

### **Practitioner Recovery Program**

- Probation Completion Report

*[none since November 2019 Board meeting]*

- Active Probation           34    Pharmacist  
                                      6    Technician
- Active Suspension       42    Pharmacist  
                                      3    Pharmacy intern  
                                     17   Technician  
                                      4    Technician candidate

### **Disciplinary Restrictions**

- Probation Completion Report

*[none since November 2019 Board meeting]*

- Active Probation           15    Pharmacist  
                                      1    Pharmacy intern  
                                      2    Technician  
                                      1    Technician candidate  
                                      5    Pharmacy permit  
                                      1    CDS-PHY license
- Active Suspension/  
  Inactivation               52    Pharmacist  
                                      1    Pharmacy intern  
                                     87   Technician  
                                     21   Technician candidate  
                                      1    Special work permit  
                                     12   Pharmacy permit  
                                      7    CDS-PHY license  
                                    101   CDS license for practitioners

Louisiana Board of Pharmacy  
Compliance Division

Complaint Investigation Completion Policy Monitor

	FY 17-18 <u>6/30/2018</u>	FY 18-19 <u>6/30/2019</u>	FY 19-20 <u>1/24/2020</u>	FY 20-21
Pending at Beginning of Fiscal Year	160	180	179	
New Cases Added	500	433	226	
Cases Closed	480	434	225	
Cases Remaining	180	179	180	
Average No. Days to Close Investigation		52	55	
No. Investigations Closed > 180 Days		19	9	
% Investigations Beyond Policy Limit		4.4%	4.0%	
% Cases Closed by Board Action		27%	34%	

National Healthcareers Association  
ExCPT

	Calendar Year 2018				Calendar Year 2019			
	<u>1st Qtr</u>	<u>2nd Qtr</u>	<u>3rd Qtr</u>	<u>4th Qtr</u>	<u>1st Qtr</u>	<u>2nd Qtr</u>	<u>3rd Qtr</u>	<u>4th Qtr</u>
<b>First-Time Candidate Group</b>								
No. of LA Candidates	7	32	34	32	48	71	58	56
No. of LA Candidates who passed	2	16	20	22	41	39	35	36
State Pass Rate	29%	50%	59%	69%	85%	56%	60%	64%
No of National Candidates					1835	3942	1536	1602
No. of National Candidates who passed					1356	2503	1123	1183
National Pass Rate	66%	61%	70%	70%	74%	63%	73%	74%
<b>Multiple Attempts Group</b>								
No. of LA Candidates	2	6	2	5	1	1	1	0
No. of LA Candidates who passed	1	3	2	2	1	1	0	0
State Pass Rate	50%	50%	100%	40%	100%	100%	0%	0%
No. of National Candidates					172	194	72	85
No. of National Candidates who passed					94	95	37	36
National Pass Rate	62%	47%	40%	55%	55%	49%	51%	42%



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Pharmacy Technician Certification Examination (PTCE™)

July – December 2019

Cumulative Record (since January 2000)

February 5, 2020

## Pharmacy Technician Certification Examination (PTCE™)

This computer adaptive competency assessment is administered by the Pharmacy Technician Certification Board (PTCB). The examination blueprint is designed to assess the applicant's competency in basic pharmacy practice and is recognized by pharmacy regulatory authorities in most of the states and territories within the USA. The examination is administered via an open window process; applicants may schedule the examination at a designated testing center at any time following approval by PTCB and receipt of an Authorization to Test (ATT) document from PTCB. Individual scores are available to applicants immediately after the test; certificates are mailed to the applicant within 30 days following the examination. Summary reports are provided to the state boards on a semi-annual basis.

### *Table of Contents*

Summary Chart of PTCE Pass Rates, National v Louisiana	03
Cumulative Report (since January 2000)	04



July 1, 2019 – December 31, 2019

	First Time Test Takers		Repeaters		Total	
	Exams Graded	Pass Rate	Exams Graded	Pass Rate	Exams Graded	Pass Rate
<b>Louisiana</b>	331	46%	136	40%	467	44%
<b>National</b>	21,127	61%	4,990	46%	26,117	58%

PTCE® performance shown in percentage of questions answered correctly by knowledge domain:

	Louisiana	National
Medication Order Entry and Fill Process	64%	68%
Medication Safety	68%	71%
Pharmacology for Technicians	59%	62%
Pharmacy Billing and Reimbursement	63%	69%
Pharmacy Information System Usage and Application	59%	63%
Pharmacy Inventory Management	70%	73%
Pharmacy Law and Regulations	67%	68%
Pharmacy Quality Assurance	71%	74%
Sterile and Non-Sterile Compounding	54%	60%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Examination (PTCB) Data

<b><u>National Data</u></b>	<b><u>1/1/2018 to 6/30/2018</u></b>	<b><u>7/1/2018 to 12/31/2018</u></b>	<b><u>Totals</u></b>	<b><u>2000-2018</u></b>	<b><u>1/1/2019 to 6/30/2019</u></b>	<b><u>7/1/2019 to 12/31/2019</u></b>	<b><u>Totals</u></b>	<b><u>2000-2019</u></b>
<i>First Attempt</i>								
No. of Candidates Attempting	22,517	17,277	39,794		21,026	21,127	42,153	
No. of Candidates Passing	13,510	10,539	24,049		12,616	12,887	25,503	
Pass Rate	60%	61%	60.0%		60%	61%	61%	
<i>Repeaters</i>								
No. of Candidates Attempting	4,814	4,235	9,049		4,610	4,990	9,600	
No. of Candidates Passing	2,166	1,948	4,114		2,167	2,295	4,462	
Pass Rate	45%	46%	45.0%		47%	46%	46%	
<i>Totals</i>								
No. Candidates Attempting	27,331	21,512	48,843	895,313	25,636	26,117	51,753	947,066
No. Candidates Passing	15,579	12,477	28,056	625,156	14,783	15,182	29,965	655,121
Pass Rate	57%	58%	57.0%	70%	57%	58%	58%	69%
 <b><u>Louisiana Data</u></b>								
<i>First Attempt</i>								
No. of Candidates Attempting	452	400	852		402	331	733	
No. of Candidates Passing	199	184	383		193	152	345	
Pass Rate	44.0%	46.0%	44.9%		48%	46%	47%	
<i>Repeaters</i>								
No. of Candidates Attempting	205	172	377		138	136	274	
No. of Candidates Passing	74	71	145		51	54	105	
Pass Rate	36.1%	41.3%	38.5%		37%	40%	38%	
<i>Totals</i>								
No. Candidates Attempting	657	572	1,229	17,062	540	467	1,007	18,069
No. Candidates Passing	269	252	521	10,185	243	206	449	10,634
Pass Rate	40.9%	44.1%	42.4%	60%	45%	44%	45%	59%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Examination (PTCB) Data

	<u>2000-2013</u>	<u>1/1/2014 to 6/30/2014</u>	<u>7/1/2014 to 12/31/2014</u>	<u>2000-2014</u>	<u>1/1/2015 to 06/30/2015</u>	<u>7/1/2015 to 12/31/2015</u>	<u>2000-2015</u>
<b><u>National Data</u></b>							
No. of Candidates Attempting	628,957	26,423	27,085	682,465	22,197	36,167	740,829
No. of Candidates Passing	470,680	15,233	15,125	501,038	13,280	21,643	535,961
Pass Rate	74.8%	57.7%	55.8%	73.4%	59.8%	59.8%	72.3%
<b><u>Louisiana Data</u></b>							
No. of Candidates Attempting	11,002	630	568	12,200	480	632	13,314
No. of Candidates Passing	7,451	287	265	8,003	255	304	8,562
Pass Rate	67.7%	45.6%	46.7%	65.6%	53.1%	48.1%	64.3%
<b><u>National Data</u></b>							
		<u>1/1/2016 to 12/31/2016</u>		<u>2000-2016</u>	<u>1/1/2017 to 12/31/2017</u>		<u>2000-2017</u>
<i>First Attempt</i>							
No. of Candidates Attempting		43,958			43,180		846,470
No. of Candidates Passing		26,814			25,908		597,232
Pass Rate		61%			60%		71%
<i>Repeaters</i>							
No. of Candidates Attempting		9,372			9,131		
No. of Candidates Passing		4,217			4,200		
Pass Rate		45%			46%		
<i>Totals</i>							
No. Candidates Attempting		53,330		794,159	52,311		846,470
No. Candidates Passing		31,031		566,992	30,108		597,100
Pass Rate		58%		71%	58%		71%
<b><u>Louisiana Data</u></b>							
<i>First Attempt</i>							
No. of Candidates Attempting		840			843		
No. of Candidates Passing		412			405		
Pass Rate		49%			48%		
<i>Repeaters</i>							
No. of Candidates Attempting		458			378		
No. of Candidates Passing		156			129		
Pass Rate		34%			34%		
<i>Totals</i>							
No. Candidates Attempting		1,298		14,612	1,221		15,833
No. Candidates Passing		568		9,130	534		9,664
Pass Rate		44%		62%	44%		61%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Examination (PTCB) Data

	2000-2009 Data	<u>1/1/2010</u> <u>3/31/2010</u>	<u>4/1/2010</u> <u>6/30/2010</u>	<u>7/1/2010</u> <u>9/30/2010</u>	<u>10/1/2010</u> <u>12/31/2010</u>	2000-2010 Data	<u>1/1/2011</u> <u>3/31/2011</u>	<u>4/1/2011</u> <u>6/30/2011</u>	<u>7/1/2011</u> <u>9/30/2011</u>	<u>10/1/2011</u> <u>12/31/2011</u>
<b><u>National Data</u></b>										
No. of Candidates Attempting	415,875	11,611	15,033	16,025	12,774	471,318	11,219	14,026	12,356	14,031
No. of Candidates Passing	309,035	8,521	11,216	12,349	9,275	350,396	8,366	10,472	9,565	10,826
Pass Rate	74%	73%	75%	77%	73%	74%	75%	75%	77%	77%
<b><u>Louisiana Data</u></b>										
No. of Candidates Attempting	9,843	217	421	320	268	11,069	247	437	268	257
No. of Candidates Passing	6,688	121	287	219	166	7,481	161	306	182	168
Pass Rate	68%	56%	68%	68%	62%	68%	65%	70%	68%	65%
							<i>Changed to semi-annual reports</i>			
	2000-2011 Data	<u>1/1/2012</u> <u>3/31/2012</u>	<u>4/1/2012</u> <u>6/30/2012</u>	<u>7/1/2012</u> <u>9/30/2012</u>	<u>10/1/2012</u> <u>12/31/2012</u>	2000-2012 Data	<u>1/1/2013 to 6/30/2013</u>	<u>7/1/2013 to 12/31/2013</u>		
<b><u>National Data</u></b>										
No. of Candidates Attempting	522,950	11,851	14,356	14,375	11,180	574,712	25,448	28,797		
No. of Candidates Passing	389,625	9,232	11,044	10,982	8,471	429,354	19,581	21,745		
Pass Rate	75%	78%	77%	76%	76%	75%	77%	76%		
<b><u>Louisiana Data</u></b>										
No. of Candidates Attempting	12,278	246	368	329	239	13,460	622	537		
No. of Candidates Passing	8,298	158	269	226	168	9,119	412	351		
Pass Rate	68%	64%	73%	69%	70%	68%	66%	65%		

Louisiana Board of Pharmacy


Pharmacy Technician Certification Examination (PTCB) Data

	2000-2005 Data	<u>3/11/2006</u>	<u>7/22/2006</u>	<u>9/9/2006</u>	<u>11/18/2006</u>	2000-2006 Data	<u>2/5/2007</u> <u>3/9/2007</u>	<u>4/24/2007</u> <u>5/25/2007</u>	<u>8/27/2007</u> <u>9/28/2007</u>	<u>11/26/2007</u> <u>12/31/2007</u>
<b><u>National Data</u></b>										
No. of Candidates Attempting	225,206	12,383	18,992	3,029	15,285	274,895	8,768	10,730	14,666	10,881
No. of Candidates Passing	177,102	8,559	12,609	2,006	9,145	209,421	6,034	7,487	10,497	7,472
Pass Rate	79%	69%	66%	66%	60%	76%	69%	70%	72%	69%
<b><u>Louisiana Data</u></b>										
No. of Candidates Attempting	5,713	288	420	59	312	6,792	216	306	266	207
No. of Candidates Passing	4,179	181	239	37	137	4,773	133	196	177	121
Pass Rate	73%	63%	57%	63%	44%	70%	62%	64%	67%	58%
	2000-2007 Data	<u>2/4/2008</u> <u>3/14/2008</u>	<u>4/28/2008</u> <u>6/20/2008</u>	<u>8/18/2008</u> <u>10/10/2008</u>	<u>11/10/2008</u> <u>12/19/2008</u>	2000-2008 Data	<u>1/1/2009</u> <u>3/31/2009</u>	<u>4/1/2009</u> <u>6/30/2009</u>	<u>7/1/2009</u> <u>9/30/2009</u>	<u>10/1/2009</u> <u>12/31/2009</u>
<b><u>National Data</u></b>										
No. of Candidates Attempting	319,940	7,547	14,291	16,385	11,792	369,955	13,087	8,424	13,735	10,674
No. of Candidates Passing	240,911	5,165	10,155	11,781	7,770	275,782	9,141	6,363	10,067	7,682
Pass Rate	75%	68%	72%	72%	66%	75%	70%	76%	73%	72%
<b><u>Louisiana Data</u></b>										
No. of Candidates Attempting	7,787	128	392	304	215	8,826	301	260	238	218
No. of Candidates Passing	5,400	72	233	182	118	6,005	184	196	166	137
Pass Rate	69%	56%	59%	60%	55%	68%	61%	75%	70%	63%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Examination (PTCB) Data

	1995-1999 Data	<u>3/25/2000</u>	<u>7/22/2000</u>	<u>11/18/2000</u>	<u>3/10/2001</u>	<u>7/14/2001</u>	<u>11/10/2001</u>	<u>3/16/2002</u>	<u>7/27/2002</u>	<u>11/16/2002</u>
<b><u>National Data</u></b>										
No. of Candidates Attempting	58,382	8,101	12,317	12,941	8,442	12,057	10,608	8,874	13,399	11,521
No. of Candidates Passing	47,973	6,206	10,006	9,520	6,116	9,799	8,354	7,072	10,681	9,164
Pass Rate	82%	77%	81%	74%	72%	81%	79%	80%	80%	80%
<b>Louisiana Data</b>										
No. of Candidates Attempting	514	141	346	327	187	310	324	269	383	308
No. of Candidates Passing	390	92	271	221	125	227	228	184	269	213
Pass Rate	76%	65%	78%	68%	67%	73%	70%	68%	70%	69%
	2000-2002 Data	<u>3/29/2003</u>	<u>7/26/2003</u>	<u>11/15/2003</u>	<u>3/20/2004</u>	<u>7/17/2004</u>	<u>11/13/2004</u>	<u>3/19/2005</u>	<u>7/23/2005</u>	<u>11/19/2005</u>
<b><u>National Data</u></b>										
No. of Candidates Attempting	98,260	12,147	14,162	13,401	11,508	15,942	13,795	13,673	18,250	14,068
No. of Candidates Passing	76,918	9,506	11,720	11,006	9,100	12,196	10,818	11,009	14,246	10,583
Pass Rate	78%	78%	83%	82%	79%	77%	78%	81%	78%	75%
<b>Louisiana Data</b>										
No. of Candidates Attempting	2,595	385	384	351	285	382	290	337	488	216
No. of Candidates Passing	1,830	294	286	271	211	281	214	274	351	167
Pass Rate	71%	76%	74%	77%	74%	74%	74%	81%	72%	77%





# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Initial Legislative Report

2020-0201 @ 1800

Regular Session of the 2020 Louisiana Legislature  
Convenes 2020-0309 @ 1200 – Adjourns 2020-0601 @ 1800

Last Items Reviewed								
HB	<b>36</b>	HR	0	HCR	0	HCSR	0	
SB	<b>27</b>	SR	0	SCR	0	SSR	0	
						SCSR	0	
							Acts 0	
Total = <b>63</b>							Items on Watch List = <b>2</b>	

## House of Representatives

### Bills

**HB 6** G. Miller House & Governmental Affairs  
Provides relative to reports by executive branch agencies. [Gov sig]  
01-21-2020 Prefiled and referred to committee

*Removes a current provision providing an automatic expiration of certain reports, and in its place, requires such agencies to prepare a special report directed to the Speaker of the House of Representatives and President of the Senate no later than 01-01-2022 and every four years thereafter, a listing of all such reports, the citation of law requiring the agency to produce the report, an estimate of the agency resources required to produce the report, and a determination regarding the continued necessity of the report. The bill requires the leader of each chamber to refer the special report to the committee of jurisdiction for their evaluation of the special report and a determination of the continued necessity of the report. When a standing committee determines a report is no longer necessary, the committee shall cause the introduction of legislation to repeal the requirement for the report.*

**HB 7** G. Miller House & Governmental Affairs  
Provides relative to reports by executive branch agencies. [Gov sig]  
01-21-2020 Prefiled and referred to committee.

*This bill simply repeals the same provision referenced in HB 6 {R.S. 49:1401} and does not replace it with the special report described in the new provisions of HB 6.*

[2]

### Resolutions

#### Concurrent Resolutions

#### Study Resolutions

#### Concurrent Study Resolutions

## Senate

Bills

Resolutions

Concurrent Resolutions

Study Resolutions

Concurrent Study Resolutions



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Agenda Item 12

Special Presentation

Report from Marijuana Pharmacies

Mr. J. Douglas Boudreaux  
President  
Louisiana Association for Therapeutic Alternatives



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Agenda Item 13

New Agenda Items Added During Meeting



**Louisiana Board of Pharmacy**  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Announcements



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



February 5, 2020

## Agenda Item 14: Announcements

- |            |   |
|------------|---|
| Feb. 25    | Mardi Gras Day – <i>Board office closed</i>                 |
| Mar. 2     | La. Medical Marijuana Stakeholder Meeting                   |
| Mar. 4     | HOPE Advisory Council Meeting                               |
| Mar. 6     | Deadline for address changes for member nomination election |
| Mar. 9     | 2020 Regular Session of Legislature convenes                |
| Mar. 11-13 | MPJE Item Development Workshop – Mount Prospect, IL         |
| Mar. 16    | Mail ballots for member nomination election                 |
| Mar. 17-18 | Violations Committee Informal Conference                    |
| Mar. 20-23 | APhA Annual Meeting – Washington, DC                        |
| April 8    | Louisiana Pharmacy Congress<br>PMP Advisory Council Meeting |
| April 10   | Good Friday – <i>Board office closed</i>                    |
| April 16   | Drug Policy Board Meeting                                   |
| April 17   | Deadline for return of member nomination election ballots   |
| April 21   | Count ballots for member nomination election                |
| April 23   | dotPharmacy Executive Board Meeting – <i>via webinar</i>    |
| May 14-16  | NABP Annual Meeting – Baltimore, MD                         |
| May 25     | Memorial Day – <i>Board office closed</i>                   |
| May 26     | Reinstatement, Impairment, & Executive Committees           |
| May 27     | Board Meeting   |
| May 28     | Administrative Hearing                                      |

End of Meeting Binder